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Abstract 
 
Cyclin-dependent kinase inhibitor p16
INK4A
 is an important tumour suppressor and  inducer of cellular 
senescence often inactivated during the development of cancer. I investigated the mechanism by 
which EBV latency-associated nuclear antigens EBNA3A and EBNA3C repress p16
INK4A 
expression. 
Using lymphoblastoid cell lines (LCL) expressing a conditional EBNA3C, I demonstrate that 
EBNA3C inactivation resets the epigenetic status of p16
INK4A
 to permit transcriptional activation: the 
polycomb-associated repressive H3K27me3 histone modification is substantially reduced, while the 
activation-related mark H3K4me3 is modestly increased. Activation of EBNA3C reverses the 
distribution of these epigenetic marks, represses p16
INK4A
 transcription and allows proliferation. LCL 
lacking EBNA3A express relatively high levels of p16
INK4A
 and have a similar pattern of histone 
modifications on p16
INK4A
 as produced by the inactivation of EBNA3C. Since binding to the co-
repressor of transcription CtBP was linked to the oncogenic activity of EBNA3C and EBNA3A, LCL 
with viruses encoding EBNA3C- and/or EBNA3A-mutants that no longer bind CtBP were 
established. These novel LCL revealed that the epigenetic repression of p16
INK4A
 requires the 
interaction of both EBNA3C and EBNA3A with CtBP. Epigenetic repression of p16
INK4A
 by latent 
EBV may facilitate p16
INK4A
 DNA methylation during lymphomagenesis. 
Furthermore, by transforming the peripheral blood lymphocytes (PBL) from an individual 
homozygous for a deletion in CDKN2A locus with recombinant EBV viruses expressing conditional 
EBNA3C, we developed a system that allows inactivation of EBNA3C in LCL lacking functional 
p16
INK4A
 protein (p16-null LCL 3CHT). EBNA3C inactivation has no impact on the proliferation rate of 
p16-null LCL, proving that the repression of p16
INK4A
 is the main function of EBNA3C in EBV-driven 
LCL proliferation. The p16
INK4A 
locus is epigenetically modified by EBNA3C despite the absence of 
functional p16
INK4A
 protein. Since the selection pressure based on faster outgrowth of 
advantageously modified subset of cells is removed, the gradual and relatively slow kinetics of 
H3K27me3 restoration at p16
INK4A
 following EBNA3C reactivation in p16-null LCL 3CHT seems to be 
genuinely related to the mechanism of EBNA3C-mediated p16
INK4A
 regulation. The p16-null LCL 
3CHT system further allows distinguishing genes regulated specifically by EBNA3C, rather than as a 
consequence of activation of p16
INK4A
/Rb/E2F1 axis.       
Lastly, new cellular targets of EBNA3C and/or EBNA3A from the group of microRNAs are identified 
in this work. Most notably, both EBNA3C and EBNA3A are shown to repress the tumour supressor 
miR-143/145 cluster and their precursor long non-coding RNAs in LCL.  
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Abbreviations 
 
 
Ab Antibody 
ANRIL Antisense Non-Coding RNA in the INK4 Locus 
ATP Adenosine Triphosphate 
BAC Bacterial Artificial Chromosome 
BART Bamhi-A Rightward Transcript 
BIM Bcl-2 Interacting Mediator of cell death 
BIM EL Extra Long Bim isoform 
BL Burkitt Lymphoma 
bp Base Pair 
BrdU Bromodeoxyuridine 
BSA Bovine Serum Albumin 
CBF-1 C-Promoter Binding Factor-1 
CDK Cyclin-Dependent Kinase 
CDKN2A Cyclin-Dependent Kinase Inhibitor 2A 
C/EBPa CCAAT-Enhancer Binding Protein 
CFSE Carboxyfluorescein Diacetate, Succinimidyl Ester 
ChIP Chromatin Immunoprecipitation 
CtBP C-Terminal Binding Protein 
CTL Cytotoxic T Lymphocyte 
ctrl Control 
CpG Cytosin-Phosphate-Guanin 
ddH20 Double Distilled Water 
DDR DNA Damage Response 
DMSO Dimethyl Sulphoxide 
DNA Deoxyribonucleic Acid 
DNMT Dna Methyltransferase 
EBER EBV-Encoded RNA 
EBNA EBV-Associated Nuclear Antigen 
EBV Epstein-Barr Virus 
E3
CtBP
 EBV-BAC or virus genome lacking all CtBP-binding sites among the EBNA3s 
E.coli Escherichia Coli 
ECL Enhanced Chemiluminescence 
EDTA Ethylenediamine Tetra-Acetic Acid 
EED Embryonic Ectoderm Development 
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EGFR Epidermal Growth Factor Receptor 
EtBr Ethidium Bromide 
EtOH Ethanol 
EZH 1/2   Enhancer Of Zeste Homolog  1/2 
FACS Fluorescence-Activated Cell Sorting 
FC Flow Cytometry 
FCS Foetal Calf Serum 
G1 Gap 1 
GC Germinal Centre 
GFP Green Fluorescent Protein 
Gp Glycoprotein 
H Histone 
h Hour 
H3K27me3 Trimethylation of lysine 27 at histone 3 
H3K4me3 Trimethylation of lysine 4 at histone 3 
HDAC Histone Deacetylase 
HL Hodgkin Lymphoma 
HPV Human Papilloma Virus 
HT 4-Hydroxytamoxifen 
IM Infectious Mononucleosis 
IP Immunoprecipitation 
JMJD3 Jumonji Domain Containing 3, Histone Lysine Demethylase 
JNK C-Jun NH(2)-terminal protein Kinases 
kDa Kilodaltons 
KO Knock-out 
KPB Potassium Phosphate Buffer 
KSHV Kaposi Sarcoma Herpesvirus 
LB Luria-Bertani Broth 
LCL Lymphoblastoid Cell Line(s) 
LCV Lymphocryptovirus 
lincRNA Long Intergenic Non-Coding Rna 
LMP Latent Membrane Protein 
LP Leader Protein 
LSD1 Lysine-Specific Demethylase 1 
mAb Monoclonal Antibody 
mRNA Messenger RNA 
MEK Mitogen-Activated or Extracellular Signal–regulated protein kinase Kinase 
min Minutes 
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miR MicroRNA 
ncRNA Non-Coding RNA 
NCR143/145   Non-Coding RNA precursor of Mir-143/145 
NFkB Nuclear Factor Kappa-light-chain-enhancer of activated B cells 
NK Natural Killer 
NPC Nasopharyngeal Carcinoma 
NP40 Nonidet P-40 
NuRD Nucleosome Remodelling and histone Deacetylation 
OIS Oncogene Induced Senescence 
oriP Origin Of Replication 
p or pp Page(s) 
PAGE Poly-Acrylamide Gel Electrophoresis 
PBL Peripheral Blood Lymphocytes 
PBS Phosphate Buffered Saline 
PBS-T Phosphate Buffered Saline Containing 0.5% V/V Tween 20 
PcG Polycomb Group proteins 
PCR Polymerase Chain Reaction 
PI Propidium Iodide 
PMSF Phenyl Methyl Sulphonyl Fluoride 
Pol II RNA Polymerase II 
ppRb Hyperphosphorylated Rb 
pRb Hypophosphorylated Rb 
PRC Polycomb Repression Complex 
PTLD Posttransplant Lymphoroliferative Disorder 
Rb Retinoblastoma Protein 
RBPJk/CBF1 Recombinant Binding Protein J Kappa/C-Promoter Binding Factor-1 
rev Revertant 
rev
CtBP
 EBV-BAC or virus genome with all CtBP- binding sites among the EBNA3s reverted to 
WT 
RIP RNA Immunoprecipitation 
RNA Ribonucleic Acid 
RPMI Roswell Park Memorial Institute Medium 
RREB1 Ras-Responsive Element-Binding Protein 
qPCR Quantitative PCR 
RT Room Temperature 
S Synthesis 
SB Superbroth 
SD Standard Deviation 
SDS Sodium Dodecyl Sulphate 
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seq Sequencing 
Ser 5 Serine 5 (of Pol II) 
shRNA Short-Hairpin RNA 
SILAC Stable Isotope Labeling of Amino acids in Cell culture 
SV40 Simian Virus 40 
TAP Tandem Affinity Purification 
TBE Tris-Borate-EDTA 
TE Tris-EDTA 
TEMED Tetramethylethylenediamine 
TF Transcription Factor 
TGFβRII Transforming Growth Factor  Beta Receptor II 
TLDA Taqman quantitative real-time PCR Low Density Array 
TNF Tumour Necrosis Factor 
TPA Tetradecanoylphorbol Acetate 
TR Terminal Repeats 
TSG Tumour Suppressor Gene 
Tween 20 Polyoxyethylenesorbitanmonolaurate 
UTX Ubiquitously Transcribed TPR protein on the X chromosome 
v/v Volume by Volume 
WB Western Blotting 
WT Wild-Type 
w/v Weight by Volume 
3A
CtBP
 EBV-BAC or virus  containing mutated  CtBP- binding sites in EBNA3A 
3CHT EBV-BAC or virus containing EBNA3C-HT fusion  
3C
CtBP
 EBV-BAC or virus containing a mutated CtBP- binding site in EBNA3C 
7-AAD 7-Amino-Actinomycin D 
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Epstein - Barr virus (EBV) epidemiology and transmission 
 
EBV (also known as Human Herpesvirus 4, HHV-4) is a large DNA virus belonging to the 
genus Lymphocryptovirus (LCV), in the subfamily Gammaherpesvirinae, family 
Herpesviridae. EBV co-evolved with the human species for millions of years. LCV are 
found only in primates, with EBV representing the only LCV that infects humans. 
Seroepidemiologic surveys indicate that EBV latently infects approximately 90% of the 
world population (Kutok and Wang, 2006). 
 
EBV is spread from host to host mostly through saliva and the subsequent infection of both 
the epithelial cells and B lymphocytes in Waldeyer’s ring (Crawford, 2001). Primary 
infection with EBV occurs usually in early childhood and is asymptomatic; if delayed until 
adolescence it may manifest as a benign lymphoproliferative syndrome known as infectious 
mononucleosis (IM) (Crawford, 2001). Primary infection is controlled by the immune system 
and the distinguishing symptoms of IM, such as lymphadenopathy and splenomegaly, are 
largely the manifestation of this immune response (Long, Taylor and Rickinson, 2011).  
 
Even though EBV elicits a robust immune response consisting mainly of cytotoxic T 
lymphocytes (CTL), EBV is still not eliminated from the body but establishes a life-long 
latent infection in the memory B cell compartment (Crawford, 2001; Kutok and Wang, 
2006). Healthy EBV carriers display stable numbers of EBV-infected B cells in the blood 
(0.5–50 per million) and low level of active EBV replication in the cells of the oropharynx 
(Thorley-Lawson, 2001). In the immunocompetent individuals, equilibrium between virus 
infection and the host immune system is established and EBV latency in the majority of 
carriers has no serious sequel throughout life. However, the more impaired the immune 
system of the host, the more substantial are the consequences of EBV reactivation 
(Lazzarino et al., 1999; Preiksaitis and Keay, 2001). 
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EBV structure and life cycle 
 
The EBV virion consists of a linear, double-stranded, approximately 184-kb DNA genome 
located within an icosahedral capsid coated with a glycoprotein-carrying lipid envelope 
(Johannsen et al., 2004). The genome comprises short and long unique sequence domains 
that contain almost all the genome coding capacity, as well as internal and terminal tandem 
and reiterated direct repeats. EBV genome becomes circular for replication and persists in 
the nucleus of a latently infected cell extrachromosomally as several plasmid copies 
(episomes) (Hung, Kang and Kieff, 2001). The number of joined terminal repeats in the 
episome after circularization remains stable in all daughter cells derived from a single 
infected cell and can therefore distinguish clonal infection events (Katz, Raab-Traub and 
Miller, 1989). 
 
An EBV major surface glycoprotein is a 350 kD antigen which binds the CD21 receptor on 
B cells and determines EBV’s tropism for B cells. Another envelope glycoprotein, gp42, 
mediates the fusion between the virus envelope and the host cell membrane. EBV can gain 
entry also into various types of CD21-negative cells, such as T lymphocytes, mesenchymal 
cells and epithelial cells, but the mechanism is less well understood (Kutok and Wang, 
2006; Shannon-Lowe et al., 2006;  Shannon-Lowe and Rowe, 2011).  
 
EBV infection of epithelial cells generally results in virus production and cell lysis, whereas 
the infection of B lymphocytes leads to activation of B cells into proliferating B blasts 
associated with the establishment of EBV latency. During lytic replication, about 80 viral 
proteins are expressed in a defined temporal order, including viral capsid antigens as the 
late gene products. EBV virions assemble in the nucleus and acquire the envelope by 
budding from the cell membrane (Kieff and Rickinson, 2007). 
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Apart from the lytic replication, EBV is able to execute several latency-associated gene 
expression programmes depending on the usage of different latency promoters (Table 1.1) 
(Klein, Kis and Klein, 2007). The expression of viral products is highly restricted during 
latency, with maximum of only 9 proteins and several RNA species. These comprise six 
nuclear (EBNAs) and three integral latent membrane proteins (LMPs), viral microRNA 
transcripts from the BamHI A region (BARTs) and non-polyadenylated EBV-encoded small 
RNAs (EBERs). In addition, it has been demonstrated recently that BHRF1, a viral 
homologue of the large BCL-2 family of proteins, usually associated with lytic EBV 
infection, might be a latent protein (Kelly et al., 2009). Furthermore, transient expression of 
several viral lytic genes that do not belong to the 'classical' latent subset is found early after 
infection of B lymphocytes with EBV (Kalla and Hammerschmidt, 2012). 
In latency, the EBV episome is replicated by cellular DNA polymerase and distributed to 
daughter cells after cell division (Schaefer, Strominger and Speck, 1997; Thorley-Lawson, 
2001). 
 
Expression programme EBV genes expressed 
Latency III (the growth programme) 
EBERs, BARTs, EBNAs (-LP, -2, -3A, -3B, -3C, and -1), 
LMPs 
Latency II (the default programme) EBERs, BARTs, EBNA1, LMP1, LMP2A 
Latency I EBERs, BARTs, EBNA1 
Latency 0 EBERs, BARTs 
 
Table 1.1. EBV latency-associated expression programmes that have been identified 
(Thorley-Lawson, 2001). EBERs: EBV encoded small RNAs, BARTs: Bam HI A rightward 
transcripts, EBNAs: EBV nuclear antigens, LMPs: latent membrane proteins  
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EBV persistence and B cell life cycle 
 
In vivo, establishment of EBV persistent infection is closely connected with the maturation 
and differentiation of its host cell – the B lymphocyte (Thorley-Lawson, 2001). B cell 
maturation begins in the bone marrow and consists of the development of functional 
receptors and the testing for and elimination of self-reactive receptors.  Mature naive B 
cells move to secondary lymphoid organs, such as lymph nodes and spleen, which 
efficiently trap antigens for exposure to T and B lymphocytes. Following encounter with the 
antigen, B cells are activated by CD4+ T cells in the germinal centres of the secondary 
lymphoid organs and differentiate into plasma cells or memory B cells (Thomas, Srivastava 
and Allman, 2006).  
EBV resides long-term in memory B cells; however, to reach this compartment for life-long 
persistence, EBV infects resting naive B cells and, mimicking antigen-induced activation, 
drives these to proliferate as activated B blasts. EBV-infected B blasts probably migrate 
into germinal centres, where they differentiate to become centroblasts, centrocytes and 
finally long-lived resting memory B cells (Thorley-Lawson, 2001; Thorley-Lawson, Duca 
and Shapiro, 2008). 
The differentiation of EBV-infected B cells is accompanied by the regulated shut-down of 
EBV gene expression by epigenetic silencing of EBV promoters and enables EBV 
persistence in an organism with an intact immune system. The full growth programme or 
latency III is expressed only transiently in the naive B cells after infection and activation 
with EBV. A portion of the EBV-activated B blasts undergoes germinal centre reaction. In 
germinal centres, the restriction of EBV protein expression continues reaching latency II. 
Out of centroblasts and centrocytes, some mature into memory cells that remain for the life 
of an individual. Within such cells EBV can persist without expressing any of its proteins 
(Küppers, 2003). 
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EBV-associated tumours 
 
EBV was the first virus associated with human neoplasia when in 1964 Anthony Epstein, 
Bert Achong and Yvonne Barr discovered EBV particles by electron microscopy in the 
specimens of Burkitt lymphoma (BL) (Pagano, 1999). To this day, EBV has been linked 
with a wide range of tumours of lymphoid and epithelial origin, including BL, Hodgkin 
lymphoma (HL), post-transplant lymphoproliferative disorder (PTLD), AIDS-associated 
lymphomas, rare cases of T cell and NK-cell lymphoma, nasopharyngeal carcinoma (NPC) 
and gastric carcinoma. EBV-associated carcinogenesis is often linked to 
immunosuppression, but occurs also in individuals with no apparent defect in immunity 
(Thompson and Kurzrock, 2004). 
EBV likely plays a role in the early phases of tumour development since homogeneous 
EBV episomes were detected with the use of the virus termini assay in several EBV-related 
tumours (HL, NPC and BL), suggesting that they develop from a single cell that was 
infected by EBV before the outgrowth (Dolcetti and Carbone, 2010). EBV is probably the 
most efficient transforming virus in culture, transforming >50% of resting primary B cells 
into continuously proliferating lymphoblastoid cell lines (LCL) that always express the full 
growth programme (latency III) (Young and Rickinson, 2004; Thorley-Lawson and Allday, 
2008). However, only a small proportion of immunocompetent EBV carriers develop 
a malignancy and in the majority of the hosts latent EBV persists without serious health 
consequences.  This is most likely a result of mutual adaptation of the virus and its host 
throughout their co-evolution. EBV-associated malignancies cluster in certain populations 
and cultures due to genetic susceptibility to viral carcinogenesis (e.g. NPC in natives of 
southern China, Southeast Asia, the Arctic, and the Middle East/North Africa) or in certain 
geographical regions where EBV co-operates in carcinogenesis with other factors such as 
malaria (e.g. BL in equatorial Africa) (Hoppe-Seyler and Hoppe-Seyler, 2011).   
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EBV-associated B cell tumours exhibit different patterns of EBV gene expression according 
to their origin; the tumours retain characteristics of the original B cell type and its location 
(Thorley-Lawson and Gross, 2004). BL originates from germinal centre or post-germinal 
centre B cells blocked from exiting the cell cycle in the memory compartment (latency I), HL 
arises from germinal centre or post-germinal centre B cells that express the centrocyte 
EBV latency II programme and PTLD arises from naive, memory or post-germinal centre B 
cells which are activated by EBV and express the latency III programme (Fig. 1.1) (Thorley-
Lawson and Gross, 2004). 
 
 
 
Fig. 1.1. The origin of EBV-associated tumours (reproduced from Thorley-Lawson and Gross, 
2004).  EBV mimics the signals provided by antigen and CD4+ T cells to enter memory B cell 
compartment by normal B cell differentiation pathway. EBV-related lymphomas originate from EBV-
infected B cells arrested in different stages of differentiation. HL arises from a virus-infected cell that 
is blocked at the germinal-center stage; BL arises from a germinal-center cell that is entering the 
memory compartment but is driven by EBV to keep proliferating. Any B cell other than the tonsilar 
naive B cell (bystander B-cell) that becomes infected by EBV and expresses the growth programme 
cannot differentiate out of the cell cycle and,  if not destroyed by CTLs, can lead to PTLD (Thorley-
Lawson and Gross, 2004). 
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Endemic BL is an EBV-associated B cell lymphoma occurring in children in Africa which 
manifests mostly as facial tumours. BL exists also in a non-endemic or sporadic variant 
which usually presents as abdominal tumours, occurs world-wide and can be EBV-positive 
or negative (Ferry, 2006). The consistent causative lesion in all cases of BL was identified 
to be Ig/myc chromosomal translocation between the c-MYC oncogene and either the 
immunoglobulin heavy chain gene (80% of cases), the kappa light chain loci (15% of 
cases), or the lambda light chain loci (5% of cases) (Kutok and Wang, 2006; Thorley-
Lawson and Allday, 2008). Similar to BL, EBV also contributes to the development of only a 
proportion (30-50%) of HL. In HL, malignant Hodgkin-Reed Sternberg cells typically 
comprise less than 1–2% of the total tumour mass, while the remainder is formed by non-
neoplastic cell populations in lymph nodes (Flavell and Murray, 2000; Gallagher et al., 
2003). The transformation process of Hodgkin-Reed Sternberg cells is not yet fully 
understood, and is thought to involve a combination of EBV-mediated constitutive NFkB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) activation, and EBV-
unrelated acquisition of apoptosis-resistant phenotype and increased genetic instability 
(Thomas et al., 2002). 
PTLD consists of LCL-like cells that express the full growth programme since the CTL 
response to latent proteins is not adequate. PTLD is a frequent complication of iatrogenic 
immunosuppression; it arises in up to 10% of solid organ transplant recipients and its 
incidence relates directly to the degree and length of immunosuppression. Early lesions are 
polyclonal; the tumours arise multifocally in extranodal sites, usually affecting the 
transplanted organ or gastrointestinal tract and exhibiting aggressive behaviour associated 
with high mortality (Taylor, Marcus and Bradley, 2005). The treatment options are either the 
reduction or withdrawal of immunosuppression, often associated with graft loss, or transfer 
of autologous (or even allogeneic) EBV-specific CTL (Taylor, Marcus and Bradley, 2005). 
AIDS-associated lymphomas form a more heterogeneous group of tumour types and their 
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association with EBV is more variable and dependent on the type of tumour (Kutok and 
Wang, 2006). 
EBV latent antigens 
 
As opposed to majority of other human tumour viruses, EBV episomes persist in latently 
infected cells and EBV-associated tumour cells without DNA integration and the 
consequences of insertional mutagenesis (Groger, Morrow and Tykocinski, 1989). EBV 
uses its viral proteins, which in part mimic several cellular growth factors, transcription 
factors, and antiapoptotic factors, to create a favourable environment for persistence of the 
virus within the host cell.  
EBV genome encodes at least 86 genes but only a fraction is necessary for the 
transformation and immortalization of primary B cells into LCL. Specifically EBNA1, 
EBNA2, LMP1, and EBNA3C are absolutely required (Young and Murray, 2003). Although 
the primary role of EBNA1 is in episome maintenance, it might also promote malignant 
transformation by conferring higher resistance to apoptosis in the context of c-MYC 
translocation and by promoting telomere dysfunction via induction of oxidative stress 
(Kamranvar and Masucci, 2011). EBNA2 and LMP1 are often considered to be the EBV 
principal oncoproteins. EBNA2 is partially interchangeable with an activated Notch receptor 
(Notch-IC), exploits the Notch signalling pathway and through the interaction of DNA-bound 
RBPJk/CBF1-complex transactivates a subset of Notch-regulated cellular promoters, 
including the c-MYC promoter (Gordadze et al., 2001; Kohlhof et al., 2009). In addition to 
transactivation of cellular genes, EBNA2 together with cellular transcription factors creates 
the LMP-1 promoter activating complex (Wang et al., 1990; Wang, Grossman and Kieff, 
2000). LMP1, in a similar manner to CD40, acts as constitutively active TNF-receptor, 
leading to induction of NFkB and c-Jun NH(2)-terminal protein Kinases (JNK) pathways 
(McFarland, Izumi and Mosialos, 1999; Wan et al., 2004).  
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EBV nuclear antigens EBNA3C and EBNA3A 
 
EBNA3s are thought to have arisen from the tandem duplication events of a single EBNA3 
gene during evolution of EBV. The proteins they encode – EBNA3A, B and C originate from 
a large transcript under the control of W or C promoter (Wp, Cp), that is spliced and 
translated to produce all six EBNAs (Fig. 1.2) (Young and Murray, 2003; Kelly et al., 2006; 
White et al., 2010). EBNA3s are expressed as a part of the latency programme III in vitro. 
In vivo, cells expressing latency III programme including EBNA3C and EBNA3A have been 
found in blood during acute IM, but not in the blood of healthy or immunosuppressed 
individuals during persistent infection (Tierney et al., 1994; Miyashita et al., 1997; Babcock 
et al., 1999). 
 
EBNA3B is not essential for EBV-mediated B cell immortalization in vitro (Chen et al., 
2005) and was not investigated in this project. EBNA3A was traditionally considered 
essential for immortalization (Tomkinson, Robertson and Kieff, 1993; Farrell, 1995); 
however, it has been shown recently that EBV-BAC with the deletion of the entire EBNA3A 
open reading frame can still immortalize primary B cells, although with lesser efficiency and 
slower outgrowth of the newly established LCL in comparison to LCL established with wild-
type (WT) EBV-BAC viruses (Hertle et al., 2009; Skalska et al., 2010; Rob White, personal 
communication). However, EBNA3C appears to be absolutely essential for immortalization 
(Maruo et al., 2009; Rob White, personal communication). 
 
Because of their large size (>900 aa), and the probability that large regions are unfolded, 
full-length EBNA3C and EBNA3A proteins have thus far proven refractory to structural 
analysis and determination of crystal structure. However, it has been established that 
EBNA3C contains a proline-rich and glutamine-proline-rich domains and a leucine zipper, 
bZIP domain. A leucine zipper is usually part of the DNA-binding domain in various 
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transcription factors; however the bZIP domain of EBNA3C is an atypical leucine zipper 
which does not appear to mediate DNA binding. The EBNA3C bZIP domain has been 
implicated in EBNA3C self-association and oligomerization, as well as in the interaction 
with transcription factor RBPJk /CBF1 (West et al., 2004).  
The concentration of EBNA3A and EBNA3C transcripts in a cell at any given time is 
estimated to be only one or few copies, however the protein half-life of both molecules is 
relatively long (>24h) (Touitou et al., 2005). 
 
Fig. 1.2. EBV episome and its latency-associated transcripts (reproduced from Young and 
Murray, 2003). The figure depicts the location and transcription of the EBV latent genes on the 
double-stranded viral DNA episome. The solid blocks represent coding exons for each of the latent 
proteins and the arrows indicate the direction in which they are transcribed. EBNA3s (together with 
the nuclear antigens EBNAs 1, 2 and –LP) are produced from the long transcript common for all six 
EBNAs and initiated from adjacent promoters Cp and Wp. EBNA-LP transcripts contain variable 
numbers of repetitive exons. During latency I and II, EBNA1 transcripts are transcribed from Qp (as 
opposed to Cp or Wp). LMPs 1 and 2 are transcribed from independent EBNA2-activated promoters. 
LMP2A and LMP2B transcripts consist of multiple exons located on either side of the terminal 
repeats (TR) region. EBV small RNAs EBER1 and EBER2 originate from the part of the genome 
adjacent to the EBV origin of replication (oriP), while BamA region of the EBV genome gives rise to 
multiple EBV microRNAs (Young and Murray, 2003). 
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EBNA3C and EBNA3A function as transcriptional regulators modulating the expression of 
both viral and cellular genes (Waltzer et al., 1996; Young et al., 2008; Zhao et al., 2011a). 
EBNA3C and EBNA3A are thought to contribute to the switch from latency III to latency II 
by epigenetic silencing of the Cp and Wp (Thorley-Lawson and Allday, 2008).  EBNA3C 
and EBNA3A both serve as a negative regulator of EBNA2 expression and/or function. 
EBNA2 extensively associates with the Notch-regulated transcription factor (TF) 
RBPJk/CBF1 (Johannsen et al., 1996; Waltzer et al., 1996). In the absence of EBNA2, 
RBPJk/CBF1 acts as a repressor through recruitment of repressive chromatin remodelling 
complexes. EBNA2 binding to RBPJk/CBF1, together with other co-activators, leads to 
gene activation (Young and Rickinson, 2004). EBNA3 proteins have the capacity to 
compete with EBNA2 for RBPJk/CBF1 binding and repress EBNA2 activation of Cp, 
limiting the “feed forward” upregulation of EBNA2 expression (Johannsen et al.,1996).  The 
association of EBNA3C and EBNA3A with RBPJk/CBF1 is essential for the growth of LCL 
(Maruo et al., 2005 and 2009).   
EBNA3C and EBNA3A exhibit robust repressor activity when targeted directly to DNA by 
fusion with the DNA-binding domain of Gal4. EBNA3C binds HDAC1 (Radkov et al., 1999; 
Knight et al., 2003), while both EBNA3C and EBNA3A bind the co-repressor of 
transcription CtBP (Touitou et al., 2001; Hickabottom et al., 2002).  
In primary rodent fibroblasts, EBNA3C and EBNA3A have both been shown to be 
oncogenic in cooperation with activated Ras, similar to oncoproteins of small DNA viruses 
such as HPV E7 or adenoviral E1A (Touitou et al., 2001; Hickabottom et al., 2002). 
EBNA3C has been reported to bind the retinoblastoma protein (Rb) and via an SCF 
ubiquitin ligase may direct the proteasome-mediated degradation of Rb. It can interact with 
cyclin A (and perhaps other cyclins) and may modulate the activity of p27KIP1 (Knight et al., 
2004; Knight, Sharma and Robertson, 2005). EBNA3C is thought to directly bind to the 
tumour suppressor protein p53 and block its transcriptional activity. EBNA3C might also 
suppress p53 function by additional mechanisms including interaction with p53-regulatory 
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proteins, the inhibitor of growth family proteins ING4 and ING5, and stabilization of MDM2, 
a negative regulator of p53 (Saha et al., 2009 and 2011). 
 
EBNA3C overexpression was shown to disrupt the mitotic spindle checkpoint and induce 
nuclear division separated from cytokinesis, leading to multinucleated cells (Parker, Touitou 
and Allday, 2000). EBNA3C might facilitate the spread of damaged DNA through 
inactivation of the mitotic spindle checkpoint and transcriptional repression of BubR1 
(Gruhne, Sompallae and Masucci, 2009).  However, EBNA3C seems to be important for 
attenuation of the EBV-induced ATM/CHK2-mediated DNA damage response in the early 
phases of primary B cell transformation (Nikitin et al., 2010). 
 
The microarray studies performed in our lab revealed that EBNA3C and EBNA3A 
extensively cooperate in the regulation of a surprisingly large number of cellular genes, 
including the gene encoding the pro-apoptotic tumour suppressor BIM (Anderton et al., 
2008; White et al., 2010). Both EBNA3C and EBNA3A have been recently shown to 
repress expression of the cyclin-dependent kinase (CDK) inhibitor p16INK4A and thus 
maintain proliferation of LCL (Maruo et al., 2006; Hertle et al., 2009).  
 
CDKN2A locus in tumour suppression and senescence 
 
The CDKN2A locus in the human genome encodes two tumour suppressor proteins – 
p16INK4A and p14ARF. The transcripts of p16INK4A and p14ARF consist of a unique first exon 
and shared second and third exons. However, the proteins are structurally unrelated since 
p14ARF utilizes an alternative reading frame to that used for p16INK4A.  In different contexts, 
these tumour suppressors can be activated and repressed by various agents 
independently, or sometime co-regulated (Gil and Peters, 2006). CDKN2B locus located 
just upstream of CDKN2A encodes p15INK4B, another tumour suppressor with functions 
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similar to p16INK4A (see below).  In addition, a non-coding RNA termed ANRIL is transcribed 
antisense to the INK4-ARF locus. The ANRIL gene (CDKN2B-AS) contains 20 exons, 
spans a region of 126.3 kb, and gives rise to approximately 4kb-long transcripts in the 
antisense orientation of the p15INK4B- p16INK4A - p14ARF gene cluster (Pasmant et al., 2007).  
 
 
 
Fig. 1.3. Genomic organization of CDKN2A in relation to CDKN2B and CDKN2B-AS (ANRIL) 
loci (reproduced from Pasmant et al., 2007). Boxes represent exons. p16
INK4A
 protein is encoded 
by exons 1α, 2, and 3 of p16/CDKN2A, whereas p14
ARF
 protein is encoded by exon 1β, spliced to 
exons 2 and 3 of p16/CDKN2A in a different reading frame and transcribed using a different 
promoter. The ANRIL gene overlaps the two exons of p15/CDKN2B and is transcribed in the 
orientation opposite to the p15
INK4B 
- p16
INK4A 
- p14
ARF
 gene cluster (Pasmant et al., 2007).  
 
 
p16INK4A is induced by DNA damage, reactive oxygen species and various other forms of 
intracellular stress. Aberrant oncogenic signals such as activated Ras also lead to p16INK4A 
induction (Macleod, 2008). p16INK4A protein is relatively stable and p16INK4A is primarily 
regulated at the level of transcription; ETS1 is the main positive transcriptional regulator of 
p16INK4A; whereas ID1 and BMI1 function as negative transcriptional regulators of p16INK4A 
(the latter also regulates p14ARF) (Ohtani, et al., 2001; Satyanarayana and Rudolph, 2004; 
Kotake, Zeng and Xiong, 2009). p16INK4A is a cyclin-dependent kinase inhibitor that 
activates the cell cycle inhibitory activity of Rb tumour suppressor by inhibiting  its 
phoshorylation either directly or indirectly. Firstly, p16INK4A binds cyclin D-dependent 
kinases CDK4 and CDK6, preventing cyclin D binding and subsequent kinase function. In 
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addition, by releasing additional CDK inhibitors p21CIP1 and p27KIP1, which are sequestered 
in cyclin D/CDK4 and CDK6 complexes, p16INK4A also suppresses CDK2 activity (Knudsen 
and Knudsen, 2008).  
 
p14ARF is generally induced by oncogenic signals or release of activating E2F factors 
(E2F1-3). It binds an E3-ubiquitin ligase MDM2 and inhibits its activity. MDM2 inhibition 
increases the stability of p53, leading either to transcriptional activation of p53-target genes 
followed by apoptosis, or more frequently to cell cycle arrest in G1 and G2 phase. Apart 
from MDM2-p53-p21CIP1- mediated arrest, p14ARF is also able to arrest cells independently 
of p53, by inhibiting the expression of a number of other transcription factors (Eymin et al., 
2003; Sherr et al., 2005; Gil and Peters, 2006; Amente et al., 2007). 
Expression of p16INK4A and p14ARF in tissues in vivo is usually low (Gil and Peters, 2006); 
however, they have been shown to increase with age in most tissues in mice and in several 
organ systems in human (including skin, kidney tissues and lymphoid progenitors) (Signer 
et al., 2008; Romagosa et al., 2011). p16INK4A has been proposed as a reliable marker of 
biological aging (i.e. aging at a cellular level) as opposed to the chronological age (i.e. age 
in years). However, p16INK4A is not merely a marker of aged tissues, but it directly promotes 
aging by limiting tissue regeneration and repair. Repression of p16INK4A and p14ARF is 
crucial for stem cell self-renewal as well as for reprogramming of differentiated cells into 
pluripotent cells (Li et al., 2009). Both p16INK4A and p14ARF are mediators of senescence, a 
state of permanent proliferative arrest and a mechanism of tumour suppression (Gil and 
Peters, 2006). 
Senescence is activated in primary untransformed cells due to telomere shortening after a 
certain number of cell divisions or prematurely as a tumour-suppressive mechanism in 
response to oxidative stress, DNA damage or aberrant mitotic (‘oncogenic’) signalling. In 
recent years, it has been shown that premature oncogene-induced senescence (OIS), 
alongside death cell programmes, prevents cells from undergoing oncogenic 
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transformation not only under the conditions of cell culture, but also in vivo. Senescent cells 
were found in human benign melanocytic nevi, precursors for melanoma, as well as in 
murine lung adenomas, T cell lymphomas and prostate tumours (Prieur and Peeper, 2008). 
Generally, OIS is found in pre-malignant or early stages of tumours and is absent in 
advanced tumours, suggesting that the tumour cells have developed mechanisms to 
bypass senescence (Larsson, 2011). Unlike apoptosis, senescence does not lead to tissue 
loss which can trigger compensatory proliferation in surrounding cells in an attempt to 
maintain tissue homeostasis (Fan and Bergmann, 2008). Senescent cells exit the cell cycle 
but stay in situ and metabolically active, influencing their neighbouring cells with active 
secretory programme. p16INK4A is thought to play a major role in tumour suppression and 
senescence in humans, and some cells depend entirely on p16INK4A for OIS. p19ARF (the 
murine homologue of p14ARF) mediates the OIS in mice; however, p14ARF seems to be less 
important in humans (Ben-Porath and Weinberg, 2005; Gil and Peters, 2006). 
 
p16INK4A is inactivated in nearly 50% of all human cancers, including pancreatic carcinoma, 
carcinoma of head and neck, oesophagus, biliary tract, liver, lung and  bladder, in colon 
and breast carcinomas; leukemia, lymphomas and glioblastomas (Romagosa et al., 2011). 
p16INK4A is inactivated predominantly by somatic homozygous deletion or p16INK4A promoter 
DNA methylation; p16INK4A  inactivation by mutation is rare (Merlo et al., 1995; Li, Poi and 
Tsai, 2011). Germline mutations and deletions in p16INK4A are found in very rare familial 
cancer syndromes, mainly familial melanoma (Hussussian et al., 1994). 
 
p16INK4A is found overexpressed in benign or pre-malignant lesions with functional p16INK4A-
Rb pathway, where it demonstrates the protective effect of OIS. However, p16INK4A is also 
overexpressed in several fully malignant cancers and the detection of p16INK4A is used as 
a diagnostic biomarker in cervical, head and neck and perinanal cancers (Romagosa et al., 
2011). In human papilloma-virus (HPV)-related neoplasms, p16INK4A  overexpression is the 
31 | P a g e  
 
consequence of Rb inactivation by HPV oncoprotein E7. In HPV-unrelated cancers, an 
inverse correlation between Rb loss and p16INK4A expression levels is also common, and 
most likely in such cases p16INK4A overexpression might also be attributed to the loss of 
negative Rb-p16INK4A feedback loop (Lu et al., 2003; Little and Stewart, 2010). 
In addition to negatively regulating the cell cycle, p16INK4A was shown to block invasion, 
angiogenesis and promote apoptosis in several cancer models. Apart from its usual 
localization in the nucleus, p16INK4A was also detected in the cytoplasm where it could 
engage in some of these additional functions (Evangelou et al., 2004; Romagosa et al., 
2011). 
Recently, the antisense non-coding RNA associated with the INK4A-ARF locus has been 
identified. The first exon of ANRIL is located in the promoter region of the p14ARF gene and 
overlaps two exons of the p15INK4B gene (Pasmant et al., 2007). At least 8 splice variants of 
ANRIL with tissue-specific expression were identified. In addition, distinct single nucleotide 
polymorphisms in the ANRIL locus seem to modulate its expression (Cunnington et al., 
2010). Several common disease genome-wide association studies showed the co-
regulation of p15INK4B, p16INK4A, p14ARF, and ANRIL gene expression in human tissues 
(Pasmant et al., 2011). Furthermore, deletion in a mouse region, homologous to the portion 
of human 9p21 that includes seven exons of ANRIL, resulted in a significantly reduced 
expression of both p16INK4A and p15INK4B in several organs and tissues through a cis-
regulatory element (Visel et al., 2010). In contrast, in a prostate cancer model, an inverse 
correlation has been found between the ANRIL and p16INK4A transcript abundance and 
ANRIL transcripts have been implicated in epigenetic repression of both p16INK4A and 
p15INK4B in cancers (Yap et al., 2010; Kotake et al., 2011).  
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G1-S checkpoint of the cell cycle 
 
Recently, Coudreuse and Nurse (2010) demonstrated in fission yeast that the eukaryotic 
core cell cycle can be built on a circuit of two CDK activity thresholds; sequence and timing 
of which are imposed by a single CDK oscillator. In eukaryotic cells, CDKs are inactive 
without binding the cyclin partner and need to be phosphoryated at the key residue. Cyclins 
are the oscillators, synthesized and destroyed in temporal order throughout the cell cycle. 
However, the long-accepted model of specific subsets of CDKs and cyclins playing distinct 
roles in each phase of the cell cycle in mammalian cells has been increasingly challenged 
recently, e.g. when a  functional cell cycle was observed in mice embryos that lack cdk2, 
cdk4 and cdk6  (Hochegger, Takeda and  Hunt, 2008). 
 
Cell cycle checkpoints are the control mechanisms that ensure the fidelity of cell division 
and warrant that alterations in the DNA molecule or incorrectly segregated chromosomes 
are not transmitted onto the daughter cell. Several switch-like checkpoints control the cell 
cycle: G1-S checkpoint is activated by either DNA damage or the DNA replication fork 
arrest, G2 checkpoint is activated if damaged DNA is detected and finally the mitosis 
checkpoint is activated by improperly connected kinetochores and spindle microtubules (de 
Bruin and Wittengerg, 2009; Malumbres and Barbacid, 2009).  
 
G1-S checkpoint regulates the transition through the G1 phase and the entry into the S 
phase of the cell cycle. The G1-specific CDK-cyclin complexes are negatively regulated by 
the members of the INK4 or KIP/CIP families of cyclin dependent kinase inhibitors. 
Following antiproliferative or aberrant pro-proliferative (‘oncogenic’) signals, the formation 
of CDK4/6-cyclin D complexes is inhibited by the members of the INK4 family such as 
p16INK4A or p15INK4B, while the CDK2 complexes with cyclins E and A are disrupted by 
p21CIP1 or p27KIP1 (Fig. 1.4) (Knudsen and Knudsen, 2008). 
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Fig. 1.4. G1-S checkpoint (reproduced from Knudsen and Knudsen, 2008).  Following mitogenic 
stimuli, the complexes of cyclin D with CDK4/CDK6 phosphorylate Rb. Rb phosphorylation is further 
augmented by the activity of CDK2 complexes with cyclins E and A. Rb phosphorylation disrupts its 
association with E2F transcription factors and enables E2F-mediated gene expression and S-phase 
progression. Anti-proliferative signals (or the inappropriate activation of certain oncogenes) induce 
p16
INK4A
 which disrupts the formation of cyclin D-CDK4/CDK6 complexes, prevents Rb 
phosphorylation and arrests the cells in the G1 phase of the cell cycle. Similarly, p21
CIP1
 and p27
KIP1
 
inhibit the formation of cyclin E/A complexes with CDK2 (Knudsen and Knudsen, 2008). 
 
Pocket protein family, Rb-E2F1 pathway 
 
The pocket protein family consists of three members - Rb, p130 and p107 which control the 
progression from G1 to S phase and prevent unscheduled entry into the cell cycle. They all 
have a pocket domain containing the motif that recognises the LxCxEx amino acid 
sequence and mediates protein-protein interactions (Dahiya et al., 2000). Pocket proteins 
exhibit some functional overlap but not complete redundancy; Rb is abundant in cells most 
of the time, whereas p107 is expressed generally in proliferating cells, and p130 in G0 
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arrested cells. Rb is a master tumour supressor mutated in 30% of all human cancers, 
while mutations of p130 and p107 are rare (Classon and Dyson, 2001). 
Rb and p107 play major roles in proliferating cells, while p130 is primarily active in G0 
arrested cells. All three proteins are regulated during the progression of cell cycle by cyclic 
phosphorylation and dephosphorylation; however, specific members of pocket proteins 
preferentially interact with distinct groups of E2F transcription factors and specific pocket 
protein/E2F complexes may regulate different subsets of target genes (Du and Pogoriler, 
2006).  
Pocket proteins are hypophosphorylated in non-cycling cells or at early G1 when they bind 
members of E2F family proteins, mask the transactivation domain of E2Fs and inhibit the 
transcriptional activation of E2F-regulated genes. Pocket protein/E2F complexes actively 
repress transcription on promoters containing E2F-binding sites through the recruitment of 
SWI/SNF complexes, histone deacetylases and other chromatin modifying enzymes 
(Ferreira et al., 2001; Zhang and Dean, 2001; Macaluso, Montanari and Giordano, 2006).  
After the phosphorylation of pocket proteins by G1-specific cyclin-CDK complexes, pocket 
protein-E2F binding is disrupted, E2F transcription factors are released and initiate 
expression of genes essential for S phase entry, DNA replication and mitosis. In the period 
from anaphase to G1, pocket proteins are re-activated by protein phosphatase 1 (Cobrinik, 
2005). They can also be activated during the active cell cycle by CDK inhibitor induction, 
down-regulation of cyclins or via protein phosphatase 2A (Cobrinik, 2005; Parisi, Bronson 
and Lees, 2009). 
At least one component of the Rb pathway (that includes D-type cyclins, CDK4 and CDK6, 
Rb itself or CDK inhibitors of INK4 family such as p16INK4A or p15INK4B  is functionally 
inactivated in the majority of cancers (Knudsen and Knudsen, 2008). 
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Genetic and epigenetic causes of cancer 
 
Cancer is the disease of cell proliferation and differentiation. It is now thought to develop 
from a population of tumour-initiating cells that have accumulated multiple alterations in 
genes regulating normal cellular turn-over, growth and differentiation. Key regulatory genes 
become either aberrantly overactive (oncogenes) or underactive (tumour suppressor 
genes, TSG). Tumour-initiating cells gain stem-cell like properties, the ability to re-grow the 
tumour and resistance to conventional cancer therapies (Zhou et al., 2009). As the tumour 
develops in time, the cell’s genetic make-up, growth properties and resistance diverge and 
the tumour becomes increasingly heterogeneous. In addition, the complexity of the tumour 
is increased with the mutual interaction between the transformed cells and their 
microenvironment or stroma consisting of epithelial cells, activated stromal cells and 
extracellular matrix (Tlsty and Coussens, 2005). 
Somatic genetic changes in cancer comprise deletion or mutation of TSG or amplification 
and activating mutations of oncogenes, including chromosomal translocations. Loss of 
heterozygosity in the case of tumour suppressors occurs in a somatic cell where the first 
allele of a gene has been inherited inactivated by a germ-line deletion/mutation and the 
remaining functional allele becomes inactivated during the lifetime of an individual (Bishop, 
1987). 
Genetic causes have been in the centre of cancer research in the past. However, research 
findings of the recent decades have shown that activation of oncogenes or inactivation of 
TSG are caused by both genetic and epigenetic alterations (Lund and van Lohuizen, 2004; 
Esteller, 2007; Sharma, Kelly and Jones, 2010). ‘Epigenetic’ is a term used to describe 
modifications other than changes of primary DNA sequence that regulate gene expression, 
are heritable during mitosis and some might be in meiosis and do not require the 
continuous presence of the initiating signal. It is the inherited genome activity that does not 
depend on the naked DNA sequence (Esteller, 2011). Epigenetic regulation links the 
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genetic background and the environment (Brower, 2011) and provides dynamic variability 
above the static genome. Epigenetic processes play an essential role during development 
and tissue differentiation, and are frequently deregulated in non-Mendelian and complex 
diseases, including cancer. Epigenetic information is stored in multiple dimensions, 
comprising DNA, RNA and protein and is mediated by DNA methylation, post-translational 
histone modifications, nucleosome remodelling and various non-coding RNA species 
(Chahwan, 2011). 
The term DNA methylation is used for the process of methylation of cytosines that precede 
guanines in CpG dinucleotides of the genome to yield 5-methylcytosine. CpGs in the 
genome are asymmetrically distributed; areas with a high frequency of CpG sites, termed 
CpG islands, are characteristic for gene promoters. In normal cells, methylation of CpG 
dinucleotides mediates the X-chromosome inactivation in females as well as silencing of 
repetitive genomic regions and parasitic elements such as endogenous retroviruses. Most 
CpG islands are generally unmethylated in normal cells (Robertson, 2005). The 
transmission of DNA methylation in mitosis is well understood. It proceeds as a templated 
copy event; the methylation pattern of the original chromatid is precisely copied by DNA 
methyltransferase DNMT1 into the newly synthesised DNA strand (Hervouet, Vallette and 
Cartron, 2010). However, the process of active demethylation is still controversial (Klug et 
al., 2010). Additional chemical modifications of DNA, such as 5-hydroxymethylcytosine and 
5-carboxylcytosine, were found in the past years and their interplay with methylcytosine 
and function in health and disease is currently being investigated (Ficz et al., 2011; He et 
al., 2011). 
Epigenetic modifications include, in addition to the chemical modifications of the DNA itself, 
the modification of the DNA-associated proteins - histones. In the nucleus, DNA must be 
heavily condensed and packaged into a tight structure. The basic packaging unit is formed 
by a nucleosome in which 147 base pairs of DNA are wrapped around an octamer of core 
histone proteins, H3, H4, H2A and H2B. About 75-90% of DNA is wrapped in nucleosomes 
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and the remaining unwrapped DNA serves as a linker DNA and is associated with the H1 
linker histone (Segal and Widom, 2009). When visualized by electron microscopy, this 
assembly appears  as beads on string -  ‘beads‘ being the individual nucleosomes and the 
‘string’ being the linker DNA (Füllgrabe, Kavanagh and Joseph, 2011).   
 
N-terminal histone tails are decorated by a variety of posttranslational covalent 
modifications including acetylation, methylation, phosphorylation, ubiquitylation, 
glycosylation, ADP-ribosylation, carbonylation and SUMOylation (Strahl and Allis, 2000). 
The functional outcome of different modifications depends on the modified residue (e.g. 
K27, K4) and the degree of modification (mono-, di-, etc.). Histone modifications work in 
concert rather than in isolation (Zhang and Reinberg, 2001; Perissi et al., 2010). The 
histone code hypothesis suggests that transcriptional outcome depends on the combination 
of various histone modifications and that distinct combinations of histone modifications 
determine specific chromatin-related functions and processes (Jenuwein and Allis, 2001). 
 
Research from recent years has clearly shown that histone modifications do not form 
a static landscape, but on the contrary, are regulated in a dynamic, reversible fashion. 
Gene transcription, DNA replication and repair all involve disruption and reassembly of the 
chromatin structure (Ho and Crabtree, 2010). The dynamic nature of chromatin is ensured 
by the families of antagonistic enzymes that add and remove histone modifications, so that 
the ‘writers’ are opposed by ‘erasers’ (e.g. methyltransferases/demethylases, 
acetyltransferases/deacetylases). Histone modifications impact on the electrostatic charge 
of the histone resulting in changes to the chromatin structure or histone binding to DNA.  
Histone acetylation and methylation play a major role in determining the degree of 
chromatin condensation and the access of transcriptional machinery, and perhaps other 
proteins, to DNA (Suganuma and Workman, 2011).  Furthermore, modified histones 
provide a selective binding platform for regulatory proteins. Many regulatory proteins 
evolved conserved domains, such as bromodomains or chromodomains, which bind 
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specific histone modifications and thus ‘read’ the histone code and mediate the 
transcriptional repression or activation (Füllgrabe, Kavanagh and Joseph, 2011). Apart 
from modification of the core histones, another level of epigenetic regulation is provided by 
histone variants with altered primary sequence and unique functions, e.g. H2AZ or H2AX 
(Khare et al., 2012). 
Non-coding RNAs involved in epigenetic regulation include a variety of species, such as 
microRNA (that will be discussed in detail later), short ncRNA (<200bp) and long ncRNAs 
(>200bp). Long mammalian ncRNAs, such as Xist, HOTAIR and Kcnq1ot1, modify 
chromatin structure by several mechanisms; they serve as a scaffold for chromatin 
remodelling enzymes or target the chromatin remodelers to the gene promoters or 
regulatory regions by carrying a sequence-specific information (Gupta et al., 2010; 
Kaikkonen, Lam and Glass; 2011). Short ncRNA also emerged as mediators of gene 
repression and heterochromatization. A group of 50-200nt short RNAs transcribed from the 
5’ end of polycomb target genes interact with polycomb repression complex (PRC) 2 
through a stem-loop structure and cause gene repression in cis. These short RNAs need to 
be depleted from polycomb target genes to allow activation during cell differentiation 
(Kanhere et al., 2010). 
Nucleosome remodelling refers to the ability of nucleosomes to alter their position at 
promoters. Depending on the exact localization on DNA, nucleosomes act as both general 
activators and repressors of gene expression (Segal and Widom, 2009). Nucleosomes are 
further arranged by long-range interactions into a higher order three-dimensional chromatin 
structure, the organization and functions of which are not yet well defined. In addition, 
entire chromosomes are arranged non-randomly in the nucleus and there seems to be 
a relationship between the organization of the nuclear space and gene transcription 
(Cremer and Cremer, 2010; Wang et al., 2011a). 
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The combinations of various modifications of specific residues at the histone tails and DNA 
methylation followed by altered nucleosome positioning govern the resulting transcriptional 
status of a gene (Kia et al., 2008; Cedar and Bergman, 2009).  Initially, the term 
‘epigenetic‘ was frequently interpreted as permanent. Recently, it has been appreciated 
that epigenetic configuration once established (at any level mentioned above) is not being 
fixed but can respond to both extrinsic and intrinsic signals.  
Epigenetic deregulation contributes to the onset and progression of cancer and seems to 
be as significant as genetic mutations. All the layers of epigenetic regulation are distorted in 
cancers. Epigenetic regulators are often inactivated by somatic genetic mutations resulting 
in alteration of the expression of multiple genes simultaneously (Tuma, 2010).   
Malignant tissues exhibit global DNA hypomethylation leading to an increase in genomic 
instability. However, the CpG islands within promoter regions of specific sets of genes, in 
normal tissues constitutively unmodified, are frequently hypermethylated in cancer 
(Esteller, 2011). Tumour suppressor genes such as hMLH1, BRCA1, VHL, Rb, p16INK4A, 
p14ARF, and p15INK4B are more frequently inactivated by such anomalous promoter 
methylation than by mutation. Increased methylation in cancer also affects the regions with 
lower CpG density up to 2000 base pairs distant from CpG islands, termed CpG island 
shores (Irizarry et al., 2009). DNA methyltransferases DNMT3A and DNMT3B, mediating 
‘de novo’ DNA methylation, are frequently differentially expressed or mutated in cancers. 
The aberrations of histone modifications in cancer occur either locally at promoters by 
improper targeting of histone-modifying activities or globally at the level of the whole nuclei. 
Global deacetylation and methylation of specific residues at histones H3 and H4 is 
a hallmark of cancer and includes global loss of acetylation of histone H4 at lysine 16 
(H4K16ac), hypoacetylation of histone H4 lysine 12 (H4K12ac), loss of  H4K20me3, and 
H3K18ac (Ellis, Atadja and Johnstone, 2009; Niller, Wolf and Minarovits, 2009; Füllgrabe, 
Kavanagh and  Joseph, 2011). Global changes of histone modifications are a result of 
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deregulated epigenetic master regulators, such as amplification or mutation in 
deacetylases or EZH2 (Esteller, 2011). The consequences of altered histone modifications 
include genomic instability and aberrant gene expression, i.e. overexpression of oncogenes 
and loss of TSG expression, which result in the incompetence of the cell cycle checkpoints 
and DNA repair (Füllgrabe, Kavanagh and Joseph, 2011).  
A strong link has been identified between the characteristics of the embryonic stem cells 
and the profile of epigenetic deregulation arising in cancer. Genes encoding tumour 
suppressor proteins and microRNAs that become aberrantly methylated and repressed in 
cancers seem to be pre-marked by the bivalent domains (see below) in embryonic stem 
cells. Cancer cells, or the subpopulation of tumour-initiating cells, by mimicking the 
embryonic gene expression programme, retain inappropriate self-renewal capacity and 
multi-lineage potential (Iliou et al., 2011). 
 
Epigenetic regulation of p16INK4A locus 
 
The p16INK4A promoter region is epigenetically regulated by an interplay of repressive 
modification - trimethylation of lysine 27 at histone H3 (H3K27me3) and activating 
trimethylation of lysine 4 at histone H3 (H3K4me3) in human stem cells (Li et al., 2009), 
primary fibroblasts (Barradas, et al., 2009) and cancer cells (Kia et al., 2008) alike.  
H3K27me3 and H3K4me3 modifications co-localize at the p16INK4A promoter and form a 
bivalent chromatin domain. Bivalent domains carry the potential of the alternate 
transcriptional status. Such domains are thought to silence certain genes while keeping 
them poised for rapid activation (Bernstein et al., 2006; Krivtsov and Armstrong, 2007). In 
differentiated cells, activated genes lose H3K27me3; while gene sets which encode 
functions that are irrelevant for a particular cell identity retain H3K27me3 and remain 
repressed.  
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Polycomb group proteins (PcG), that establish the H3K27me3 mark, control the expression 
of hundreds of genes with roles in differentiation, development and cell proliferation. In 
vertebrates, PcG assemble into two discrete complexes. The minimal subunit of the 
polycomb repression complex 2 (PRC2) consists of EED, SUZ12, RbAp46/48 and histone 
methyltransferase EZH2 (or EZH1 in certain cell types) which methylates H3K27 (Simon 
and Kingston, 2009). H3K27me3 is a very stable and abundant histone modification that 
results from monomethylation of H3K27me2. With exception of a single viral protein 
(Paramecium bursaria Chlorella Virus 1 methyltransferase), PRC2 containing either EZH2 
or EZH1 is the only complex found so far that both di- and tri-methylates H3K27. It is likely 
that mono-methylation of H3K27 is catalyzed by a complex different from PcG (Margueron 
and Reinberg, 2011).   
Although the core components EZH1/2, SUZ12, EED and RbAp46/48 are conserved 
across species, several other components of PRC2 in mammals have been identified 
recently, including JARID2, AEBP2 and  PCL (Nekrasov et al., 2007; Kim, Kang and Kim, 
2009; Li et al., 2010). These additional components do not seem to be strictly required for 
PRC2 enzymatic activity in vitro but are necessary for optimum PRC2 activity in vivo. 
Another polycomb repressive complex PRC1 includes BMI1, RING1A/B, and CBX family 
proteins (CBX2, CBX4, CBX6, CBX7, and CBX8) (Vincenz and Kerppola, 2008; 
Schuettengruber et al., 2009). It has been generally accepted that PRC1 is recruited by 
methylated H3K27 and acts downstream of PRC2 as a direct executor of silencing. The 
chromodomains of CBX family proteins can specifically recognize H3 trimethylated on K27, 
while the PRC1 ubiquitin ligases, RING1A and RING1B, monoubiquitylate Lys 119 of 
histone H2A (H2AK119ub). H2AK119ub restrains poised RNA Polymerase II (Pol II) at 
bivalent promoters and inhibits transcriptional elongation (Sugamuna and Workman, 2008; 
Tiwari et al., 2008; Simon and Kingston, 2009).  
However, recently, the redundancy of PRC1 and PRC2 in gene repression was described 
and it was suggested that both complexes might act in parallel (Leeb et al., 2010).  Both, 
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genes targeted by PRC2 that lack H2AK119ub, and genes targeted by PRC1 in the 
absence of PRC2, were found (Schoeftner et al., 2006; Ku et al., 2008; Margueron and 
Reinberg, 2011). PRC2 with the H3K27me3 mark and PRC1 complexes separately have 
the ability to compact the chromatin structure and silence the target genes (Eskeland et al., 
2010). 
Targeting of PRC complexes to the mammalian gene promoters is not yet fully understood. 
In Drosophila, PRC dock at the composite DNA elements termed polycomb response 
elements; however, similar DNA motifs in mammals involved in the global targeting of 
polycomb were not identified. Recent studies point to the role of sequence-specific TFs 
and/or non-coding RNA, acting either in trans or in cis (Bracken and Helin, 2009). The 
transcript antisense to INK4/ARF - ANRIL - has been implicated in direct epigenetic 
repression of p16INK4A. ANRIL was shown to bind to PRC1 component CBX7 and mediate 
the recruitment of the polycomb proteins to the CDKN2A locus (Yap et al., 2010). 
The repression of p16INK4A is mediated by PcG in both humans and mice. The p19ARF (the 
mouse homologue of p14ARF) is repressed by PcG in mice; however it is unclear whether 
PcG play equally important roles in  p14ARF repression in human cells (Kotake et al., 2007; 
Barradas et al., 2009). 
Trithorax group proteins were identified in Drosophila as antagonists of the PcG silencers. 
Trithorax group proteins function in transcriptional activation and form complexes similar to 
PcG but less well defined. H3K4 methylation is established by the SET1 and MLL family of 
histone methyltransferases (Ruthenburg et al., 2007). MLL1, MLL2, MLL3, MLL4, MLL5, 
Set1A and Set1B each contains a SET domain mediating H3K4-specific methyltransferase 
activity; however, their mechanism of action, target genes and the distinct functions of 
different MLLs are still unclear (Ansari and Mandal, 2010). MLL complexes catalyze   
mono-, di- and trimethylation of H3K4 and each of these modifications has distinct 
functions (Cosgrove and Patel, 2010). 
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During the induction of p16INK4A, whether oncogene-induced or senescence-associated, 
PRC1 and PRC2 complexes are removed from the p16INK4A locus and the H3K27me3 mark 
at the p16INK4A promoter decreases. This is in some cases accompanied by the recruitment 
of trithorax MLL1 activators and the concomitant increase in the H3K4me3 mark (Agherbi 
et al., 2009; Kotake, Zeng and Xiong, 2009). For example, in the rhabdomyosarcoma cell 
line lacking functional SWI/SNF chromatin remodelling complexes, the reconstitution of 
SWI/SNF function leads to eviction of PcG silencers and loss of H3K27 trimethylation, 
simultaneously with MLL1 recruitment and H3K4 trimethylation, resulting in p16INK4A 
induction (Kia et al., 2008). The H3K27me3 demethylase JMJD3/KDM6B contributes to 
plasticity of the p16INK4A locus, and functions in a switch from the repressive chromatin in 
response to oncogenic stress (Agger et al., 2009; Barradas et al., 2009).  Functional Rb, 
which negatively regulates p16INK4A expression, may collaborate with PcG on p16INK4A 
repression via H3K27me3 (Kotake et al., 2007).   
Additionally, it has been demonstrated that overexpression of an essential regulator of DNA 
replication, CDC6, represses the entire CDKN2A locus (together with the neighbouring 
CDK inhibitor p15INK4B) through recruitment of histone deacetylases and H3K9 methylation 
(Gil and Peters, 2006; Borlado and Mendez, 2008). 
In a variety of cancers, including lung, colon and prostate carcinomas as well as 
lymphomas, p16INK4A promoter undergoes DNA methylation; p16INK4A is one of the most 
frequently aberrantly methylated genes in cancer (Das and Singal, 2004).  
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C-terminal binding protein (CtBP) family 
 
The CtBP family in vertebrates consists of two proteins CtBP1 and CtBP2 which are largely 
homologous (henceforth referred to as CtBP). CtBP major splice variants function 
predominantly as transcriptional co-repressors in the nucleus, while the minor splice 
isoforms perform various cytosolic functions. A range of DNA binding TFs recruit CtBP 
through a PLDLS motif to which CtBP binds; CtBP forms dimers to bridge the proteins 
containing PLDLS motifs (Chinnadurai, 2009). 
CtBP is found in the supercomplexes consisting of enzymes mediating co-ordinated 
epigenetic modifications that are targeted by CtBP-binding sequence-specific TFs to the 
promoters of target genes (Fig. 1.5) (Shi et al., 2003; Kuppuswamy et al., 2008).  CtBP 
recruits chromatin remodelers including histone deacetylases (HDAC1/2), the lysine-
specific demethylase (LSD1) and histone methyl transferases (G9a and GLP).  In addition, 
CtBP nuclear complexes contain two SUMO E3 ligases, HPC2 and PIAS1, and also certain 
other co-repressors such as Co-REST (co-repressor for element-1-silencing transcription 
factor) that might link the enzymatic constituents to CtBP (Kuppuswamy et al., 2008). Apart 
from the gene-specific repression, CtBP have been indicated in global repression by 
antagonizing the action of transcriptional co-activator p300 and the associated histone 
acetyltransferases (Chinnadurai, 2007). CtBP has also been implicated in the PcG-
mediated transcriptional repression. Although the requirement for CtBP in repression of 
PcG target genes is currently well-defined in Drosophila rather than vertebrates, CtBP 
might also recruit human PcG through PRC2 subunit HPC2 (Shi et al., 2003). Furthermore, 
binding of transcription factor YY1 to DNA and the subsequent PcG-mediated silencing of 
some genes in mammals is dependent on CtBP (Sewalt et al., 1999; Atchison et al., 2003; 
Basu and Atchison, 2010). 
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Fig. 1.5. CtBP supercomplex (reproduced from Kuppuswamy et al., 2008). The CtBP dimer can 
interact with chromatin-anchoring transcriptional repressors through a PLDLS-dependent interaction. 
CtBP can recruit a variety of chromatin-remodelling enzymes such as HDAC1/2, CoREST/LSD1 
complex, G9a/GLP complex, Ubc9 and E3 ligases (HPC2 and PIAS1).  
 
 
LSD1/KDM1 
 
LSD1 (also known as KDM1) is an enzyme which, by an FAD-dependent oxidative 
reaction, demethylates mono- and di-methylated lysines, specifically histone 3 lysines 4 
and 9 (H3K4 and H3K9). It is found in the repressor complexes containing Co-REST and 
NuRD (nucleosome remodelling and histone deacetylation) (Forneris et al., 2007; Wang et 
al., 2009b). LSD1 function in the demethylation of H3K4me1/me2 mediates gene 
repression, while demethylation of H3K9me1/me2 results in gene activation (Metzger et al., 
2005; Wang et al., 2007a). LSD1 mediates the epithelial-to-mesenchymal transition 
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characterized by reprogramming of specific promoters across the genome (McDonald et 
al., 2011).  It regulates the critical balance between H3K4 and H3K27 methylation and 
through the regulation of bivalent domains maintains pluripotency (Adamo et al., 2011). 
LSD1/Co-REST and PRC2 members are co-recruited to promoter regions of HOX genes 
by long intergenic non-coding (linc) RNA HOTAIR and such synchronized targeting of 
these chromatin remodelers by lincRNAs might serve as a general mechanism in the 
maintenance of bivalency (Tsai et al., 2010) 
LSD1 also demethylates non-histone templates such as DNMT1 and E2F1 (Wang et al., 
2009a; Kontaki and Talianidis, 2010). The LSD1/Co-REST complex serves as an HIV Tat 
K51-specific demethylase and is required for the activation of HIV transcription in latently 
infected T cells (Sakane et al., 2011). 
 
Cellular microRNAs in cancer 
 
In humans, 721 miRs have been identified so far (Philippidou et al., 2010). MiRs regulate 
the expression of hundreds of genes through sequence-specific binding to mRNA and 
subsequent inhibition of translation and/or degradation of target mRNAs. .Mature miRs are 
between 19 and 22 nucleotides in length and their production is regulating by transcription, 
posttranscriptional processing and export. Nucleotides 2–7 of the mature miR sequence 
create the 'seed region' which specifies the specific mRNA to which the miR will bind. The 
binding between the miR’s seed region and the target mRNA is mostly in perfect base pair 
complementarity, this does not always apply for the miR’s flanking regions. A gene can 
harbour binding sites for several miRs and a single miR can regulate as many as 200 
genes. The targets of one miR can have diverse functions. The miRs usually cause 
quantitatively modest changes in the target protein expression. They generally fine-tune the 
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expression of a group of genes rather than robustly modulating a single target (Nelson et 
al., 2003; Didiano and Hobert, 2006; Croce, 2009; Janga and Vallabhaneni, 2011). 
MiRs were discovered initially as developmental regulators; therefore it is not surprising 
that they were recognised to play a major role in tumour development. In cancers, miRs are 
globally downregulated and the miR processing machinery (e.g. DICER) is frequently 
mutated (Esteller, 2011). Simultaneously, specific subsets of microRNAs with either 
oncogene or tumour suppressor functions are deregulated in cancers (Lu et al., 2005; van 
Kouwenhove, Kedde and Agami, 2011).  
 
MicroRNA 143 and 145 (miR-143/145) 
 
Genomic loci of both miR-143/145 are co-located within 1.3 kb at chromosome 5q32. MiR-
143/145 originate from non-coding transcripts approximately 11, 7.5, and 5.5 kb- long 
termed NCR143/145 (Non-coding RNA encoding miR-143/145). The expression of 
NCR143/145 is coordinated with that of resident miRs in normal and cancer tissues (Iio et 
al., 2010). Apart from both miRs being produced as a bicistronic unit from the long 
transcripts, miR-145 can be also generated independently from a shorter 1.9-kb transcript 
(Iio et al., 2010). MiR-143/145 co-operatively promote differentiation and repress 
proliferation of smooth muscle cells; miR-145 alone can induce differentiation of multipotent 
neural crest stem cells into vascular smooth muscle (Cordes et al., 2009). MiR-143/145 are 
both up-regulated approximately 3.5-fold during senescence in human foreskin fibroblasts 
and transfected synthetic mimic of miR-143 inhibits the proliferation of fibroblasts in a dose-
dependent manner (Bonifacio and Jarstfer, 2010).  
MiR-143/145 and their precursors NCR143/145 are down-regulated in a variety of cancers, 
including B cell malignancies (Iio et al., 2010). The target genes of miR-143 include 
DNMT3A and KRAS in colorectal cancer (Ng et al., 2009; Chen et al., 2009) and ERK5 in 
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prostate cancer (Clape et al., 2009). MiR-145 targets consist of EGFR and NUDT1 in lung 
adenocarcinoma (Cho, Chow and Au, 2011), YES and STAT1 in colon cancer (Gregersen 
et al., 2010) and BNIP3 in prostate cancer (Chen et al., 2010a). 
Not much is known about the regulation of miR-143/145 locus. Activation of Notch 
receptors by Jag-1 increases promoter miR-143/145 activity, and this is dependent on 
intact RBPJk/CBF1 consensus sites within the promoter in vascular smooth muscle cells 
(Boucher et al., 2011). In pancreatic cancers, miR-143/145 is repressed by oncogenic Ras 
and this requires the Ras-responsive element-binding protein (RREB1) (Kent et al., 2010). 
 
MiR-221 and miR-138 
 
MiR-221  (together with miR-222) are  encoded on chromosome X and  induce cell growth 
and cell cycle progression via direct targeting of p27KIP1 and p57KIP2 in various human 
malignancies (Gillies and Lorimer, 2007; Galardi et al., 2007; Chun-zhi et al., 2010; Pineau 
at al., 2010). MiR-221/222 inhibit cell apoptosis by targeting the product of the pro-
apoptotic gene PUMA and enhance cell migration by down-regulating protein tyrosine 
phosphatase μ in human glioma cells (Zhang et al., 2010; Quintavalle et al., 2011). MiR-
221/222 decrease expression of epithelial-specific genes and increase expression of 
mesenchymal-specific genes, promoting the epithelial-to-mesenchymal transition in breast 
cancer (Stinson et al., 2011). MiR-221 is strongly down-regulated upon differentiation and 
maturation of skeletal muscle cells (Cardinali et al., 2009). NFkB and c-Jun induce miR-221 
(and miR-222) expression in glioblastoma and prostate cancer (Galardi et al., 2011) and 
the inhibition of EGFR (epidermal growth factor receptor) or MEK (mitogen-activated or 
extracellular signal–regulated protein kinase kinase) downregulates miR-221 expression in 
breast cancer (Stinson et al., 2011). 
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As opposed to the pro-proliferative miR-221, miR-138 originating from chromosome 3, 
seems to possess tumour-suppressive capabilities. Down-regulation of miR-138 has been 
observed in various cancers, including head and neck squamous cell carcinomas.  
Expression of miR-138 suppresses cell invasion and leads to cell cycle arrest and 
apoptosis (Liu et al., 2009). MiR-138 targets the histone H2AX 3'-UTR, reducing histone 
H2AX expression and inducing chromosomal instability following DNA damage (Wang et 
al., 2011b). 
 
Tumour viruses and epigenetic regulation 
 
Viruses annually account for over 1.3 million cancer cases worldwide (Hoppe-Seyler and 
Hoppe-Seyler, 2011). Human hepatitis B and C viruses are associated with 80% of 
hepatocellular carcinomas, HPV is present in >95% of cervical carcinomas, EBV is 
associated with 30% of HL, 95% of endemic BL, 15% of sporadic BL, >95% of NPC and 
60%–80% PTLD, including 100% of early-onset PTLD patients (Chan et al., 1995; Butel, 
2000; Liao, 2006; Carbone, Gloghini and Dotti, 2008; Cohen et al., 2011). These viruses 
contribute to the cancer development by insertional mutagenesis and/or by oncoproteins 
that disrupt the cell cycle and apoptosis regulating pathways. However, generally virus 
alone is not sufficient for carcinogenesis and additional co-factors are required (Liao, 2006; 
Fernandez and Esteller, 2010).  
 
Tumour viruses often infect cells that are fully differentiated and have left the cell cycle. 
Non-cycling, resting cells need to be induced to proliferate to support viral replication and 
further host to host spread (Ferrari, Berk and Kurdistani, 2009).  The development of 
cancer is often the by-product of such virally-induced host cell cycle deregulation. 
Oncogenic viruses typically target the same pathways that are altered in many cancers of 
non-infectious aetiology. The common feature is inactivation of p53 and Rb pathway (Cann, 
50 | P a g e  
 
2011). However, oncogenesis is not only the by-product of S phase initiation in non-dividing 
cells, but also of the viral long-time persistence strategy (e.g. modifying the genes involved 
in apoptosis and senescence) and frequently develops only after decades of viral 
persistence (Butel, 2000; Liao, 2006; Fernandez and Esteller, 2010). 
 
During viral latency, shut-down of the majority of viral protein expression, for the reasons of 
long-term immune evasion, typically occurs and is regulated by epigenetic machinery 
usually involving both viral and host factors (Günther and Grundhoff, 2010; Tempera, et al., 
2010). Moreover, viruses can modify the epigenome of the host cell on all levels including 
DNA methylation, histone modification and microRNA expression.  
 
Paramecium bursaria Chlorella virus 1, which infects algae, encodes its own viral histone 
methyltransferase, which methylates histone H3K27 and represses certain host genes 
(Mujtaba et al., 2008). Although this is the only viral histone lysine methyltransferase 
identified to date, multiple viruses have been shown to usurp or regulate parts of the 
cellular epigenetic machinery.  
EBV, KSHV, HBV and HPVs all express viral oncoproteins which target cellular key 
epigenetic regulators, such as DNMTs and histone-modifying enzymes (Hoppe-Seyler and 
Hoppe-Seyler, 2011). The most reported virally-induced epigenetic modification is DNA 
methylation of cellular TSG, such as E-cadherin, p16INK4A and p73, through induction of 
DNMTs (Paschos and Allday, 2010). 
Tumour viruses modify histones both globally and at specific promoters. Global reduction   
( 70%) and redistribution of H3K18ac occurs during transformation of primary human 
fibroblasts with adenoviral small E1A (Horwitz et al., 2008; Ferrari et al., 2008). EBV LMP1 
induces increased JMJD3/KDM6B expression in germinal-centre B cells and can in 
consequence modulate H3K27me3 pattern genome-wide (Anderton et al., 2011). Similarly, 
human papillomavirus type 16 E6/E7 cause alterations in EZH2, BMI1 and H3K27–specific 
51 | P a g e  
 
demethylase UTX/KDM6A (Hyland et al., 2011). In an independent study, human 
papillomavirus E7 was found to epigenetically reprogramme cells through induction of both 
UTX/KDM6A and JMJD3/KDM6B histone demethylase expression (McLaughlin-Drubin, 
Crumb and Münger, 2011). Published examples of targeted silencing of specific tumour 
suppressors by repressive chromatin include repression of the BIM promoter by EBV 
(Paschos et al., 2009) or TGFβRII promoter by KSHV (Di Bartolo et al., 2008). 
 
Lastly, tumour viruses not only use their virally-encoded microRNA in tumorigenesis; they 
also modulate the expression of cellular microRNAs (Pfeffer and Voinet, 2006; Seto et al., 
2010; Dreher et al., 2011; Gottwein et al., 2011). 
 
Viral proteins and senescence 
 
Genome-wide analysis of genes upregulated in cancer showed that nearly 50% of them 
were downregulated upon senescence (Rovillain et al., 2011). This suggests that 
overcoming senescence is a crucial step in malignant transformation and nearly half of the 
genes upregulated in cancer are related to it (Rovillain et al., 2011). Overcoming the 
mechanisms of senescence induction is a common strategy for tumour viruses. 
Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing 
p16INK4A expression via promoter DNA methylation (Oishi et al., 2007; Kim et al., 2010).  
When ectopically expressed in rat embryonic fibroblasts and human epithelial-like 
osteosarcoma cell line, EBV LMP1 is capable of suppressing p16INK4A promoter in a 
promoter reporter assay. Additionally, LMP1 prevents primary mouse embryonic fibroblasts 
from entering into replicative senescence in vitro and prevents Ras-induced premature 
senescence in rat embryonic and human diploid fibroblasts (Yang et al., 2000). In human 
epithelial cells, LMP1 promotes nuclear export of ETS2, thereby reducing the level of 
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p16INK4A gene expression and simultaneously promotes nuclear export of E2F4 and E2F5, 
the essential downstream mediators for a p16INK4A-induced cell cycle arrest (Ohtani et al., 
2003). HTLV-1 Tax can directly bind and inhibit p16INK4A (Low et al., 1997). Furthermore, 
p16INK4A is lost in KSHV-associated primary effusion lymphoma (Platt, Carbone and 
Mittnacht, 2002) and KSHV-cyclin activates CDK6, alters its substrate specificity, and 
renders CDK6 insensitive to inhibition by p16INK4A (Swanton et al., 1997; Kaldis et al., 
2001). 
In addition to blocking the p16INK4A function, viruses overcome the induction of senescence 
directly by inhibiting p21CIP1 (Park et al., 2011) or indirectly by the modulation of Rb and 
p53-pathways by a variety of mechanisms (Ferrari, Berk and Kurdistani, 2009).  
 
Systems for the study of EBV pathogenesis 
 
EBV-infected B cells are rare in healthy virus carriers (1–50 per million B cells) and are 
very difficult to analyse directly (Kuppers, 2003; Thorley-Lawson and Gross, 2004). B cell-
derived EBV-carrying cell lines are the most common model used to study EBV. Burkitt 
lymphoma (BL) cells and LCL differ phenotypically. BL are small and round, similar to non-
activated resting B cells while LCL are large and irregular and resemble antigen-activated 
lymphoblasts (Nilsson and Ponten,1975; Klein, Kis and Klein, 2007). LCL always express 
latency III programme. Although BL lines that maintain the type I expression have been 
established, in culture BL typically drift to latency III programme (Gregory, Rowe and 
Rickinson, 1990).  
One of the greatest obstacles in the study of EBV-related pathogenesis is the lack of 
animal models. γHV68 virus has been used  as a surrogate for EBV and KSHV in the 
infection of mice; it leads to a robust acute infection in the lung and a long-term latent 
infection in the spleen (Dong et al., 2010). Furthermore, EBV-initiated tumour lines can be 
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introduced into severe combined immunodeficiency (SCID) mice allowing the study of in 
vivo functions of EBV (Kaul et al., 2007). More recently, immunodeficient mice have been 
reconstituted with components of the human immune system to produce humanized mice 
(Strowig et al., 2011) and these can be infected with recombinant EBV in order to analyse 
viral genes function (White et al., under revision). 
Rhesus macaque LCV contains a repertoire of genes similar to that of EBV, and 
experimental infection of naive rhesus macaques with rhesus macaque LCV accurately 
reproduces some aspects of lytic and latent EBV infection. Such non-human primate 
models could be instrumental in gaining insight into the mechanisms of immune evasion by 
LCV and by extension EBV (Moghaddam et al., 1997). However the macaque immune 
system is poorly characterized and there are financial and ethical constrains on developing 
such models. 
EBV viruses cannot be easily produced due to the lack of permissive cell lines. Therefore in 
order to establish genotype-phenotype connection and study viral ORFs, a herpesviral 
genome was cloned into the bacterial artificial chromosome (BAC). This allows 
manipulation of the large virus genome as a plasmid in E. coli. Genomes can be shuttled 
between E.coli and eukaryotic cells and the viruses produced after transfection of EBV-
BACs into 293 epithelial producer cell lines (Delecluse et al., 1998). EBV-BAC is an 
essential tool to genetically modify gammaherpesvirus genomes and to create the deletion 
mutants. Revertant viruses are established alongside the deletion mutants to prevent the 
bias caused by any effects arising from second site mutations. Revertants also allow 
distinguishing whether the observed biology results from the interruption of a protein 
sequence or whether it is caused by an alteration to a cis-element. A more physiological 
study of viral proteins and RNA is carried out in the context of the entire virus rather than 
expression of isolated EBV components (WT or mutated), since frequently viral proteins 
and RNA species work in concert and are inter-dependent. Lastly, using EBV-BACs, rather 
than over-expression systems, leads to physiological expression levels of all viral 
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components in the infected BL or LCL (Kanda et al., 2004; Delecluse et al., 2008; Feederle, 
Bartlett and Delecluse, 2010). 
 
The 4-hydroxytamoxifen–inducible fusion protein system 
 
In contrast to the systems based on transcriptional induction, fusions with hormone-binding 
domains of steroid receptors allow posttranslational functional control of a chimerical 
protein depending on the presence of a small molecule ligand (Guo et al., 2008). 
Posttranslationally inducible fusion proteins were traditionally produced by fusion with the 
hormone-binding domain of the oestrogen receptor. The caveats associated with this 
system were the need for the removal of phenol red and steroid hormones from culture 
medium, unsuitability for in vivo usage due to high levels of circulating steroid hormones 
and the remaining inherent transactivation activity of the hormone-binding domain 
(Littlewood et al., 1995). The system was advanced by the introduction of a point mutation 
into the murine oestrogen receptor that renders it unable to bind oestrogen. This modified 
receptor is responsive to the synthetic oestrogen antagonist 4-hydroxytamoxifen, and the 
hormone-binding domain is completely transcriptionally inactive. 
As documented on numerous fusion proteins such as c-myc ERTAM, in the presence of the 
ligand, the fusion protein is transcriptionally active in the nucleus. After ligand removal, the 
fusion protein translocates from the nucleus to the cytoplasm where it is captured in 
inhibitory complexes with cytoplasmic proteins, especially heat shock proteins, and 
inactivated. In some cases, inactive complexes might be targeted for proteasomal 
degradation. So in addition to inactivation, the quantity of fusion protein in cell might 
decrease in the absence of the ligand (Sipo et al., 2006; Chu et al., 2008; Stevanato et al., 
2009).  
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Project background – starting point 
 
More than a decade ago EBNA3C was shown to act in a similar manner to E7 of 
papillomaviruses by enabling G1 to S progression through inactivation of the Rb axis; 
however, the mechanism was not determined (Parker et al., 1996). Recently, in our lab a 
conditional EBNA3C was constructed by fusing the C-terminus of EBNA3C with 4-
hydroxytamoxifen (HT)-dependent mutant murine oestrogen receptor. This gene was then 
engineered into EBV strain B95.8 using a BAC system and the resulting virus was used to 
produce LCL (LCL 3CHT) from primary human B cells (Melanie Franz and Michaela 
Ruhmann, personal communication). Previously, Maruo et al. (2003) showed using a 
similar system based on the Akata strain of virus that after withdrawal of HT from the 
medium, EBNA3C gradually disappears, LCL arrest in the G1 phase of the cell cycle and 
exhibit elevated levels of apoptosis. The G1 arrest is accompanied by the accumulation of 
p16INK4A and decrease in the hyperphosphorylated form of Rb.  
In analogous conditional EBNA3A system, EBNA3A inactivation leads to LCL growth arrest 
and cell death (Maruo et al., 2006). Consistent with this finding, a recent study using 
recombinant EBV viruses lacking EBNA3A and microarray technology showed that 
although EBNA3A knock-out (EBNA3A KO) LCL can be established, the absence of 
EBNA3A (similarly to EBNA3C) leads to reduced proliferation and increased apoptosis. 
EBNA3A KO LCL fail to suppress p16INK4A and display decreased levels of Rb mRNA 
(Hertle et al., 2009).   
Microarray data produced in our lab have revealed that EBNA3A and EBNA3C co-operate 
in the regulation of subset of cellular genes (White et al., 2010). Furthermore, the physical 
association of EBNA3A and EBNA3C proteins was firmly established. The EBNA3s can be 
co-precipitated with each other from lysates of EBV-infected B cells. The presence of all 
three EBNA3s is not necessary for successful co-immunoprecipitations, neither are other 
EBV proteins. The interaction of EBNA3C with EBNA3A was further convincingly confirmed 
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using the LCL produced with recombinant EBV-BAC viruses expressing strep-FLAG (TAP)-
tagged EBNA3C (Gill Parker, Kostas Paschos and Oak Watanatanasup, personal 
communication). 
 
Taking the BIM locus as a model for regulation by EBV, it has been demonstrated for the 
first time that EBNA3A and EBNA3C can mediate heritable repression of a cellular gene via 
epigenetic mechanisms including H3K27me3 and DNA methylation (Anderton et al., 2007; 
Paschos et al., 2009; Paschos et al., under revision). Following genome-wide studies in our 
lab, which integrated the profile of cellular transcripts with the profile of epigenetic marks at 
cellular promoters, have strongly suggested that EBNA3C and EBNA3A manipulate cellular 
gene expression through epigenetic mechanisms, most notably the polycomb-imposed 
repressive histone mark H3K27me3 (Kostas Paschos and Ian Groves, personal 
communication; White et al., 2010). 
CtBP has been shown to mediate the repression of p16INK4A (but not p14ARF) in primary 
human fibroblasts and keratinocytes via H3K27me3 (Mroz et al., 2008). Our group has 
demonstrated that LCL immortalized by recombinant EBV viruses with engineered 
mutations that abolish CtBP-binding sites present in EBNA3C and EBNA3A  (henceforth 
referred to as CtBP-binding mutant LCL) grow out poorly following B cell transformation 
and express elevated levels of p16INK4A in comparison to LCL transformed with WT EBV-
BAC viruses (WT LCL) (Rob White, personal communication).  
Lastly, all known tumour viruses interact with the cellular miR network (Hoppe-Seyler and 
Hoppe-Seyler, 2011). Latent EBV is known to regulate cellular microRNA expression (Yin 
et al., 2008; Imig et al., 2011), and the role of certain EBV latent antigens such as LMP1 in 
the regulation of cellular miRs has been well documented (Cameron et al., 2008; 
Anastasiadou et al., 2010). However, the participation of EBNA3C and/or EBNA3A on 
posttranscriptional gene regulation of cellular genes via microRNAs has not been 
investigated so far.  
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Aims of the project 
 
 
For decades, EBNA3C and EBNA3A have been implicated in transcriptional regulation of 
both viral and cellular genes, but little is known about the precise molecular mechanisms 
involved or about the consequences of the EBNA3C and/or EBNA3A-mediated gene 
regulation in lymphomagenesis. In this project, I aimed to address: 
 
1) the details of p16INK4A repression by EBNA3C and EBNA3A in LCL and by extension 
perhaps the mechanism of EBNA3C and EBNA3A-mediated epigenetic regulation 
of other cell gene(s) 
 
2) the functional significance of EBNA3C and EBNA3A-mediated p16INK4A repression 
in LCL proliferation and B cell transformation and immortalization 
 
 
3) a putative new role of EBNA3C and/or EBNA3A in posttranscriptional gene 
regulation 
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Chapter 2 
 Materials and Methods 
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All chemical grade reagents were supplied by BDH chemicals, UK and were of AnalR 
grade purity unless otherwise stated. All autoradiography film (Hyperfilm), Amplify and 
Enhanced Chemi-Luminescence (ECL) reagents were supplied by GE Healthcare, UK.  
Solutions and Buffers  
 
Unless otherwise stated, all solutions were prepared in ddH2O. 
6x Agarose gel loading buffer 
20% (w/v) Sucrose 
0.1% (w/v) Bromophenol blue 
10% (v/v) 10xTBE 
 
Alkaline SDS 
1% SDS 
0.2 M NaOH 
 
Blocking Solution for Western Blots 
5% (w/v) skim milk powder (Sigma, UK) was reconstituted in 1xPBS/0.05% Tween (Sigma, 
UK) 
 
4-hydroxytamoxifen (HT) 
4mM (10 000x) stock was prepared by resuspending 5mg of HT (Sigma) in 3.22 ml of 95-
100% ethanol. The aliquots of the stock were stored at -20C in dark. 
 
Immunoprecipitation (IP) lysis buffer  
50 mM Tris-HCl, pH 8.0 
150 mM NaCl  
10% Glycerol  
0.5% Triton X-100  
2 mM Phenylmethylsulfonyl fluoride (PMSF) 
2 mM mixture of proteinase inhibitors (Roche Molecular Biochemicals) 
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Phosphate Buffered Saline (PBS) [Dulbecco’s PBS without CaCl2 and MgCl2 
(Dulbecco and Vogt, 1954)], pH 7.2 
12.5mM NaCl 
2mM Na2HPO4 
1mM NaH2PO4 
 
100mM PMSF (phenylmethylsulfonyl fluoride) 
Dissolved in isopropanol and stored at –20C.  
 
 
Protease Inhibitor Cocktail Solution  
 
1 tablet of Complete Protease Inhibitors Cocktail (Roche) was dissolved in 2ml ddH2O. 
Stored at -20C for up to 2 months. 
 
 
 
Resolving gel for Western Blotting 
 7.5% 10% 12.5% 15% 
30% Acrylamide  1.98ml 10 ml 3.30ml 3.96ml 
1 M Tris-HCl (pH 8.8) 2.96ml 2.96ml 2.96ml 2.96ml 
SDS (10% w/v) 79.2l 79.2l 79.2l 79.2l 
ddH2O 2.96 ml 8.7 ml 1.64 ml 0.98 ml 
APS (10% w/v) 26.4l 26.4l 26.4l 26.4l 
TEMED 5.3l 5.3l 5.3l 5.3l 
 
 
5x Radioimmunoprecipitation (RIPA) Lysis Buffer  
0.75M NaCl   
5% (v/v) NP40   
2.5% (w/v) Deoxycholate  
0.5% (w/v) SDS   
0.25M Tris-HCl pH 8.0 
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10x SDS Running Buffer for SDS-PAGE  
250mM Tris   
1.92M Glycine 
1% (w/v) SDS 
 
2x SDS Sample Buffer 
100mM Tris-HCl (pH 6.8) 
20% (v/v) Glycerol 
1% (v/v) β-mercaptoethanol 
1% (w/v) SDS 
0.025% (w/v) Bromophenol blue 
 
Stacking gel (5%) for Western Blotting 
30% Acrylamide 828µl 
1 M Tris-HCl (pH 6.8) 620µl 
SDS (10% w/v) 49.6µl 
ddH2O 3.47ml 
APS (10% w/v) 24.8µl 
TEMED 5µl 
 
10x TBE (Tris-Borate-EDTA) Buffer 
89mM Tris 
89mM Boric acid 
10mM EDTA 
 
TE  
10mM Tris-HCl pH 7.5 
1mM EDTA pH 8.0 
 
Transfer Buffer for Western Blots 
 
300ml 10xSDS Running Buffer  
700ml EtOH  
2l ddH2O  
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Western Blotting (WB), Immunoprecipitation (IP) and Flow Cytometry (FC) - Primary 
Antibodies 
Antigen Antibody Species Supplier Application 
BrdU-FITC  B44 Mouse BD Biosciences 
FC 20ul per 
sample 
Co-REST 26/CoRest Mouse BD Biosciences IP  1:50 
CtBP1 D2D6 Rabbit Cell Signaling WB 1:2000 
CtBP --- Rabbit Prof. Martin Allday IP   1:300 
DNMT3A aa 50-150 Rabbit Abcam WB 1:300 
HDAC1 aa  466-482 Rabbit Abcam 
WB 1:2000 
IP  1:200 
E2F1 cKH20 and KH95 Mouse Millipore WB 1:200 
EBNA1 --- Human serum  Prof. Paul Farrell WB 1:750 
EBNA2 PE2 Mouse DAKO WB 1:500 
EBNA3A --- Sheep  Exalpha WB 1:1000 
EBNA3B --- Sheep  Exalpha WB 1:333 
EBNA3C A10  Mouse
1
   Dr. Martin Rowe WB 1:10 
EBNA-LP JF186  Mouse
1
   Dr. Lindsey Spender WB 1:10 
ERK5 
--- 
Rabbit Cell Signaling WB  1:1000 
Fascin  IM20, C-terminus Mouse Abcam  WB 1:100 
EZH2 aa  1-370 Rabbit Active Motif WB 1:1000 
LMP1 CS1-4 Mouse DAKO WB 1:50 
LMP2A 14B7  Rat Prof. Georg Bornkamm WB 1:10 
LSD1 C-terminus Rabbit Abcam IP  1:200 
LSD1 N-terminus Rabbit Cell Signaling IP  1:50 
p14
ARF
 aa 118-132 Rabbit Merck WB 1:100 
p16
INK4A
 JC8 Mouse
1
 Dr Gordon Peters WB 1:10 
p16
INK4A
 DCS50.1 Mouse Abcam WB 1:500 
p21
CIP1
 SX 118 Mouse
1
 Prof. Xin Lu WB 1:10 
p53 DO-1 Mouse
1
 Prof. Xin Lu WB 1:50 
p107 C-18 Rabbit Santa Cruz WB 1:500 
p130 C-20 Rabbit Santa Cruz WB 1:500 
phospho-p38 28B10, Thr180/Tyr182 Mouse Cell Signaling WB 1:2000 
phospho-Rb Ser 807/811 Rabbit Cell Signaling WB 1:500 
Rb G3-245 Mouse BD Pharmingen WB 1:200 
RTKN aa 451-550 Mouse Abcam WB 1:500 
γ-H2AX 20 E3, Ser 139 Rabbit Cell Signaling WB 1:1000 
γ-tubulin GTU-88 Mouse Sigma WB 1:2000 
 
1
 Tissue culture supernatant  
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Western blotting - Secondary Antibodies 
Specificity Species-Conjugate Supplier Application 
Human Ig Rabbit-peroxidase conjugated DAKO WB 1:2000 
Mouse Ig Sheep–peroxidase conjugated GE Healthcare WB 1:2000 
Rabbit Ig Goat-peroxidase conjugated DAKO WB 1:2000  
Rat Ig Rabbit-peroxidase conjugated DAKO WB 1:2000 
Sheep Ig Rabbit-peroxidase conjugated DAKO WB 1:2000 
All secondary antibodies were diluted in 5% Milk/0.05% Tween-20/PBS. 
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Cell culture 
 
Established LCL were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% 
fetal calf serum (FCS), penicillin and streptomycin. BL31 cell lines were cultured in the 
same medium as LCL with the addition of 1 mM sodium pyruvate (Sigma) and 50 µM α-
thioglycerol (Sigma). For cultures of BL31 containing recombinant hygromycin-resistant 
EBV-BACs, 100 µg/ml hygromycin B (Roche) was added. LCL 3CHT were cultured with 
400nM 4-hydroxytamoxifen (HT, Sigma).  
Cells recovered from liquid nitrogen were cultured for about 10 days before the start of any 
experiment. At the end of an experiment (a maximum of 35 days), the cells were discarded. 
Twenty-four hours before any experimental treatment, cells were seeded at a density of 
2.5x105  cells/ml.  
 
Generation of recombinant EBV-BACs 
 
All recombinant EBV-BACs used in this work were already available in the lab. EBNA3C-
HT fusion EBV-BAC was produced by M. Franz and R. White (Skalska et al., 2010), 
EBNA3A KO and revertants by E. Anderton (Anderton et al., 2007) and CtBP-binding 
mutants and revertants by R. White (Skalska et al., 2010).  
An EBNA3C-HT fusion (3CHT) in the B95-8 background was constructed with the same 
linking sequence and 4-hydroxytamoxifen-sensitive murine oestrogen receptor that has 
previously been described in the Akata background (Maruo et al., 2006). The connection 
between the 3C and HT is a single proline residue between the last amino acid of EBNA3C 
and amino acid 281 of the murine oestrogen receptor alpha (modified by the replacement 
of glycine at position 525 by arginine to make it 4-hydroxytamoxifen-specific). This fusion 
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was recombined into the B95-8 BAC (Delecluse et al.,1998) using previously described 
methods (White et al., 2003; Anderton et al., 2007) to produce two independent BACs 
containing 3CHT (A and C).  
A set of CtBP-binding-mutant viruses were generated in which the EBNA3A and/or 
EBNA3C binding site(s) for CtBP were replaced with previously characterized mutations 
(Touitou et al., 2001; Hickabottom et al., 2002) that lack the ability to bind CtBP (Fig. 2.1). 
This was achieved by a sequential set of recombinations, initially mutating the pair of CtBP 
binding sites in EBNA3A (to generate the 3ACtBP mutant). The EBNA3C binding site for 
CtBP in this was then mutated to create a virus genome lacking all CtBP binding sites 
among the EBNA3s (E3CtBP). Then the EBNA3A mutant sequence was replaced with WT 
sequence, leaving only the EBNA3C sequence as mutant (3CCtBP) and finally the EBNA3C 
sequence was reverted to WT sequence, generating the CtBP revertant (revCtBP).  
 
 
Fig. 2.1. Mutations of CtBP-binding sites in EBNA3C and EBNA3A in CtBP-binding mutant 
EBV-BACs. EBNA3C contains a single consensus CtBP binding site (PLDLS) which has been 
mutated into ALDAS. EBNA3A contains two non-consensus CtBP binding sites which synergize to 
produce efficient binding to CtBP (Touitou et al., 2001; Hickabottom et al., 2002).  ALDLS site has 
been mutated into ALDAA and VLDLS binding site into VLDAA. 
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Infection of peripheral blood lymphocytes (PBL) with recombinant 
EBV 
 
Recombinant BACs were transfected into HEK293 cells [(ATCC, CRL-1573), a kind gift of 
Claire Shannon-Lowe, University of Birmingham]; clonal hygromycin B-resistant cell lines 
were then selected and screened for integrity of the EBV genome by episome rescue and 
pulsed-field gel analysis of BAC restriction digests. Infectious virus was produced by the 
transfection of EBV-BAC-containing 293 cells with BZLF1 and BALF4 expression 
constructs (Neuhierl et al., 2002), and after 4 days, supernatant was filtered through 0.45 
m filters. Virus titre was assessed by infection of Raji cells and counting green cells on an 
inverted fluorescent microscope after enhancement of GFP expression by overnight 
treatment with 5 nM tetradecanoylphorbol acetate (TPA) and 1.25 mM sodium butyrate. 
Virus titres were typically in the range of 50 to 250 Raji green units per microlitre of tissue 
culture supernatant. 
PBL for generation of LCL 3CHT-A and -C were isolated from buffy coat residues (UK 
blood transfusion services) by centrifugation over Ficoll-Paque. EBNA3A KO LCL, CtBP-
binding mutant LCL and LCL 3CHT-B, D and E (described herein) were generated by 
infection of PBL isolated from donated EBV-seronegative blood from five donors 
(annotated 1-5) (a kind gift of Ingo Johannessen, University of Edinburgh). LCL 3CHT-A 
were produced by the infection of PBL from mixed donors by EBV-3CHT-A virus and LCL 
3CHT-C by EBV-3CHT-C virus. LCL 3CHT-B, D and E were made by infection of PBL in 
blood from a single donor 1, 3 and 2 respectively with EBV-3CHT-A virus. EBNA3A KO and 
revertant LCL, as well as CtBP-binding mutant and revertant LCL were established using 
the viruses and PBL from various single donors listed in the table 2.1. Essentially, between 
50 l and 1 ml of virus was added to 106 PBL (typically 2-8% of which are B-cells by FACS 
for CD20; not shown) in a well of a 24 well plate, and cultured in RPMI supplemented for 
the first 2-3 weeks with 15% FCS and Cyclosporine A (500 ng/ml).  When LCL grew out to 
the volume of about 60ml at a density of 3x105 cells/ml or greater, multiple aliquots were 
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frozen in liquid nitrogen. This took 4-8 weeks for WT LCL, revertant LCL and LCL 3CHT 
(cultured with HT) and 6-12 weeks for the EBNA3A and CtBP-binding mutant LCL.  
 
Infection of p16-functionally null PBL with recombinant EBV 
 
We have acquired PBL containing a germline homozygous 19bp-deletion in the second 
exon of CDKN2A locus, known as p16-Leiden (Gruis et al., 1995; de Vos tot Nederveen 
Cappel et al., 2003), as a kind gift from Gordon Peters (Institute for Cancer Research, UK) 
and Alison Sinclair (University of Surrey). The details of transcripts and proteins produced 
from the CDKN2A locus are described in Chapter 3.2.; this homozygous deletion in the 
CDKN2A locus renders the cells null for p16INK4A function (Brookes et al., 2002; Hayes et 
al., 2004).  
PBL containing the p16-Leiden deletion were isolated from the blood of the male born in 
1972, with the clinical history of multiple atypical naevi developed in childhood and puberty 
and seven superficial spreading melanomas developed and removed by the age of 25 
(Brookes et al., 2002). PBL were used to produce p16-functionally null LCL 3CHT lines by 
infection with two independent E3CHT BACs [two lines with EBV-3CHT-A virus (A1, A2) 
and two using EBV-3CHT-C virus (C1, C2)] Due to the limited number of these rare PBL, 
only a single pair of p16-functionally null EBNA3A KO and revertant LCL was produced. 
The p16-functionally null LCL were established using the exactly same procedure 
described above for production of the p16-competent lines.  The p16-competent and -null 
cell lines most frequently used during the course of this study are listed in the table 2.1. 
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Annotation Virus 293 
clone 
Donor LCL 
clone 
LCL 3CHT-A 3CHT A13 Mixed donor PBL  
LCL 3CHT-C 3CHT C19 Mixed donor PBL  
LCL 3CHT-B 3CHT A13 Single donor 1 PBL  
LCL 3CHT-D 3CHT A13 Single donor 3 PBL  
LCL 3CHT-E 3CHT A13 Single donor 2 PBL  
EBNA3A KO LCL 3AKO M16 Single donor 4 PBL  
EBNA3A KO LCL 3AKO M11 Single donor 5 PBL  
EBNA3A rev LCL 3A rev M4 Single donor 4 PBL  
EBNA3A rev LCL 3A rev M4 Single donor 5 PBL  
E3
CtBP
 LCL E3CtBP K5 Single donor 4 PBL  
E3
CtBP
 LCL E3CtBP K10 Single donor 1PBL  
3A
CtBP 
LCL 
3A
CtBP
 
K4 Single donor 4 PBL  
3A
CtBP
 LCL 
3A
CtBP
 
K5 Single donor 1 PBL  
3C
CtBP 
LCL  
3C
CtBP
 
K10 Single donor 4 PBL  
rev
CtBP 
LCL 
rev
CtBP
 
K11 Single donor 4 PBL  
WT LCL 
WT BAC 
I6 Single donor 1 PBL  
WT LCL 
WT BAC  
I6 Single donor 4 PBL  
WT LCL 
WT BAC  
I6 Single donor 5 PBL  
WT LCL 
WT BAC 
I6 Mixed donor PBL  
p16-null LCL 3CHT A1 3CHT A13 Single donor p16-null PBL 1 
p16-null LCL 3CHT A2 3CHT A13 Single donor  p16-null PBL 2 
p16-null LCL 3CHT C1 3CHT C19 Single donor p16-null PBL 1 
p16-null LCL 3CHT C2 3CHT C19 Single donor p16-null PBL 2 
p16-null EBNA3A KO LCL 3AKO M11 Single donor p16-null PBL  
p16-null EBNA3A rev LCL 3Ar rev M4 Single donor p16-null PBL  
 
Table 2.1. List of the most frequently used cell lines. p16-null LCL are highlighted in blue. 
Additional p16-competent LCL 3CHT produced with 3CHT-C(19) virus by infection of PBL from 
donor 1, 2 and 3 and CtBP-binding mutant and revertant LCL produced with viruses listed in the 
table by infection of PBL from donor 1 and 5 were used in replicate experiments. 
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Analysis of cell gene expression during B cell transformation by EBV 
 
Fresh EBV B95-8 virus was produced as follows. B95-8 cell line, made functionally 
conditional for BZLF1/Zta activation of lytic replication by an in-frame fusion with a mutant 
oestrogen receptor (Johannsen et al., 2004), was a kind gift from Eric Johannsen (Harvard 
University). This line was induced to produce virus by adding HT at 200nM final 
concentration for 4 days. The supernatant containing EBV B95-8 virus was harvested by 
centrifugation at 1300 rpm for 4 min at 4°C. To concentrate the viral yield by approximately 
100-fold, the supernatant was ultracentrifuged at 25000 rpm for 1h at 4°C, then 
resuspended in RPMI, aliquoted, snap-frozen and stored in liquid nitrogen.  
Infectivity of the supernatant was assayed by infection of the Raji cells. Ten-fold dilutions of 
viral supernatant harvested from 293 cells and concentrated by ultracentrifugation (1 ml, 
0.1 ml and 0.01 ml made up to 1 ml volume using RPMI/10% FCS) were used to infect 106 
Raji cells in 1ml RPMI/10% FCS. Raji cells were harvested after 40h for western blotting for 
EBNA-LP expression. The amount of virus was judged sufficient for infection of 106 Raji 
cells in the cases when EBNA-LP was detected as a well-expressed ladder of proteins as 
opposed to a single band detectable in the Raji cells prior infection with EBV B95-8 virus. 
1-5 µl of concentrated B95-8 virus was sufficient to infect 106 Raji cells.  
Excess (10 µl of the virus per 106 primary B cells) was used in the B cell transformation 
experiment in an attempt to infect every primary B cell. Two experimental designs were 
employed (with duplicate experiments for each design): either PBL or B cells, purified by 
anti-CD19 coated MACS micro-beads (using a MACS separator from Miltenyi Biotec 
according to the manufacturer’s instructions), were used in EBV infection. In the case of 
PBL infection, Cyclosporine A (500ng/ml) was added to the culture medium of PBL after 
the infection and the first harvesting time-point was set 7 days post-infection, when the 
majority of PBL other than B cells should be eliminated from the culture (i.e. T cells and NK 
cells would be eliminated; however, macrophages/monocytes would still survive).  
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In order to avoid harvesting heterogeneous cell populations, the EBV-infected cells were 
separated using Ficoll-Paque reagent into the high-density, most likely apoptotic cells 
(Belloni et al., 2008 and 2010), and normal-density cells. The equal volume (7ml) of culture 
medium with cells was poured on the top of 7ml of Ficoll-Paque reagent in 15 ml tube and 
centrifuged for 30 min at 1380 rpm at RT. The lymphocytes of normal density separated at 
the interphase between the culture medium and the Ficoll-Paque reagent, while the high-
density cells were pelleted at the bottom of the tube (Fig. 2.2). The normal density fraction 
was transferred to the new tube, mixed and pelleted by centrifugation for 5 min at 1300 
rpm. The same end points were analyzed in both, the high-density and the low-density 
fraction. Transcript quantities were assessed by qPCR, and multiple reference genes 
(GNB2L1, ALAS1 and RPLP0) were used to accurately normalize the expression data. 
 
 
Fig. 2.2. Scheme of the separation of lymphocytes into high- and normal-density fractions 
using Ficoll-Paque reagent. High-density fraction is pelleted at the bottom of the tube, while the 
lymphocytes of the normal density separate in the interphase between the Ficoll-Paque reagent and 
the culture medium.   
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Flow cytometry 
 
To assess the cell cycle distribution, cells were harvested at the times indicated and fixed 
in 80% ethanol. Fixed cells were resuspended in PI solution [(PBS containing 18 µg/ml 
propidium iodide (PI) and 8 µg/ml RNase A (both Sigma Aldrich)] and incubated at 4°C for 
1h. Flow cytometry was performed using a Beckton-Dickinson FACSort flow cytometer and 
analysed with CellQuest software. 
To analyse the proportion of cells entering and passing through S phase, 2x106 cells were 
incubated with 5-bromo-2'-deoxyuridine (BrdU, Sigma) at a concentration of 10 µM for 1h, 
after which cells were immediately harvested, centrifuged at 1300 rpm for 5 min, washed 
twice in 2 ml of 1% bovine serum albumin (BSA) in PBS, resuspended in 500 µl of ice-cold 
70% ethanol and incubated  on ice for 30 min before storage at -20°C or direct analysis.  
Cells were then washed in PBS before thorough resuspension in 750 µl of 2N HCl 
containing 0.5% (vol/vol) Triton X-100 for 30 min at room temperature (RT) to denature the 
labelled, double-stranded DNA. Acid was neutralized by resuspending cells in 750 µl of 
0.1M sodium tetraborate (pH 8.5) and incubation at RT for 5 min. Cells were centrifuged 
and resuspended in 20 µl of fluorescein isothiocyanate (FITC)-conjugated anti-BrdU 
antibody (Becton Dickinson, United Kingdom), which was then further diluted with 380 µl of 
1% BSA-0.5% Tween 20-PBS. After incubation in the dark at RT for 60 min, cells were 
washed twice in 0.5% Tween 20-PBS and resuspended in 500 µl of PI solution. Flow 
cytometry was performed using a DAKO CyanADP flow cytometer and analysed with 
Summit software. 
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Western immunoblotting 
 
Cells were washed twice in PBS and lysed in RIPA buffer, equivalent to the volume of the 
cell pellet, for 10 min on ice. After centrifugation at 4°C for 10 min, the supernatant was 
removed and protein concentration was estimated colorimetrically using the Bio-Rad 
detergent-compatible assay. 20-40 µg of protein was added to an equal volume of 2xSDS 
protein sample buffer and loaded onto SDS-polyacrylamide gel of appropriate percentage. 
Alternatively, in some experiments the whole cell lysates were loaded, after lysing cell 
pellets directly in 2xSDS protein sample buffer (50µl of buffer per 106 cells) and sonicating 
to fragment DNA using Bioruptor sonicator (UCD-200; Diagenode) on a high setting for a 
total of 15 min (30 sec ‘on’/30 sec ‘off’ intermittent sonication). Gels were transferred at 
constant voltage 100W for 1h onto a Protran nitrocellulose membrane (Schleicher and 
Schuell Bioscience). Membranes were blocked with 5% milk powder in PBS/0.05% Tween 
20 for 1h at RT. After incubation with primary antibody overnight at 4°C, membranes were 
washed in changes of PBS-0.05% Tween 20 for a total of 1h, incubated with secondary 
antibody conjugated to horseradish peroxidase (1:2000 in PBS-M) for 1h at RT, then 
washed as previously, and visualized by enhanced chemiluminescence (Amersham) as 
recommended by the supplier.  
 
RNA and Quantitative real time PCR (qPCR) 
 
For qPCR, RNA was extracted from approximately 5x106 cells for each cell line using the 
RNeasy mini kit from Qiagen and following the manufacturer's instructions. One microgram 
of each RNA sample was reverse-transcribed using SuperScript III First-Strand Synthesis 
Supermix for qPCR (Invitrogen). Between 0.5-1% of cDNA product (equivalent to 5-10 ng 
RNA) was used per qPCR reaction. In the case of low-abundance transcripts (e.g. ANRIL 
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and p14ARF), up to 20% of cDNA product was used in a qPCR reaction performed in an 
upscaled volume to avoid PCR inhibition.  
The majority of qPCR measurements were performed using sybr green chemistry. Platinum 
Sybr Green qPCR SuperMix UDG kit (Invitrogen) was used with Applied Biosystems (ABI) 
7900HT real-time PCR machine. The cycling conditions were generally 95°C for 2 min, 
followed by 40 cycles of 1 sec at 95°C and 20 sec at 60°C on a fast block. Dissociation 
curve analysis was performed during each run to confirm absence of non-specific products. 
Sequences of the assays used with sybr green chemistry are listed in table 2.2. Primer 
assays were either developed using Primer Express software (ABI), or published previously 
(Table 2.5).  
qPCR measurements using the taqman chemistry were performed with TaqMan® Gene 
Expression Assays (ABI) listed in table 2.3 and Taqman Fast Universal PCR Mastermix 
(ABI). For low-abundance non-coding RNA (ncRNA) detection, the TaqMan® Gene 
Expression Mastermix was used with the standard mode of cycling (initial 10min hold at 
95°C, followed by 40 cycles of 15 sec at 95°C and 1min at 60°C). 
Standard curves, used to standardise amplification efficiency, were produced by six 5-fold 
serial dilutions of a mixture containing all cDNA samples used. Results were analyzed with 
qbasePLUS software (Biogazelle). Precise normalization was achieved using internal 
average control calculated from the controls (housekeeping genes - table 2.4) with the 
highest stability rating (usually ALAS1 and GNB2L1). The error barrs in the graphs 
represent the standard errors from three replicate qPCR reactions for each mRNA in a 
single experiment. To obtain statistical significance data were analysed by unpaired 
student t-test. P value p<0.005 was considered as highly significant. 
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 Assay Forward primer Reverse Primer 
ANRIL  
(15/16) CAACATCCACCACTGGATCTTAACA AGCTTCGTATCCCCAATGAGATACA 
BIM EL GCTGTCTCGATCCTCCAGTG GTTAAACTCGTCTCCAATACG 
CDKN2A CATAGATGCCGCGGAAGGT GATGATCTAAGTTTCCCGAGGTTTC 
DNMT3A TATTGATGAGCGCACAAGAGAGC GGGTGTTCCAGGGTAACATTGAG 
Loc 3 GACCAGACCCCAGGAAAGA TTACAGCCGTTGCTCTCCTT 
Loc 10 AGCAAGAACTCTGGAGAAGCA GAGAGGCGTGGGTGAGAG 
NOTCH2 GCCCCAGCCAAAGAAAGTAAA CGATGGTGTCCTACGGATGTC 
p14
ARF
 AGCAGCCGCTTCCTAGAAGAC CACGGGTCGGGTGAGAGT 
p16
INK4A
 CCCCTTGCCTGGAAAGATAC AGCCCCTCCTCTTTCTTCCT 
p21
CIP1
 CTGGAGACTCTCAGGGTCGAA GCGGATTAGGGCTTCCTCTT 
Rb CCAGCACACCCTGCAGAAT TGCCATACATGGAACACATCATAA 
TGFβRII GGCTCAACCACCAGGGCA CTCCCCGAGAGCCTGTCCAGA 
Table  2.2. Primer sequences for mRNA quantification using sybr green chemistry. 
 
 
ABI Taqman Expression Assay ID 
ANRIL (1/2 exon boundary) Hs 01390879_m1 
CDKN2A Hs 00923894_m1 
MALAT-1 Hs 00273907_s1 
Table  2.3. Primer sequences for mRNA quantification using taqman chemistry. 
 
 
Assay Forward primer Reverse Primer 
ALAS1 GGATTCGAAACAGCCGAGTG TGACATCATTGTGGCGGAAG 
GNB2L1 GAGTGTGGCCTTCTCCTCTG GCTTGCAGTTAGCCAGGTTC 
RPLP0 ACTCTGCATTCTCGCTTCCT GGACTCGTTTGTACCCGTTG 
Table  2.4. Primer sequences for mRNA quantification of housekeeping genes using sybr 
green chemistry. 
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Assay Original source 
ANRIL (15/16) Pasmant et al., 2007 
BIM EL Anderton et al., 2007 
GNB2L1 Zhang, Ding and Sandford, 2005 
Loc 3 and loc 10 Iio et al., 2010 
p16
INK4A
 Kia et al., 2008 
RPLP0 Christin Down, unpublished data 
Table  2.5. The source of the primer sequences that have been developed prior to this 
project. 
 
MicroRNA profiling by TaqMan quantitative real-time PCR Low 
Density Array (TLDA) 
 
RNA was isolated using mirVana™ miRNA Isolation Kit (Ambion) including the optional 
step for enrichment of small RNA (<200 bp) which enables more sensitive detection of low-
level small RNAs. TaqMan® MicroRNA RT Kit and Megaplex Primer Pool A (ABI)   were 
used to reverse transcribe up to 381 microRNAs in a single reaction according to the 
manufacturer’s instructions. 300ng of RNA was reverse transcribed per reaction and the 
cDNA product was used in qPCR without pre-amplification. 
377 human microRNAs were profiled by real-time qPCR using the TaqMan® Array 
MicroRNA A Card v 2.0 (ABI). cDNA was diluted, mixed with TaqMan® Universal PCR 
Master Mix II (ABI) and loaded into the pre-configured micro fluidic card. Real-time reaction 
was run on a 7900HT Real-Time PCR System (ABI) and data analyzed using the SDS RQ 
manager software (ABI). Two biological replicates (two LCL 3CHT lines cultured with or 
without HT and two EBNA3A KO LCL and respective revertants) were analyzed. Ct values 
were normalized to endogenous U6 snRNA and comparative 2−ΔΔCt method was used to 
evaluate the fold change of miRNAs in LCL with or without functional EBNA3C or EBNA3A.  
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MicroRNA qPCR detection 
 
Both, the mirVana™ miRNA Isolation Kit (Ambion) with the step enriching for small RNA 
and the miRCURY RNA Isolation Kit (Exiqon) that isolates total RNA (ranging from large 
messenger and ribosomal RNAs down to microRNAs and other small RNAs) were used. 
10ng RNA was reverse transcribed using microRNA specific RT primers (supplied with 
TaqMan® MicroRNA Assays) and TaqMan® MicroRNA RT Kit (ABI). RNA isolated by 
miRCURY RNA Isolation Kit allowed for reverse transcription and quantification of both 
microRNAs and their longer RNA precursors or target mRNA in the same RNA preparation.  
MicroRNAs were quantified by qPCR using the TaqMan® MicroRNA Assays listed in the 
table 2.6, the TaqMan® Universal PCR Master Mix II and ABI 7900HT real-time PCR 
machine with emulation mode (initial 10 min hold at 95°C, followed by 40 cycles of 15 sec 
at 95°C and 1 min at 60°C). 
 
 
 
 
 
 
Table  2.6.  TaqMan® MicroRNA Assays and U6snRNA (RNU6B) endogenous control 
 
 
 
Assay ID 
miR-143 002249 
miR-145 002278 
miR*-143 002146 
miR*-145 002149 
miR-221  000524 
miR-138 002284 
RNU6B 001093 
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Quantification of promoter DNA methylation 
 
Genomic DNA was extracted with the DNeasy Blood and Tissue Kit (Qiagen) according to 
the manufacturer’s protocol. 200–500 ng of genomic DNA was converted by bisulphite 
using EZ DNA Methylation Kit (Zymo Research). Bisulfite treatment lead to the complete 
conversion of cytosine to uracil in unmethylated DNA, leaving 5-methylcytosine residues 
unaffected. The uracil was amplified as thymine in subsequent PCR reaction. The degree 
of p16INK4A promoter methylation was assessed quantitatively by duplex real-time qPCR 
using EpiTect MethyLight Hs_CDKN2A Assay (Qiagen). Two CpGs in p16INK4A promoter 
(21964737-21964742 of NT_008413.17) were interrogated. The FAM labelled TaqMan 
probe detected the methylated site, while the VIC® labelled TaqMan probe detected the 
unmethylated site in the same reaction. Starting amount of 10 ng bisulfite converted DNA 
was used in each reaction with EpiTect MethyLight PCR kit (Qiagen).  EpiTect Control DNA 
set (Qiagen) supplied control methylated and unmethylated bisulfite converted DNA to 
assess the specificity of primers, as well as methylated and unmethylated (unconverted) 
genomic DNA to monitor the efficiency of bisulphide conversion.  
 
Chromatin immunoprecipitations (ChIP) 
 
All ChIP were carried out using the Chromatin Immunoprecipitation Assay Kit or EZ ChIP 
Kit from Upstate (Millipore), according to the manufacturer’s protocol. To obtain sheared 
chromatin with DNA of 200 bp – 1000 bp in length, extracted chromatin from 2x106 cells 
per ChIP was sonicated in 200 µl lysis buffer for five 20 sec sonication rounds, using a 
Heat Systems Sonicator Ultrasonic Processor XL at 10% intensity or Bioruptor sonicator 
(UCD-200; Diagenode) on a high setting for a total of 12 min (30 sec ‘on’/30 sec ‘off’ 
intermittent sonication). 
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ChIP for histone modifications was performed using anti-H3K27me3 antibody, anti-
H3K4me3 antibody and rabbit IgG serum as a negative control (all from Upstate). 
Precipitated DNA was cleaned using QIAquick Gel Extraction Kit (Qiagen) and was 
assayed by qPCR. Input DNA Ct was adjusted from the 5% used in the qPCR to 100% 
equivalent by subtracting 4.32 (Log2 of 20) cycles. ‘Percent input’ precipitated was then 
calculated by 100 x 2^ (Ct adjusted input – Ct IP). Non-specific background was estimated 
by precipitation with IgG (data generally not shown since all values were below 0.03% of 
input). The error bars represent standard deviations from triplicate qPCR reactions for both 
input and IP. Sequences of the primers mapping the modifications across the CDKN2A 
locus are listed in table 2.7. The position of these assays is specified in the figure 2.3 and 
table 2.8. The sequences of the p14ARF and control promoter assays are listed in the table 
2.9.  
 
CDKN2A  ChIP  
assay Forward primer Reverse primer 
A GGAGCGATGTGATCCGTTATC TGAAATCCCAATCGTCTTCCAC 
B CTCAAAGCGGATAATTCAAGAGC AAGCCTTAAGAACAGTGCCACAC 
C (i) CCCCTTGCCTGGAAAGATAC AGCCCCTCCTCTTTCTTCCT 
C (ii) AGAGGGTCTGCAGCGG TCGAAGCGCTACCTGATTCC 
C1 GCCAAGGAAGAGGAATGAGGAG CCTTCAGATCTTCTCAGCATTCG 
D TAGGAGGCCCCATTAAGCATAC TGTAGTTGCCAGGAGTTGGAGG 
Table  2.7. Primer sequences of the assays spaced across the CDKN2A locus. 
All assays were developed by Bracken et al., 2007 with the exception of C(i) which is from  Kia et al., 
2008. 
 
 
 
 
 
 
79 | P a g e  
 
 
 
 
 
 
 
Fig. 2.3. Localization of the ChIP assays across the CDKN2A locus. Schematic of the human 
CDKN2A locus showing the location of coding exons (boxes) and transcription start sites (horizontal 
arrows) – not drawn to scale. The vertical (A-D) arrows refer to the approximate locations of primer 
pairs used for qPCR analysis of precipitated chromatin. 
 
CDKN2A ChIP  assay Position 
A 4.5kb downstream of p14
ARF 
 TSS 
B 1kb  upstream p16
INK4A 
promoter 
C (i) 85bp in 16
INK4A
  exon 1  (starts at nt 21964992 of NT_008413.17) 
C (ii) 3’ end of 16
INK4A
  exon 1 (starts at nt  21964638 of NT_008413.17) 
C1 200bp downstream of 16
INK4A
  exon 1 
D 800bp downstream 16
INK4A
 exon 3 
Table  2.8.  Localization of the ChIP assays across the CDKN2A locus 
Two assays designed in a very similar location were used for the GC-rich region of 16
INK4A
 exon 1 (C 
i and ii) to ensure precision. 
 
 
 
Promoter assay Forward primer Reverse primer 
GAPDH TACTAGCGGTTTTACGGGCG TCGAACAGGAGGAGCAGAGAGCGA 
γ-globin GCCTTGACCAATAGCCTTGACA GAAATGACCCATGGCGTCTG 
p14 
ARF
(i) GTGGGTCCCAGTCTGCAGTTA CCTTTGGCACCAGAGGTGAG 
p14 
ARF
(ii) CGCCGTGTCCAGATGTCG TGCTCTATCCGCCAATCAGG 
Table  2.9. Primer sequences of the p14
ARF
 and control promoter assays 
GAPDH promoter assay was developed by Millipore 
γ-globin – Bottardi et al., 2011 
p14
ARF
 (i) - Bracken et al., 2007 
p14
ARF
 (ii) - Kia et al., 2008 
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Immunoprecipitation 
 
107 cells were harvested and washed once in ice-cold PBS. The cells were collected by 
centrifugating at 1300 rpm for 4min and the pellet re-suspended in 600 μl of IP lysis buffer. 
The cell lysates were incubated at 4°C for 20 min and the debris was pelleted by 
centrifugating at 13 000 rpm at 4°C for 15 min. The supernatant was split into 200 μl 
aliquots per immunoprecipitation reaction.  20 μl of protein G-Sepharose beads was added 
to each aliquot and mixed at 4°C for 1h to pre-clear the lysate. The beads were next 
pelleted by centrifugation at 1000 rpm at 4°C for 1 min and the supernatant was transferred 
to a fresh tube. Complexes were then precipitated with an antibody specific for the protein 
of interest and the mixture was incubated at 4°C on an orbital rotor for 2h. After this, 30 μl 
of protein G-Sepharose beads were added to the mixture and it was left to rotate at 4°C for 
1h. The beads were next washed 4 times in IP lysis buffer. 30 μl of SDS sample buffer was 
added to the pelleted beads, boiled, centrifuged, and the supernatant was loaded on a 
SDS-PAGE gel for Western blot analysis.  
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Chapter 3 
 Results 
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3.1 Mechanism of p16INK4A epigenetic 
repression by EBNA3C and EBNA3A 
 
3.1.1 EBNA3C and EBNA3A co-operate with CtBP to epigenetically 
repress p16INK4A 
 
 
Objectives 
 
Maruo et al. (2006) reported that conditional EBNA3C inactivation in LCL leads to robust 
growth inhibition and accumulation of p16INK4A.. This important report raised a series of 
questions regarding the nature of the cell cycle arrest following EBNA3C inactivation and 
the mechanism of p16INK4A repression by EBNA3C. In addition, since EBNA3A inactivation 
in LCL was shown to result in similar growth inhibition (Maruo et al., 2003), it became of 
interest whether EBNA3A also contributes to p16INK4A repression in LCL.  It has been well 
established in the past that EBNA3C and EBNA3A are transcriptional regulators of both 
viral and cellular genes (Waltzer et al., 1996; Bourillot et al., 1998; Radkov et al., 1999; Lin 
et al., 2002); however, the mechanism by which they modulate gene expression has 
remained elusive. The regulation of p16INK4A expression by conditionally active EBNA3C in 
LCL therefore offered an attractive model to study in detail the mechanism of EBNA3C-
mediated repression of this crucial cell-cycle regulator.  
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Results 
 
Inactivation of EBNA3C leads to proliferative arrest of LCL 3CHT that can be 
reversed by re-adding HT 
The construction of the EBV-BAC containing EBNA3C-HT fusion and subsequent 
production of LCL 3CHT cell lines has been described previously (see Materials and 
Methods pp. 64-67). It has been predicted from the use of other oestrogen receptor fusion 
systems, such as EBNA2 (Kempkes et al., 1995), that after removal of HT from the 
medium, the protein fused to the HT domain would be rapidly inactivated; in addition, some 
fusions are also targeted for proteasomal degradation. In LCL 3CHT, three to seven days 
after removal of HT from the medium, EBNA3C protein had almost entirely disappeared 
from the whole cell lysates. After re-adding HT into the medium, EBNA3C protein levels 
were mostly reconstituted within 24 hours (Fig. 3.1.1). There were no consistent changes in 
the expression of other latent EBV proteins that correlated with EBNA3C inactivation for up 
to 26 days (Fig. 3.1.2). 
 
Fig. 3.1.1. EBNA3C inactivation and reactivation in LCL 3CHT. Cells that had been grown in 
culture medium containing HT were washed and re-suspended in medium with HT omitted. After 
culturing for the number of days indicated, protein extracts were western blotted and probed with an 
anti-EBNA3C MAb to reveal EBNA3C-HT. After 17 days some cells were transferred to medium 
containing HT and after 1, 5 or 8 days samples were again taken for western blotting. The WB was 
re-probed with anti-γ-tubulin (γ-tub) to ensure equal loading of the proteins. EBNA3C-HT protein is 
considerably decreased by day 7 following HT removal but is reconstituted within first day after HT 
re-adding. WB shown is a representative of at least three replicate experiments. 
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Fig. 3.1.2. Validation of LCL 3CHT.  Western blot of latency-associated EBV proteins in 
representative LCL 3CHT-A, -B and -E cultured for 26 days with (+) or without (-) HT. No consistent 
changes in the expression of EBV latent proteins following EBNA3C inactivation were detected. 
Data shown are representative of two replicate experiments. 
 
Maruo et al. (2006) demonstrated that EBNA3C inactivation leads to cessation of LCL 
proliferation. Consistent with this report, PI staining followed by flow cytometric analysis 
confirmed that there were reduced numbers of cells in the S phase and to a lesser extent in 
G2/M phase in LCL 3CHT cultured for 24 days without HT in comparison to LCL 3CHT 
cultured with HT (Fig. 3.1.3A). In order to test whether EBNA3C inactivation prevents S 
phase entry, BrdU incorporation was used to assess the amount of newly synthesised 
DNA. LCL 3CHT cultured for 33 days with or without HT were pulsed for 1h with BrdU, 
harvested immediately after the pulse, fixed, co-stained with anti-BrdU-FITC conjugate and 
PI and  analysed by flow cytometry. The BrdU/PI profile of cells cultured for a prolonged 
time without active EBNA3C showed a dramatic decrease in cells in S phase of the cell 
cycle (i.e. cells which have highly incorporated BrdU and their DNA content was between 
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2N and 4N) and accumulation of the cells in the G1 phase of the cell cycle (i.e. cells which 
did not incorporate BrdU and their DNA content was 2N) (Fig. 3.1.3B). 
 
 
 
 
 
Fig. 3.1.3.  PI and BrdU/PI profiles of LCL 3CHT with or without HT. (A) LCL 3CHT cells cultured  
for 24 days with or without HT, fixed, stained with PI and analysed by flow cytometry. M1 gate 
represents sub G1 phase, M2 - G1 phase, M3 - S phase and M4 - G2/M phase of the cell cycle. PI 
profile of LCL 3CHT cultured for 24 days without HT shows reduction of cell population in the S 
phase and G2/M phase of the cell cycle compared to LCL 3CHT cultured with HT. A representative 
image of two separate experiments each including two LCL 3CHT lines is shown alongside the 
mean and SD of percentage of cells in the S phase. (B) LCL 3CHT cells cultured for 33 days with or 
without HT, pulsed for 1 hour with BrdU, fixed, stained with anti-BrdU-FITC/PI and analysed by flow 
cytometry. The gated population, which comprises the cells that have undergone DNA replication 
while incubated with BrdU, is considerably reduced in the absence of HT. The image shown is 
representative of two measurements each including two LCL 3CHT lines. 
 
S phase 
 (M3) 
 24d with HT 24d w/o HT 
mean (%) 17.50 6.71 
SD 0.24 0.37 
S phase 
 (R3) 
 33d with HT 33d w/o HT 
mean (%) 38.72 7.44 
SD 2.33 1.85 
B 
 
A 
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In the next step, the kinetics of the onset and progression of LCL proliferative arrest 
following EBNA3C inactivation were assessed. The apparent reduction in LCL proliferation 
was seen within 14 days of culturing LCL 3CHT without HT, by which time BrdU 
incorporation was reduced by about 60% in comparison to proliferating LCL 3CHT cultured 
with HT (controls). When the LCL 3CHT were cultured without HT for an extended period of 
time (33 days), the reduction of cells entering S phase progressed and reached 70 to 90% 
(Fig. 3.1.4A). 
In order to test whether the growth arrest could be reversed after EBNA3C reactivation and 
whether the period LCL 3CHT were cultured without HT would have any effect on the 
restoration of proliferation, HT was re-added after 14 and 33 days without HT. Surprisingly, 
EBNA3C had little immediate effect on cell proliferation, but rather cells increased their 
proliferation very gradually over a number of days. The full restoration of proliferation after 
reactivation of EBNA3C took in the region of weeks in both instances and took longer 
where cells had been cultured for a greater time without functional EBNA3C: if the HT was 
re-added following 14 days without HT, the full proliferation rate was reached in 12 days 
(Fig. 3.1.4B), while if the HT was re-added at the later time-point (after 33 days without 
HT), the period needed to re-establish the full proliferation rate was increased to 16 days 
(Fig. 3.1.4C). Although the times needed for the restoration of the original proliferation rate 
differed only by days, this suggests that at the level of the cell population -if a total 
population of cells is analyzed rather than a single cell- the proliferative arrest following 
EBNA3C inactivation is not a static condition and the speed of its reversal after EBNA3C 
reactivation is dependent on the degree of its progression. 
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Fig. 3.1.4. Proliferation of LCL 3CHT after inactivation and reactivation of EBNA3C. (A) Two 
LCL 3CHT (-A and -C) generated from independent 3CHT-BACs using PBL from mixed donors 
analysed by BrdU/PI (as in Fig. 3.1.3B) after 14 and 33 days without HT. Histograms show BrdU 
incorporation relative to the control, cycling population (ctrl) grown with HT. (B) LCL 3CHT-A and -C 
cultured for 14 days in the absence of HT (0) and after 4, 7 and 12 days after re-adding HT. (C) A 
similar experiment performed on cells cultured for 33 days without HT. Proliferation of LCL 3CHT is 
progressively reduced during weeks following EBNA3C inactivation and can be fully restored after 
EBNA3C is reactivated; however, the restoration occurs gradually over number of days and appears 
to depend on the intensity of the previous proliferative arrest. The error bars represent the standard 
deviation from the means of two technical replicates for each sample.  
 
C 
 
B 
 
A 
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Proliferation of LCL 3CHT correlates with the regulation of p16INK4A expression 
Maruo et al. (2006) described how p16INK4A accumulates in the absence of functional 
EBNA3C. Here, I tested whether the changes in p16INK4A levels in response to EBNA3C 
inactivation and reactivation correlate with (and could account for) the changes in 
proliferation of LCL 3CHT. 
The DNA sequence of the unique first exon of p16INK4A is GC rich and contains substantial 
secondary structure. A qPCR assay specific for p16INK4A only transcripts, which detects 
amplicon located within the first exon of p16INK4A (p16INK4A assay), is quantitative only in the 
presence of higher quantities of the template. Therefore, an assay quantifying an amplicon 
located within the second and third exon shared by p16INK4A and p14ARF was designed 
(CDKN2A assay), which is quantitative over 5 log units of template (Fig. 3.1.5).  
 
 
 
 
 
 
 
 
Fig. 3.1.5. Scheme of the CDKN2A locus and the localization of qPCR assays (adapted from 
Walker and Hayward, 2002a and 2002b).  p16
INK4A
 and p14
ARF
 transcripts share the second and 
third exons but not the first. The p16
INK4A
 transcript uses exon 1α, whereas the p14
ARF
 transcript 
uses exon 1β. The unshaded portions of each exon correspond to the untranslated regions of the 
transcripts. p16
INK4A 
 qPCR assay detects amplicon in exon 1α, p14
ARF 
qPCR assay detects an 
amplicon in exon 1β, while the CDKN2A assay detects an amplicon across the exon2/exon3 
boundary. The details of the primers are listed in the Material and Methods, table 2.2 and table 2.3. 
The localization of sybr green CDKN2A assay and taqman CDKN2A assay (ABI) is similar.  
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Using the comparative Ct method and comparing in each sample the Ct values of CDKN2A 
assay and the assay that detect only p16INK4A (p16INK4A assay) or only p14ARF 
(p14ARFassay), it was estimated that the majority of the transcripts measured by CDKN2A 
assay in LCL 3CHT cultured with or without HT were p16INK4A transcripts (data not shown). 
After 14 days in culture in the absence of HT, there was a 2-2.5 fold increase in CDKN2A 
transcripts. After re-adding HT into the medium, CDKN2A transcripts gradually decreased 
over 12 days (Fig. 3.1.6A).  When the period of culture in the absence of HT was extended 
to 33 days, there was a 3-5 fold increase in the level of CDKN2A transcripts. After re-
adding HT into the medium, CDKN2A transcripts gradually decreased, but it seemed to 
require a longer period of at least 16 days (Fig. 3.1.6C). This was consistent with fold 
changes measured by the assay specific for p16INK4A only transcripts (Fig. 3.1.6B and 6D). 
Both, the accumulation of CDKN2A transcripts in LCL 3CHT cultured 33 days without HT 
relative to the cycling controls cultured with HT and the decrease of CDKN2A transcripts 
after HT was re-added for 16 days relative to day 0, were found statistically singificant (Fig. 
3.1.6C). 
Correspondingly, after reactivation of EBNA3C in LCL 3CHT, p16INK4A protein expression 
gradually diminished (Fig. 3.1.6E). The levels of p16INK4A protein correlated with p16INK4A 
mRNA. The regulation of p16INK4A in LCL 3CHT seems to be exclusively or at least 
predominantly at the level of the transcript as has been previously shown in various types 
of cell, including LCL (Gil and Peters, 2006; Maruo et al., 2006). 
In the context of the total LCL 3CHT cell population, with extended time of culture without 
functional EBNA3C, p16INK4A progressively accumulated and the population arrest became 
more profound. Depending on the degree of p16INK4A accumulation and the intensity of 
proliferative arrest, different time periods were needed to fully repress p16INK4A and restore 
the original rate of proliferation after reactivation of EBNA3C. Taken together, p16INK4A 
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levels in LCL 3CHT cultured with or without HT seemed to be in inverse relation to the 
proportion of cells entering S phase. 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.6. Repression of p16
INK4A
 following reactivation of EBNA3C. (A) After 14 days without 
HT (0), total RNA was extracted from aliquots from two LCL 3CHT populations (-A and -C). HT was 
re-added to the remaining cells and further RNA samples were taken at the times indicated. 
C 
 
91 | P a g e  
 
CDKN2A transcripts were quantified by qPCR. The histogram corresponds to CDKN2A mRNA 
relative to that in control cycling populations of each LCL 3CHT (ctrl). (B) As in (A) but using a 
p16
INK4A
-specific qPCR. (C) & (D) Similar assays to those described in (A) and (B) after 33 days 
without HT. ** p<0.005; *** p<0.001 (E) Western blot – probed with a p16
INK4A
-specific MAb – of cell 
lysates from LCL 3CHT-C cells to which HT was re-added after 14 or 33 days in its absence (014 and 
033 respectively). The control (ctrl) is LCL 3CHT-C cells continuously cultured with HT.  
CDKN2A/p16
INK4A
 mRNA and p16
INK4A
 protein gradually decrease following EBNA3C reactivation. 
The results are representative of two similar experiments each including two LCL 3CHT lines. 
 
 
 
Inactivation of EBNA3C leads to dephosphorylation of the retinoblastoma protein 
(Rb), reduced expression of p107 and an increase in p130; activation of EBNA3C 
reverses these processes 
In the next step I tested the consequences of p16INK4A accumulation following EBNA3C 
inactivation on the downstream components of the p16INK4A -Rb axis.  LCL 3CHT were 
cultured with HT (controls) or without HT for 14 and 33 days and subsequently, HT was re-
added at day 14 and at day 33. In arrested cells, Rb was initially hypophosphorylated; as 
the arrest intensified with extended time of culture without HT, hypophosphorylation 
seemed to be accompanied by Rb downregulation (Fig. 3.1.7A). Simultaneously, with the 
length of time in culture in the absence of functional EBNA3C, p130 protein accumulated 
and p107 was diminished (Fig. 3.1.7B, samples annotated 014 and 033). Consistently with 
previous data monitoring LCL 3CHT proliferation and p16INK4A repression in response to re-
addition of HT, after reconstitution of functional EBNA3C, Rb was gradually phoshorylated 
and upregulated (Fig. 3.1.7B). Expression of p130, although still detectable, decreased as 
cells entered the proliferation cycle and conversely, p107 was upregulated (Fig. 3.1.7B). 
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Fig. 3.1.7. Regulation of the quantity and phosphorylation of pocket proteins in response to 
EBNA3C (A) Western blot analysis of three LCL 3CHT lines (-A, -B and –D) performed on whole cell 
lysates from cells cultured for 26 days with (+) or without HT (-). As the amount of EBNA3C protein 
decreases and p16
INK4A
 accumulates, so hyperphosphorylated Rb (ppRb) protein disappears and 
only hypophosphorylated Rb (pRb) is detected. The levels of E2F1 and γ-tubulin (γ-tub) remain 
unchanged irrespective of the culture conditions. (B) Western blot analysis of extracts from LCL 
3CHT -C after re-addition of HT to cultures starved of HT for either 14 or 33 days (014 and 033 
respectively). A pan-specific anti-Rb MAb and phospho-specific MAb (Ser 807-811) both show an 
increase in hyperphosphorylated Rb (ppRb) after HT was added. After 12-16 days the degree of 
phosphorylation is equivalent to that in the proliferating control LCL 3CHT population (ctrl). As Rb 
becomes phosphorylated, expression of p107 increases and expression of p130 decreases. The 
level of γ-tubulin (γ-tub) does not alter throughout the experiment.  Data shown are representative of 
at least three separate experiments in (A) and two biological replicates (LCL 3CHT lines) in (B). 
 
A 
 
B 
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Regulation of H3K27me3 and H3K4me3 across the p16INK4A locus in LCL 3CHT 
requires EBNA3C   
 
The repression of p16INK4A by H3K27me3 mark and PcG silencers has been previously well 
characterized in primary fibroblasts. In pre-senescent proliferating fibroblasts H3K27me3 
mark forms a broad peak centred on the first exon of p16INK4A.  Induction of senescence is 
associated with eviction of PcG silencers and a profound reduction of H3K27me3 on the 
chromatin associated with p16INK4A  exon 1 (Barradas et al., 2009). The p16INK4A exon 1 
serves as a promoter-like transcription-defining region in p16INK4A locus. 
We hypothesised that the transcriptional up-regulation of p16INK4A in the absence of 
functional EBNA3C might result from the loss of PcG-mediated repression. Therefore, ChIP 
combined with a set of qPCR assays detecting amplicons spaced across the entire 
CDKN2A locus was performed to assess the level of H3K27me3 at p16INK4A  in LCL 3CHT 
cultured with or without HT (Fig. 3.1.8A). After EBNA3C inactivation, H3K27me3 at the 
p16INK4A exon 1 gradually decreased over the period of several weeks (Fig. 3.1.8B). This 
process could be reversed by reconstitution of functional EBNA3C after re-addition of HT 
with similar delay (Fig. 3.1.8B sample annotated +). The progressive reduction of 
H3K27me3 at p16INK4A with the length of time in culture without functional EBNA3C 
inversely correlated with the gradual p16INK4A transcriptional induction (Fig. 3.1.8C and D). 
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Fig. 3.1.8. Simultaneous ChIP analysis quantifying the H3K27me3 mark on p16
INK4A
 exon 1 
and qPCR analysis of p16
INK4A
 transcription in response to EBNA3C. (A) Schematic of the 
human CDKN2A locus showing the location of coding exons (boxes) and transcription start sites 
(horizontal arrows) – not drawn to scale. The vertical (A-D) arrows refer to the approximate locations 
of primer pairs used for qPCR analysis of precipitated chromatin (as described in Materials and 
Methods, Table 2.7 and Table 2.8). (B) ChIP analysis of H3K27me3 distribution on p16
INK4A
 exon1 
(site C- two assays in similar location, see Table 2.8). Histogram shows the decline in H3K27me3 in 
LCL 3CHT-A cultured for up to 35 days without HT and H3K27me3 restoration after HT was re-
added for 16 days (annotated as +). (C) Similar histogram as in (B) shows a decline in H3K27me3 
relative to a cycling LCL 3CHT (day 0) in LCL 3CHT-C. (D) Corresponding increase in p16
INK4A
 
mRNA in LCL 3CHT-C quantified by qPCR. 
 
A 
 
B 
 
C 
 
D 
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Relatively high quantities of an activation-associated H3K4me3 were detected at p16INK4A 
exon 1 compared to the surrounding regions even when EBNA3C was active and p16INK4A   
was repressed (i.e. in LCL 3CHT with HT and with HT re-added) (Fig. 3.1.9B). This 
suggests that p16INK4A exon 1 in LCL contains a bivalent chromatin domain which can 
facilitate prompt p16INK4A induction following anti-proliferative or aberrant pro-proliferative 
signals. ChIP analyses were performed to assess the quantities of both modifications at the 
p16INK4A locus in LCL 3CHT in response to EBNA3C. EBNA3C inactivation affected 
epigenetic marks at the p16INK4A locus in a way consistent with transcriptional activation; 
the repressive H3K27me3 mark was reduced while the activation-related H3K4me3 
modestly increased. After EBNA3C reactivation, the epigenetic modifications at p16INK4A 
locus were reversed (Fig. 3.1.9A and B).   
 
          
Fig. 3.1.9. ChIP analysis quantifying the H3K27me3 and H3K4me3 marks at the p16
INK4A
 locus 
in response to EBNA3C. (A) ChIP analysis of H3K27me3 distribution across the CDKN2A locus in 
LCL 3CHT-A proliferating in the presence of HT, after 30 days without HT and 20 days after re-
adding HT. (B) Similar ChIP analysis of H3K4me3. Repressive chromatin is detected at p16
INK4A
 
exon 1 when EBNA3C is active and the chromatin is remodelled to support transcription following 
EBNA3C inactivation. 
 
 
A 
 
B 
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To confirm specificity of p16INK4A regulation, H3K27me3 and H3K4me3 quantities at 
p16INK4A locus were compared to the quantities at the surrounding upstream region located 
4.5kb downstream of p14ARF transcription start site (assay A in Fig. 3.1.9A). As described 
previously (Barradas et al., 2009), in human primary fibroblasts H3K27me3 mark is broadly 
distributed at CDKN2A locus and spans into the chosen control region A. Similarly, the 
control region in LCL 3CHT was still associated with some although low H3K27me3 
binding.  However, H3K4me3 was present in insignificant amounts in the control region 
compared to p16INK4A exon 1. The peak binding of H3K27me3 (in the presence of functional 
EBNA3C) and H3K4me3 detected at p16INK4A exon 1 strengthens the evidence that the 
regulation of p16INK4A locus is specific. In addition, the presence of two inversely regulated 
modifications excludes the possibility that the reduction in histone methylation is due to 
nucleosome re-positioning and reduction of the total histone H3 at p16INK4A exon 1. 
Parallel ChIP experiments were performed with anti-IgG antibody of the same species as 
the anti-H3K27me3/H3K4me3 antibodies to assess the level of background. The 
background binding was found to be insignificant in all lines and conditions. In addition, the 
anti-H3K27me3 and anti-H3K4me3 ChIPs were validated using qPCR assays located in 
control promoters either repressed (γ-globin) or active (GAPDH)  in LCL 3CHT regardless 
of EBNA3C activity (Fig. 3.1.10A and B, qPCR of GAPDH and γ-globin in LCL 3CHT with 
or without HT – data not shown). γ-globin genes are developmentally regulated and usually 
expressed only in the fetal liver, spleen and bone marrow; otherwise they are repressed by 
H3K27me3 (Xu et al., 2010b; Sankaran et al., 2011). GAPDH is a highly expressed 
housekeeping gene, widely used as a positive control for anti-H3K4me3 ChIP (Rugg-Gunn 
et al., 2010). 
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Fig. 3.1.10. Validation ChIPs in LCL 3CHT. (A) Comparison of H3K27me3, H3K4me3 and IgG 
quantities at p16
INK4A
 exon1 and repressed γ-globin promoter in LCL 3CHT cultured with HT, after 30 
days without HT and 20 days after re-adding HT. (B) Similar analysis comparing p16
INK4A
 exon1 and 
active GAPDH promoter. Insignificant background is detected at all times by anti-IgG ChIP. 
H3K27me3 is correctly detected at the repressed γ-globin promoter but not at the active GAPDH 
promoter, while reverse holds true for H3K4me3.  The H3K27me3 and H3K4me3 marks at γ-globin 
promoter or GAPDH promoter are not regulated in response to EBNA3C. 
A 
 
B 
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In order to test whether in proliferating WT LCL, when p16INK4A locus is tightly repressed, 
EBNA3C is being recruited to the p16INK4A, a ChIP analysis with purified anti-EBNA3C 
antibody was performed to quantify EBNA3C at p16INK4A locus.  However, to date, a positive 
control for EBNA3C ChIP, i.e. a cellular or viral locus occupied by EBNA3C, has not been 
reliably identified. It remains unclear whether the anti-EBNA3C antibodies available work in 
ChIP assays. Therefore it is hoped that ChIP-validated anti-FLAG antibody could be used 
to assess the EBNA3C association with p16INK4A locus in LCL produced using  recombinant 
EBV-BAC viruses encoding strep-FLAG (TAP)-tagged EBNA3C (Gill Parker and Kostas 
Paschos, personal communication). 
 
EBNA3C-mediated regulation of p16INK4A does not require Rb  
To avoid biases due to limited number of cell lines, I decided to confirm our findings using 
six newly established LCL 3CHT established using PBL from several single donors. It was 
immediately apparent that one of the cell lines did not arrest after the removal of HT from 
the medium (data not shown). In addition to western blots, which failed to detect Rb protein 
in this cell line (LCL 3CHT-E) cultured with or without HT, it was found using qPCR that 
LCL 3CHT-E expressed very low levels of Rb mRNA in comparison to other LCL 3CHT 
lines and WT LCL (Fig. 3.1.11A and B). It has been well established that functional Rb 
regulates p16INK4A levels through a negative feedback loop and that Rb-negative tumours 
(such as carcinoma of cervix) express high levels of p16INK4A (Little and Stewart, 2010). 
However, even in this Rb-reduced cell line, p16INK4A was repressed in the presence of 
active EBNA3C, and this repression was relieved after EBNA3C inactivation.  Furthermore, 
ChIP analysis confirmed that p16INK4A locus was still epigenetically repressed by EBNA3C 
even when Rb was notably reduced. H3K27me3 and H3K4me3 distribution across the 
CDKN2A locus in LCL 3CHT-E cells following EBNA3C inactivation and reactivation 
showed chromatin remodelling identical to that seen in other LCL 3CHT lines (Fig. 3.1.11C 
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and D).  This reinforces the view that the epigenetic regulation of p16INK4A by EBNA3C is 
independent of Rb expression.  
 
      
 
           
Fig. 3.1.11. EBNA3C-mediated regulation of p16
INK4A
 does not require Rb. (A) Western blot 
analysis of whole cell lysates from two LCL 3CHT (-D and -E) cultured for 26 days with (+) or without 
(-) HT. Although Rb is undetectable in LCL 3CHT-E, when HT is removed from the growth medium, 
EBNA3C decreases and p16
INK4A
 (p16) increases. E2F1 and γ-tubulin (γ-tub) levels do not alter. (B)  
qPCR of the steady-state levels of Rb mRNA in LCL 3CHT-E relative to 3 other LCL 3CHT and a 
WT LCL all cultured with HT. (C) ChIP analysis of H3K27me3 distribution across the CDKN2A locus 
in LCL 3CHT-E cells (expressing little or no Rb) cultured for 21 days with HT or without HT. (D) 
Similar ChIP analysis of H3K4me3. The p16
INK4A
 locus is epigenetically regulated by EBNA3C even 
in Rb-reduced LCL 3CHT-E line. 
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EBNA3A also contributes to the regulation of p16INK4A 
 
A conditional EBV-BAC EBNA3A-HT fusion virus has been produced in our lab. However, 
BL31 cell line infected with EBNA3A-HT virus in the presence of HT failed to repress 
proapoptotic BIM which was used as a read-out for the efficiency of the system. 
Furthermore there was evidence of WT EBNA3A protein in LCL produced with EBNA3A-
HT virus (data not shown). We decided not to use this EBNA3A-HT virus, but will consider 
constructing a new recombinant, with a more stable EBNA3A-HT fusion.  
Recently, EBNA3A was shown to regulate p16INK4A transcripts in a microarray study using 
EBNA3A KO LCL (Hertle et al., 2009). In our hands also, LCL carrying EBNA3A KO 
recombinant viruses can be established; however, the outgrowth of LCL produced with 
EBNA3A KO virus is much slower and less efficient in comparison to LCL produced with 
WT or revertant viruses (Rob White, personal communication). It is likely there is a strong 
selection for pro-proliferative mutations in cells during transformation with EBNA3A KO 
viruses, so EBNA3A KO LCL may not be an optimal system to study EBNA3A function. 
Nevertheless, EBNA3A KO LCL have produced data consistent with a role for EBNA3A in 
p16INK4A regulation. 
It has been demonstrated in our lab that EBNA3C and EBNA3A co-operate to regulate 
cellular genes (Paschos et al., 2009; White et al., 2010). Despite the pitfalls mentioned 
above, I was keen to investigate whether EBNA3A-associated p16INK4A repression shows 
similarities to EBNA3C-mediated repression. Therefore two EBNA3A KO LCL lines 
produced in our lab were tested to determine whether our system is equivalent to the one 
described by Hertle et al. (2009). It was confirmed that in both EBNA3A KO LCL p16INK4A 
protein was indeed elevated in comparison to LCL established from the PBL of the same 
donors (as used to produce EBNA3A KO LCL) with WT virus. However, this increased 
expression was modest compared to p16INK4A accumulation in LCL 3CHT cultured without 
HT (Fig. 3.1.12A). A comparison of steady state levels of H3K27me3 and H3K4me3 at the 
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p16INK4A locus revealed that in the absence of EBNA3A, the ratio of H3K27me3 to 
H3K4me3 associated with p16INK4A exon 1 was reversed relative to LCL established with 
WT EBV BACs (Fig. 3.1.12B and C). Although the remodelling of chromatin at p16INK4A in 
EBNA3A KO was not as pronounced as in the case of EBNA3C inactivation, the low level 
of H3K27me3 and high level of H3K4me3 were consistent with a more transcriptionally 
active locus and the higher levels of p16INK4A protein detected in the EBNA3A KO lines.  
This suggests that EBNA3A, together with EBNA3C, is involved in the chromatin 
remodelling of p16INK4A. 
 
 
 
 
      
Fig. 3.1.12. EBNA3A contributes to the regulation of p16
INK4A
. (A) Western blot analysis of three 
LCL established with virus derived from B95.8-EBV BAC (WT) and two established with EBNA3A 
KO recombinants. The steady state levels of p16
INK4A
 (p16) are elevated in the EBNA3A KO cells 
relative to the WT-EBV infected cells. An LCL 3CHT (3CHT) with (+) or without (-) HT is shown for 
comparison. WB shown is a representative of three separate experiments each including two 
EBNA3A KO LCL. (B) & (C) ChIP analysis of H3K27me3 and H3K4me3 distribution on p16
INK4A
 
exon 1 (site C) and  site A in the CDKN2A locus from an EBNA3A KO LCL (EBNA3A KO) and a WT 
LCL (WT). The chromatin at p16
INK4A
 exon 1 is remodelled in EBNA3A KO LCL to support 
transcription. 
A 
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102 | P a g e  
 
LCL expressing CtBP-binding mutants of EBNA3C and EBNA3A grow relatively 
poorly and express higher than normal levels of p16INK4A 
 
It has been demonstrated that EBNA3C and EBNA3A mutant proteins that are unable to 
bind CtBP are inferior in their ability to transform primary rat embryo fibroblasts in co-
operation with activated Ras in comparison to WT EBNA3C and EBNA3A (Touitou et al., 
2001; Hickabottom et al., 2002).  Moreover, recently Mroz et al. (2008) found that CtBP is 
involved in the repression of p16INK4A but not p14ARF locus in primary human fibroblasts and 
keratinocytes. This led me to hypothesize that interaction of EBNA3C and/or EBNA3A with 
CtBP might contribute to the repression of p16INK4A in proliferating LCL. 
Recombinant EBV-BAC viruses in which the CtBP-binding sites of EBNA3A (3ACtBP) or 
EBNA3C (3CCtBP) or both EBNA3s (E3CtBP) were mutated were produced and validated 
(see Materials and Methods, pp. 64-67).  It was confirmed by immunoprecipitations that in 
CtBP-binding mutant LCL the interaction between respective EBNA3s and CtBP was 
abolished and that the expression of EBV latent proteins did not exhibit any consistent 
changes in comparison to the respective revertant LCL or WT LCL (Skalska et al., 2010). 
Although it was possible to establish LCL using all three types of CtBP-binding mutant 
viruses, the rate of outgrowth of these LCL was considerably slower than of the respective 
revertant or WT LCL (Rob White, personal communication). Even once LCL were 
established, CtBP–binding mutant LCL continued to show a growth defect, exhibiting 
reduced rate of population growth relative to WT and revertant LCL. They also tended to 
have a much lower maximum cell density, with CtBP-binding mutants struggling to grow 
much beyond 0.7x106 cells/ml (Skalska et al., 2010; Rob White, personal communication).  
When p16INK4A transcripts and protein were quantified by qPCR and WB respectively (Fig. 
3.1.13) it was apparent that all the mutants express more p16INK4A mRNA and protein than 
either the WT or revertant LCL. 
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Fig. 3.1.13. Expression of p16
INK4A
 in CtBP-binding mutant LCL relative to revertant and WT 
LCL. (A) The relative levels of CDKN2A transcripts  quantified by qPCR in E3
CtBP
, 3A
CtBP
, 3C
CtBP
 and 
two rev
CtBP
 LCL harvested 28 days after the infection of PBL with the recombinant EBVs. (B) The 
relative levels of CDKN2A transcripts in RNA extracted from two established E3
CtBP
 LCL, two 3A
CtBP
 
LCL, 3C
CtBP 
LCL, a revertant (rev
CtBP
) and a WT LCL. (C) Western blot analysis of protein extracts 
from two E3
CtBP
 LCL, two 3A
CtBP 
LCL and a 3C
CtBP
 LCL all established  from  PBL of a single donor. 
A revertant (rev
CtBP
) and a WT LCL are shown for comparison. Levels of p16
INK4A
 (p16) are shown 
relative to γ-tubulin (γ-tub). p16
INK4A
 is increased in all CtBP-binding mutant LCL early during the 
outgrowth and later in culture. Data are representative of three separate experiments including WT 
and CtBP-binding mutant LCL established from PBL of three different single donors (my 
data and Rob White, personal communication).  
 
Although the CtBP-binding mutant LCL examined here expressed elevated levels of 
p16INK4A protein, the cells were clearly capable of cell division. Rb competence was 
therefore investigated. Rb protein and mRNA expression in the CtBP-binding mutant LCL 
were notably reduced and some E3CtBP LCL appeared to lose Rb expression completely 
(Fig. 3.1.14, also Rob White, personal communication). 
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Fig. 3.1.14. Reduction of Rb in CtBP-binding mutant LCL. (A) Western blot analysis showing the 
reduction of Rb protein expression in the established E3
CtBP
 and 3A
CtBP
 LCL in comparison to rev
CtBP
 
and WT LCL. The levels of p16
INK4A
 are shown for comparison. γ-tubulin (γ-tub) was used as a 
loading control. B) Steady-state levels of Rb mRNA in the RNA harvested from the same lines as in 
(A). Data are representative of two separate experiments including WT and CtBP-binding mutant 
LCL established from PBL of two different single donors (my data and Rob White, personal 
communication).  
 
 
Interaction of EBNA3C and EBNA3A with CtBP is necessary for the chromatin 
remodelling associated with the repression of p16INK4A 
CtBP has been implicated in PcG-mediated repression (Sewalt et al., 1999; Atchison et al., 
2003; Basu and Atchison, 2010); in addition CtBP-containing supercomplexes have been 
shown to contain multiple histone modifying enzymes including a H3K4 dimethyl and 
monomethyl demethylase LSD1 (Shi et al., 2003). We therefore hypothesised that CtBP 
might co-operate with EBNA3C and EBNA3A in epigenetic repression of p16INK4A.  ChIP 
analysis revealed that all CtBP-binding mutant LCL (E3CtBP, 3ACtBP and 3CCtBP LCL) contain 
active chromatin at the p16INK4A locus in comparison to WT LCL and the corresponding 
revertant (Fig. 3.1.15A and B). The E3CtBP LCL profile resembled those of LCL-3CHT cells 
cultured without HT. In contrast, the WT and revertant profiles resembled LCL 3CHT 
A 
 
B 
 
105 | P a g e  
 
cultured in the presence of HT (Fig. 3.1.15C and D and Fig. 3.1.9A and B). This implies 
that the interaction of both EBNA3C and EBNA3A with CtBP is important for EBV-mediated 
chromatin remodelling and repression of p16INK4A in LCL. 
 
               
  
         
Fig. 3.1.15. The interaction of EBNA3C and EBNA3A with CtBP is necessary for the chromatin 
remodelling associated with the repression of p16
INK4A
.  (A) & (B) ChIP analysis of H3K27me3 
and H3K4me3 at p16
INK4A
  exon 1 (two assays in similar location within exon 1) on an E3
CtBP
 LCL, a 
3A
CtBP
 and a 3C
CtBP
 LCL. Similar analysis of a WT LCL is shown for comparison. (C) & (D) ChIP 
anaysis of H3K27me3 and H4Kme3 distribution across the CDKN2A in an E3
CtBP
 LCL. Similar 
assays performed on revertant (rev
CtBP
) and WT LCL are shown for comparison. Repressive 
chromatin is maintained at p16
INK4A
 locus only when EBNA3C and EBNA3A are able to bind CtBP. 
A 
 
B 
 
C 
 
D 
 
106 | P a g e  
 
The regulation of overall EZH2 expression or p16INK4A promoter DNA methylation 
does not play a major role in the mechanism of EBNA3C-mediated p16INK4A 
repression  
 
H3K27me3 mark is established by SET-containing EZH2 subunit of the PRC2 complex 
(Margueron and Reinberg, 2011). PRC2 core members (EZH2, SUZ12 and EED) are 
interdependent; the withdrawal of EZH2 or other core components of PRC2 complex 
results in the genome-wide de-repression of the PRC2 target genes (Landeira and Fisher, 
2011).  To assess whether the overall degree of EZH2 expression in LCL 3CHT contributes 
to the regulation of  p16INK4A locus in response to EBNA3C, four LCL 3CHT lines, including 
the Rb-reduced line (LCL 3CHT-E), were cultured for 26 days with or without HT and the 
expression of EZH2 was assessed by western blotting of whole cell lysates.  
In all Rb-competent lines, the expression of EZH2, a direct E2F1 target (Bracken et al., 
2003), was significantly decreased. However, in Rb-reduced LCL3CHT line (-E), 
proliferation of which was not influenced by EBNA3C inactivation, EZH2 levels remained 
similar before and after EBNA3C inactivation (Fig. 3.1.16). However, the p16INK4A locus was 
de-repressed and H3K27me3 mark was erased after EBNA3C inactivation in all LCL 
3CHT, including LCL 3CHT-E, irrespective of EZH2 levels (Fig. 3.1.11). This suggests that 
epigenetic regulation of p16INK4A by EBNA3C is not primarily through regulation of overall 
EZH2 expression. 
The expression of H3K27me3 demethylases JMJD3/KDM6B and UTX/KDM6A was also 
assessed in LCL 3CHT cultured with or without HT and no changes in expression in 
response to EBNA3C activity were detected (data not shown). 
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Fig. 3.1.16.  EZH2 expression in LCL 3CHT.  Western blot illustrating the EZH2 expression in four  
LCL 3CHT including the Rb-reduced line (-E) cultured 26 days with (+) or without  (-) HT. EZH2 is 
reduced following EBNA3C inactivation in all three LCL 3CHT in which proliferation was inhibited (-
B, -C, -D). In Rb-reduced line (-E), the expression of EZH2 remains stable. This is consistent with 
EZH2 being a direct E2F1 target gene and implies EBNA3C does not regulate p16
INK4A 
locus via 
modulation of overall EZH2 expression. EBNA3C-HT fusion protein was quantified to demonstrate 
the consistent EBNA3C inactivation followed by its degradation in all LCL 3CHT lines and γ-tubulin 
(γ-tub) was used as a loading control. WB shown is a representative of two replicate experiments. 
 
Next, I asked whether DNA methylation status at p16INK4A changes in response to 
EBNA3C. Genomic DNA from 2 newly established LCL 3CHT lines (i.e. 3 months from the 
day of infection) cultured for 33 days with or without HT was isolated, bisulphite converted 
and the degree of the CpG island methylation at p16INK4A promoter was quantitatively 
measured by qPCR using commercially available CDKN2A methylight assay (Qiagen, for 
details see Materials and Methods, p.77). DNA isolated from BL31, where p16INK4A 
promoter is known to be heavily methylated, was used as a control, in addition to 
commercially available completely unmethylated and methylated control DNA.  p16INK4A 
promoter in LCL 3CHT was not methylated in proliferating cells cultured with HT at the start 
of the experiment (day 0), or after 33 days of culture with and without HT (Fig. 3.1.17). 
Consistent with the findings of Maruo et al. (2011), DNA methylation of the p16INK4A 
promoter did not contribute to the changes in p16INK4A expression in response to EBNA3C 
and H3K27me3 alone was sufficient for p16INK4A repression in LCL with active EBNA3C. 
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Fig. 3.1.17.   p16
INK4A 
promoter DNA methylation in newly established LCL in response to 
EBNA3C.  Methylation-specific qPCR (methylight) was used to assess the degree of p16
INK4A 
promoter methylation in two LCL 3CHT (-A  and -C) harvested in day 0 and then again after 33 days 
of being cultured  with or without HT.  DNA from BL31 and commercially available control DNA were 
used as controls. p16
INK4A 
promoter is unmethylated in these relatively newly established LCL 
regardless of EBNA3C activity. Results are representative of two similar experiments. 
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3.1.2 The association of EBNA3C and EBNA3A with components of 
CtBP supercomplexes 
 
Objectives 
Even though I was unable to detect EBNA3C, EBNA3A and CtBP at the p16INK4A locus 
(data not shown), I clearly showed the co-operation of these viral oncoproteins with CtBP is 
required in the epigenetic repression of p16INK4A. In addition, in a microarray analysis 
performed using LCL and BL31 carrying CtBP-binding mutants of EBNA3C and/or 
EBNA3A or revertant and WT viruses; it was shown that the ability of EBNA3C and/or 
EBNA3A to bind CtBP was required for regulation of a subset of cellular genes (Rob White, 
personal communication). Furthermore, the epigenetic repression of another EBNA3C and 
EBNA3A-regulated gene BIM by H3K27me3 was modestly but significantly reduced in 
BL31 carrying CtBP-binding mutants of EBNA3C and/or EBNA3A (Kostas Paschos, 
personal communication). In order to gain further insight into the mechanics of epigenetic 
regulation of p16INK4A locus and perhaps other genes by EBNA3C and EBNA3A, I decided 
to investigate the composition of EBNA3C and/or EBNA3A and CtBP-containing complexes 
in B-cell derived lines. 
 
Results 
 
EBNA3C and EBNA3A are co-immunoprecipitated with several chromatin 
remodelling members of CtBP supercomplex  
First, the co-immunoprecipitation procedure was tested by confirming the known 
association of EBNA3C and EBNA3A with CtBP in protein extracts from WT LCL. As 
expected, anti-CtBP antibody pulled down both EBNA3C and EBNA3A, but did not pull 
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down EBNA3B, which does not contain any CtBP-binding sites. Next, I tested whether 
H3K4 demethylase LSD1, a known component of CtBP supercomplexes, associates with 
EBNA3C and/or EBNA3A. Anti-LSD1 antibody convincingly pulled down EBNA3C and 
EBNA3A but not EBNA3B in WT LCL (Fig. 3.1.18). The same findings were confirmed in 
several WT LCL lines and with an alternative anti-LSD1 antibody (data not shown).   
 
In further co-immunprecipitation experiments, a panel of other members of CtBP 
supercomplex including HDAC1/2, Co-REST, G9a, Ubc 9 and HPC2 (Chinnadurai, 2007) 
were tested for their ability to pull down EBNA3s. Anti-co-REST pulled down EBNA3A but 
not EBNA3B in WT LCL protein extracts (Fig.3.1.19A). Co-REST-EBNA3C pull down was 
not included for technical reasons (both anti-CoREST and anti-EBNA3C antibodies 
available were of the same species). Furthermore, anti-HDAC1 pulled down EBNA3C, 
EBNA3A and CtBP in WT LCL (Fig. 3.1.19B).  
 
 
 
 
Fig 3.1.18.  Co-immunoprecipitation with anti-CtBP and anti-LSD1 antibody in WT LCL. On the 
right, western blot of EBNA3s precipitated by anti-CtBP and anti-IgG antibody from the same input. 
On the left, western blot depicting the quantity of EBNA3s precipitated by anti-LSD1 and the 
corresponding anti-IgG antibody from the same input. Input represents 10% of the total cell extract 
used for the immunoprecipitation.  In WT LCL, co-immunoprecipitation procedure was validated by 
CtBP pull-down which correctly showed that anti-CtBP pulls down EBNA3C and EBNA3A but not 
EBNA3B. Anti-LSD1 similarly pulls down EBNA3C and EBNA3A but not EBNA3B in WT LCL. Data 
shown are representative of at least three replicate experiments including different WT LCL lines. 
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Fig 3.1.19.  Co-immunoprecipitation with anti-Co-REST and anti-HDAC1 antibody in WT LCL.  
Input represents 5% of the total cell extract used for the immunoprecipitation. (A) Western blot of 
EBNA3A and EBNA3B precipitated by anti-co-REST and the corresponding anti-IgG antibody from 
the same input. (B) Western blot of EBNA3C, EBNA3A and CtBP1 precipitated by anti-HDAC1 and 
anti- IgG antibody from the same input.  Anti-HDAC1 and anti-co-REST pull-down EBNA3A, and 
anti-HDAC1 pulls down EBNA3C in WT LCL. WBs shown are representative of two (in A) or three 
(in B) separate experiments. 
 
To verify that these co-immunoprecipitations are not an artefact of using a single cell line, 
similar experiments were performed in BL31 infected with WT EBV-BAC virus (WT BL31). 
Anti-LSD1 and anti-HDAC1 pulled down EBNA3C (and CtBP) also in the protein extracts 
from WT BL31 (Fig. 3.1.20). 
 
 
 
 
Fig. 3.1.20. Co-immunoprecipitation with anti-HDAC1 and anti-LSD1 antibody in WT BL31.  
Western blot of EBNA3C and CtBP1 precipitated by anti-HDAC1, anti-LSD1 and corresponding anti-
IgG antibodies from the same input.  Input represents 10% of the total cell extract used for the 
immunoprecipitation. Anti-LSD1 and  to a lesser degree anti-HDAC1 pull down EBNA3C and CtBP1 
in WT BL31 protein extracts. WB shown is a representative of two separate experiments. 
 
 
A 
 
B 
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EBNA3C binding of CtBP seems to make its association with LSD1 more robust  
A direct physical interaction between EBNA3C and HDAC1 was reported previously 
(Radkov et al., 1999), so it is very likely that EBNA3C can bind HDAC1 in both CtBP-
dependent and -independent manner. I was interested to determine whether the co-
immunuprecipitation of LSD1 with EBNA3C and EBNA3A is strictly dependent on the intact 
CtBP-binding sites of EBNA3C and EBNA3A and is likely to be mediated via CtBP.  
Anti-LSD1 pulled down EBNA3C in WT LCL more efficiently than in LCL produced with 
viruses where the CtBP-binding sites of either EBNA3C (3CCtBP LCL) or EBNA3A (3ACtBP 
LCL) or both EBNA3s were mutated (E3CtBP LCL) (Fig. 3.1.21A and B). Similarly, anti-
HDAC1 seemed to pull down more EBNA3C in WT LCL (Fig. 3.1.21B). 
Since in 3ACtBP LCL, the pull down of EBNA3C by anti-LSD1 was also reduced, it is 
possible that EBNA3C and EBNA3A co-operate in binding LSD1 through CtBP. It is yet to 
be investigated whether anti-LSD1 pulls down EBNA3A in CtBP-binding LCL less efficiently 
than in WT LCL and whether in 3CCtBP LCL, co-immunoprecipitation of LSD1 with EBNA3A 
will be reduced.  
Anti-LSD1 antibody seemed to pull down slightly more EBNA3C than the negative control 
anti-IgG in protein extracts from E3CtBP LCL (Fig. 3.1.21B). It therefore remains to be 
excluded whether EBNA3C and/or EBNA3A with mutated CtBP-binding site(s) might still 
associate with LSD1. 
Finally, I confirmed that the physical associations detected were not influenced by the 
different availability of the CtBP supercomplex constituents in various cell lines. According 
to the microarray studies and protein quantification, CtBP, LSD1, HDAC1 and Co-REST 
are either well or robustly expressed in both LCL and BL31 lines. Their expression was not 
found to be regulated by EBNA3s (Hertle et al., 2009; White et al., 2010 and data not 
shown). 
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Fig. 3.1.21. Co-immunoprecipitation with anti-LSD1 (and anti-HDAC1) antibody in WT and 
CtBP-binding mutant LCL. Input represents 10% of the total cell extract used for the 
immunoprecipitation. (A) Western blot of EBNA3C precipitated with anti-LSD1 antibody in WT LCL, 
E3
CtBP
, 3C
CtBP
 and 3A
CtBP
 LCL. Anti-LSD1 antibody pulls down EBNA3C more efficiently in WT LCL 
than in any CtBP-binding mutant LCL. (B) Western blot of EBNA3C precipitated by anti-HDAC1, 
anti-LSD1 and anti-IgG in WT LCL and E3
CtBP 
LCL. Anti-LSD1 and perhaps also anti-HDAC1 pull 
down EBNA3C more efficiently in WT LCL than in E3
CtBP
 LCL.  Data are representative of two 
separate experiments including WT and CtBP-binding mutant LCL established from PBL of two 
different single donors.  
 
 
EBNA3C, EBNA3A, CtBP, HDAC1 and LSD1 are not detectable at the 16INK4A locus 
In addition to previous effort to locate EBNA3C at the 16INK4A locus, ChIP experiments were 
carried out to search also for occupancy by EBNA3A, CtBP, HDAC1 and LSD1. At the time 
of writing, neither EBNA3 oncoproteins nor the constituents of the CtBP supercomplex 
could be convincingly detected at 16INK4A locus (data not shown).  Currently, the ChIP 
technique and the choice of antibodies are being optimized. 
B 
 
A 
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3.1.3 Other potential mechanisms of p16INK4A  de-repression  
 
 
H2AX is phosphorylated in LCL following EBNA3C inactivation and in CtBP-binding 
mutant LCL 
In eukaryotes, DNA double strand breaks have been shown to trigger the phosphorylation 
of serine 139 at the carboxy terminus of histone H2AX mediated by ATM kinase. H2AX 
phosphorylation is important for recruitment and maintenance of the DNA repair machinery 
at the site of the break (Rogakou et al., 1998). The accumulation of DNA damage or the 
activation of DNA-damage response (DDR) can be monitored by the increase in 
phosphorylated H2AX (gamma-H2AX) either by western blotting or immunofluorescnce. It 
has been shown recently that following EBV infection of primary B lymphocytes, activation 
of the host cell ATM/CHK2-mediated DDR pathway suppresses B cell transformation. 
However, EBNA3C appeared to disable the ATM/CHK2-mediated host defence and 
permitted B cell transformation (Nikitin et al., 2010).   
The p16INK4A locus is known to be activated in response to various cellular stresses, 
including DNA damage (Shapiro et al.,1998). Therefore it was tested whether DNA damage 
occurs and/or DDR is activated following EBNA3C inactivation. The degree of H2AX 
phosphorylation was assessed by western blotting in the whole cell lysates of three LCL 
3CHT cultured for 26 days with or without HT. A modest increase in phosphorylation of 
H2AX was detected in all three lines cultured without HT. Similarly, the majority of CtBP-
binding mutant LCL seemed to exhibit more gamma-H2AX than the respective revertant or 
WT LCL (Fig. 3.1.22).  The question of EBNA3C having either a protective effect against 
DNA damage and/or attenuating the DDR pathway  in established LCL was therefore 
further addressed in additional set of experiments (see Chapter 3.2) 
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Fig. 3.1.22.  Phosphorylation of H2AX in LCL 3CHT and in CtBP-binding mutant LCL. Western 
blot quantifying  the γ-H2AX in three LCL 3CHT (-B, -C, -D) cultured for 26 days with (+) or without  
(-) HT and in CtBP-binding mutant LCL and respective revertant or WT LCL. γ-tubulin (γ-tub) was 
used as a loading control. The phosphorylation of H2AX is modestly increased following EBNA3C 
inactivation and in CtBP-binding mutant LCL. WBs shown are representative of two experiments. 
 
EBNA3C inactivation does not lead to increase in p38 MAPK phosphorylation 
Since it has been established that stress-induced p38 mitogen-activated protein kinase 
(p38 MAPK) acts downstream of MEK to mediate Ras-induced p16INK4A expression and 
senescence (Han and Sun, 2007; Freund et al., 2011), it was tested whether p38 MAPK 
could be similarly activated by phosphorylation following EBNA3C inactivation.  However, 
only partial phosphorylation of p38 MAPK was detected in all LCL 3CHT irrespective of 
EBNA3C activity (Fig. 3.1.23).  
 
 
 
 
Fig. 3.1.23.  Phosphorylation of p38MAPK in LCL in response to EBNA3C. Western blot 
quantifying the p38 MAPK phosphorylation in three LCL 3CHT (-B, -C, -E) cultured for 26 days with 
(+) or without (-) HT and in protein lysates from supplier validated as a positive and negative control. 
γ-tubulin (γ-tub) was used as a loading control. Partial p38 MAPK phosphorylation was detected in 
all lines regardless of EBNA3C activity. 
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ANRIL expression is positively correlated with CDKN2A expression in LCL 
Since the long non-coding RNA (ncRNA) ANRIL, transcribed antisense to the INK4-ARF-
locus, has been implicated in p16INK4A repression mediated by PcG in prostate cancer (Yap 
et al., 2010), I asked whether a similar mechanism could contribute to EBNA3C and 
EBNA3A-mediated p16INK4A repression in LCL. Since in the prostate cancer model, ANRIL 
expression inversely correlated with p16INK4A transcription and the increased ANRIL levels 
were thought to facilitate repression of the p16INK4A locus, the expression of CDKN2A 
mRNA and ANRIL ncRNA was examined in LCL 3CHT cultured with or without HT. ANRIL 
ncRNA was co-regulated simultaneously with CDKN2A mRNA in response to EBNA3C. 
ANRIL transcription followed the same trend as CDKN2A, but to a lesser extent (Fig. 
3.1.24).                   
                                                     
   
Fig. 3.1.24.  Co-regulation of ANRIL ncRNA with CDKN2A (p16
INK4A 
+ p14
ARF
) mRNA  in LCL 
3CHT lines. ANRIL, CDKN2A and control ncRNA transcript Malat-1 were quantified in two LCL 
3CHT. LCL 3CHT-A was cultured with HT (A +HT), 14 and 31 days without HT (A -14 and A -31) 
and 12 days after HT was re-added (A re-add HT). Similarly, LCL 3CHT-C was cultured with HT (C 
+HT) and 21 days without HT (C -21). ANRIL ncRNA was upregulated following EBNA3C 
inactivation, however, to a lesser degree than CDKN2A mRNA. Control ncRNA Malat-1 remained 
unaltered regardless of EBNA3C activity. 
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Since the positive correlation of CDKN2A and ANRIL transcription in LCL 3CHT was the 
opposite to that seen in prostate cancer, I tested whether these transcripts were generally 
co-expressed in LCL. The analysis was performed on a number of samples (approximately 
30) including WT LCL, EBNA3A KO LCL and corresponding revertant, E3CtBP and revCtBP 
LCL, EBNA3B KO LCL and revertants and several LCL 3CHT cultured with or without HT. 
A positive correlation between CDKN2A and ANRIL expression in LCL was observed (Fig. 
3.1.25). 
 
 
Fig. 3.1.25. Positive correlation between CDKN2A mRNA and ANRIL ncRNA in LCL carrying 
various EBV-BAC recombinant viruses. qPCR analysis of about 30 LCL samples including WT 
LCL, EBNA3A KO LCL and corresponding revertant; E3
CtBP
 LCL, EBNA3B KO LCL and revertants 
and LCL 3CHT cultured for up to 31 days with or without HT.  ANRIL ncRNA expression shows 
positive correlation with CDKN2A mRNA expression. The samples of LCL 3CHT cultured without HT 
are highlighted by arrows.  
 
All quantifications described above were performed using ANRIL assay positioned across 
the exon 1/2 boundary. However, the ANRIL gene consists of 20 exons, and the ANRIL 
transcripts are differentially spliced into at least 8 variants. In a further experiment, an 
amplicon positioned at the opposite end of this long transcript, across 15/16 exon 
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boundary, that might be part of the different splice variants, was quantified in the same 
samples. Although the transcription trend was similar, the extent of regulation appeared to 
be much higher for the amplicons positioned across the 15/16 exon boundary (Fig.3.1.26). 
 
        
Fig. 3.1.26. Comparison of the quantity of two amplicons positioned in the opposite ends of 
the ANRIL transcript in the same samples. ANRIL transcripts were quantified using two assays 
positioned either in exon1/2 or exon 15/16 boundary in WT BL31, LCL 3CHT cultured with HT (LCL-
A +HT), 31 days without HT (LCL-A -31) and after HT was re-added for 12 days (LCL-A re-add HT). 
Prostate cancer cell line (PC3) was used as a positive control. The regulation of the amplicons 
followed the same trend, however, the extend of the regulation was greater in case of the amplicon 
located across the exon 15/16 boundary.  
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3.1.4 Regulation of  p14ARF by EBNA3C in LCL 3CHT 
 
Objectives 
 
Although p14ARF is transcribed from a separate promoter, it shares second and third exons 
with p16INK4A. As a result, p14ARF and p16INK4A can be regulated either separately or co-
regulated in human cells and tissues depending on the context.  I therefore tried to assess 
whether p14ARF (in addition to p16INK4A) is regulated by EBNA3C in LCL and investigate the 
functional significance of such regulation.  
 
Results 
 
EBNA3C might repress p14ARF; however p14ARF de-repression following EBNA3C 
inactivation is not convincingly reflected at the level of protein or in the activation of 
the p53-p21CIP1 pathway 
In LCL 3CHT cultured without HT, p14ARF transcripts generally increased at the same time 
as p16INK4A; however, p14ARF de-repression was not entirely consistent between cell lines 
and between experiments. The degree of p14ARF mRNA upregulation varied greatly and 
was at times of small magnitude or entirely undetectable (Fig. 3.1.27 LCL 3CHT-C cell 
line). After the reactivation of EBNA3C by re-adding HT, p14ARF mRNA gradually decreased 
with kinetics similar to p16INK4A (Fig. 3.1.27).   
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Fig. 3.1.27.  Repression of p14
ARF
 mRNA following EBNA3C reactivation. (A) After 14 days 
without HT (0), total RNA was extracted from aliquots from two LCL 3CHT populations (-A and -C). 
HT was re-added to the remaining cells and further RNA samples were taken at the times indicated. 
qPCR was performed to quantify p14
ARF
 transcripts. The histogram corresponds to p14
ARF
 mRNA 
relative to that in control cycling populations of each LCL 3CHT. (B) Similar assays to those 
described in (A) after 33 days without HT. p14
ARF
 transcripts are at times de-repressed following 
EBNA3C inactivation; however, not consistently in all lines and experiments.  
 
It has been noted previously (O’Nions and Allday, 2004), that p14ARF protein is very poorly 
expressed in WT LCL and is usually undetectable by western blotting. In LCL 3CHT 
cultured with HT, p14ARF protein was barely detectable but increased to a detectable level 
within 14 days of culture without HT (Fig. 3.1.28A). The subtle increase of p14ARF was 
further confirmed in other LCL 3CHT lines following EBNA3C inactivation (Fig. 3.1.28B); 
however this required the use of concentrated anti-p14ARF antibody and an increased 
amount of protein extract loaded on the separating gel indicating that the expression level 
of p14ARF in LCL with or without HT was indeed very low. Subsequently, it was tested 
whether p14ARF-p53-p21CIP1 pathway is engaged in the absence of active EBNA3C. For up 
to 24 days following EBNA3C inactivation, the level of p53 protein did not increase (Fig. 
3.1.28C) and p21CIP1 transcriptional up-regulation was not observed (Fig. 3.1.28D). 
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Fig. 3.1.28.  p14
ARF
-p53-p21
CIP1
 axis in LCL 3CHT after inactivation of EBNA3C (A) Western blot 
depicting the p14
ARF
 protein levels following EBNA3C inactivation. After 14 and 33 days without HT, 
faint bands can be detected if concentrated anti-p14
ARF
antibody and higher amounts (60ug) of LCL 
3CHT total protein are used. (B) Western blot of p14
ARF
 protein in three LCL 3CHT  (-A, -B, -E) 
cultured for 26 days with (+) or without (-) HT. Subtle upregulation of p14
ARF
 protein is visible in all 
three lines following EBNA3C inactivation. (C) Western blot monitoring p53 protein levels following 
inactivation of EBNA3C. No increase in p53 protein is observed up to 24 days without HT. (D) qPCR 
monitoring p21
CIP1
 transcripts following inactivation of EBNA3C. The levels of p21
CIP1
 mRNA are 
stable for at least 24 days without HT. Data are representative of three separate experiments 
including at least three different LCL 3CHT lines. 
 
C 
 
D 
 
A 
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In CtBP-binding mutant LCL, p14ARF also seemed to be modestly upregulated at the level 
of transcription in comparison to the revertant and WT LCL (Fig 3.1.29A). However, p14ARF 
protein could not be easily detected in CtBP-binding mutants (data not shown), and the 
p53-p21CIP1 axis did not appear to be activated (Fig. 3.1.29B and data not shown). 
 
 
      
 
Fig. 3.1.29.   p14
ARF
 and p21
CIP1
  transcripts  in CtBP-binding mutant LCL.  (A) The relative 
levels of p14
ARF
 transcripts in RNA extracted from two established E3
CtBP
 LCL, two 3A
CtBP
 LCL, 
3C
CtBP 
LCL, a revertant (rev
CtBP
) and a WT LCL. p14
ARF
 transcripts are upregulated in all CtBP-
binding mutant LCL in comparison to revertant and WT LCL. (B) The relative levels of p21
CIP1 
transcripts in RNA extracted from three WT LCL, two established E3
CtBP
 LCL and two 3A
CtBP
 LCL.  
p21
CIP1 
transcripts do not consistently increase in CtBP-binding mutant LCL. 
 
 
p14ARF promoter contains only background levels of H3K27me3 in LCL regardless of 
EBNA3C activity or the ability of EBNA3C and EBNA3A to bind CtBP 
 
To date it is not well understood whether the repression of p14ARF in human pre-senescent 
or  tumour cells is mediated by polycomb-based H3K27me3 owing to the low quantities of 
H3K27me3 detectable at p14ARF promoter, and the absence of a ‘peak’ of H3K27me3  
when p14ARF is repressed. Intriguingly, distinct H3K4me3 peak has been found associated 
A 
 
B 
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with the p14ARF promoter even when p14ARF is repressed (Bracken et al., 2007; Kia et al., 
2008; Barradas et al., 2009; Li et al., 2009). 
Consistent with the published findings, in LCL 3CHT lines cultured  with or without HT and 
in CtBP-binding mutant and revertant LCL, in the context of H3K27me3 distribution across 
the entire CDKN2A locus, only low levels of H3K27me3 could be detected at the p14ARF 
promoter at any time (Fig. 3.1.30B and D). In two LCL 3CHT lines, the p14ARF promoter 
was not found to be convincingly regulated via H3K27me3 in a time-course following 
EBNA3C switch (Fig.3.1.30A). Intriguingly, the distinct peak of H3K4me3 detected at the 
p14ARF promoter was quantitatively equivalent to that localized at p16INK4A exon1 and was 
stable regardless of EBNA3C activity or the ability of EBNA3C and EBNA3A to bind CtBP 
(Fig. 3.1.30C and E). 
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Fig. 3.1.30.  ChIP–qPCR analysis of H3K27me3 and H3K4me3 at the p14
ARF
 promoter in LCL. 
(A) ChIP analysis of H3K27me3 distribution on p14
ARF
 promoter (using two independent qPCR 
assays) in LCL 3CHT-A cultured for up to 33 days without HT and after HT was re-added for 16 
days (sample annotated +). (B) ChIP analysis of H3K27me3 distribution across the entire CDKN2A 
locus including p14
ARF
 promoter (p14) in LCL 3CHT cultured with HT, after 30 days without HT and 
20 days after re-adding HT. (C)  Similar ChIP analysis of H3K4me3 distribution as in (B). (D) & (E) 
Similar analysis as in (B) and (C) in E3
CtBP
 and rev
CtBP
 or WT LCL. Histograms show very low levels 
of H3K27me3 and a distinct peak of H3K4me3 at p14
ARF
 promoter in all lines. 
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Summary key points 
 
 EBNA3C and EBNA3A together repress p16INK4A at the level of transcription 
 EBNA3C inactivation or the absence of EBNA3A reset the epigenetic status of 
p16INK4A   locus to support transcription 
•  repressive H3K27me3 is diminished 
•  activation-associated H3K4me3 moderately increases 
 Interaction between EBNA3C and EBNA3A and CtBP is required to maintain 
repressive chromatin at the p16INK4A locus  
 LSD1, Co-REST and HDAC1 are found in complexes containing EBNA3C and 
EBNA3A  
 ANRIL expression is positively co-regulated with CDKN2A in LCL  
 EBNA3C might repress p14ARF, however not via H3K27me3 and without impacting 
on the p53-p21CIP1 axis 
 
Discussion 
 
DNA viruses often infect cells within their human or animal hosts that are differentiated and 
have left the cell cycle. They therefore evolved multiple strategies to force the infected cells 
back into the cell cycle and gain access to the replication machinery (Ferrari, Berk and 
Kurdistani, 2009). It is common for the oncoviruses to inactivate simultaneously both Rb 
and p53 pathways. Oncoproteins such as adenoviral E1A, papillomaviral E7 and E6 and 
SV40 large T antigen target cell cycle regulators Rb and/or p53 directly to disrupt cell cycle 
checkpoints (Howley and Livingston, 2008). However, the evidence for direct association 
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between an EBV protein and Rb or p53 is not as convincing as in other tumour viruses and 
it seems that EBV might use a more distinctive strategy to facilitate B cell proliferation.  
 
EBV in regulating epigenetic processes 
Like other herpesviruses, EBV epigenetically regulates its own genome to control the 
establishment and maintenance of latency and to evade the host immune system (Günther 
and Grundhoff, 2010; Takacs et al., 2010; Tempera et al., 2010). Similarly, through 
epigenetic mechanisms, EBV regulates host transcription to ensure a favourable 
environment for its persistence by modifying genes to prevent apoptosis or growth arrest 
(White et al., 2010). Recently, our lab has demonstrated that EBNA3C and EBNA3A co-
operate to epigenetically repress the proapoptotic regulator BIM by trimethylation of H3K27 
and subsequent DNA methylation at the BIM promoter. EBNA3C and EBNA3A inhibit 
productive BIM transcription in BL31 by two distinct but perhaps related mechanisms.  
Firstly, EBNA3C and EBNA3A are both essential for the complete assembly of PRC2 on 
the BIM promoter. Secondly, EBNA3C and EBNA3A activity (either directly or indirectly) 
prevents the phosphorylation of Ser 5 on Pol II on a previously H3K4me3-marked BIM 
promoter (Paschos et al., 2009; Paschos et al., under revision). On the whole, there is 
accumulating evidence that EBNA3C and EBNA3A modulate the expression of cellular 
genes by epigenetic mechanisms, specifically by regulating the establishment and 
maintenance of H3K27me3 at specific promoters. 
 
 
EBNA3C and EBNA3A co-operation 
Although EBNA3C and EBNA3A have probably originated by a duplication event in an 
ancestral EBV genome, there is no evidence to suggest that their functions are broadly 
redundant. However, they share two important features, the ability to bind RBPJk/CBF1 
and to bind CtBP.  EBNA3C and EBNA3A are also likely present in the cell in the same 
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complexes. They were reproducibly co-immunoprecipitated in protein extracts from LCL 
and EBV positive BL31 lines (M. Hickabottom and K. Paschos, personal communication) 
and their physical association has recently been confirmed by a very reliable anti-FLAG 
pull-down in the protein extracts from LCL carrying EBNA3C strep-FLAG (TAP)-tagged 
virus (Oak Watanatanasup and Gill Parker, personal communication).  In a  microarray 
study, apart from genes regulated separately by either EBNA3C or EBNA3A, a large 
subset of cellular targets was found to be co-regulated by both EBNA3s  (White et al., 
2010). Since inactivation of either EBNA3C or EBNA3A in LCL was reported to result in 
similar growth inhibition (Maruo et al., 2003 and 2006), it does not come as a surprise that 
both EBNA3C and EBNA3A contribute to p16INK4A repression in LCL and that they achieve 
this by directly or indirectly remodelling the chromatin at p16INK4A locus.  
 
Conditional EBNA3C 
EBNA3C appears to be absolutely essential for primary B cell immortalization and can only 
be inactivated conditionally once the LCL have been established. Due to the strict 
requirement for EBNA3C function in transformation, successful establishment of LCL 3CHT 
means that modified EBNA3C retains the functions needed in transformation.  In addition, 
by dividing the lines and studying simultaneously the cells cultured without HT alongside 
those cultured with HT, the system provides a very reliable isogenic control.  Importantly, 
the expression of LMP1 does not decrease following EBNA3C inactivation in LCL 3CHT 
(Fig. 3.1.2 and Maruo et al., 2006).  LMP1 has been shown previously by others to repress 
p16INK4A (Ohtani et al., 2003) and LMPs are currently emerging as important regulators of 
the cellular epigenome in EBV-associated epithelial tumours (Paschos and Allday, 2010). It 
is therefore crucial that an indirect mechanism of p16INK4A regulation via LMP1 in LCL 
3CHT system could be excluded.  
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Putative mechanisms of EBNA3C and EBNA3A-mediated p16INK4A epigenetic 
repression 
I have shown that EBNA3C inactivation initiates chromatin remodelling that resets the 
epigenetic status of the p16INK4A promoter. In the presence of active EBNA3C the p16INK4A 
promoter region displays repressive chromatin and the locus is closed for transcription. In 
contrast when EBNA3C is inactivated the chromatin is remodelled into an active state 
supporting transcription (Fig. 3.1.9). LCL carrying EBNA3A KO virus show similar 
chromatin remodelling changes at the p16INK4A locus as in the case of EBNA3C 
inactivation, perhaps to a lesser extent (Fig. 3.1.12B and C).  
 
EBNA3C and EBNA3A might be acting on chromatin at the p16INK4A locus either directly or 
indirectly. Although Paramecium bursaria Chlorella virus 1 encodes its own viral 
H3K27me3 methyltransferase (Mujtaba et al., 2008), surprisingly, this is the only H3K27 
methyltransferase  identified  to date in addition to PcG EZH1 and EZH2. Structural and 
biochemical properties of EBNA3C and EBNA3A were extensively studied in the past 
(Jiang, Cho and Wang, 2000; West et al., 2004; West, 2006). Neither EBNA3C nor 
EBNA3A were judged to possess any enzymatic activity, but they certainly could facilitate 
the activity of other cellular chromatin remodelling enzymes, most notably PcG, at the 
p16INK4A locus in several ways. Even though EBNA3C and EBNA3A cannot bind DNA 
directly, they may target PRC complexes to the p16INK4A locus through interaction with 
p16INK4A promoter-binding proteins or binding of sequence-specific non-coding RNA. 
Alternatively, EBNA3C and EBNA3A might be necessary for the maintenance of the 
repressive complexes at 16INK4A locus, fine-tuning their composition or stability or might be 
required for the transmission of the epigenetic marks at p16INK4A locus during the cell 
division.  Of course, these viral proteins might not be present at p16INK4A locus or physically 
engaged in targeting but instead transcriptionally regulate chromatin-modifying machinery 
or sequence-specific elements engaged at p16INK4A locus.  The co-operation of a cellular 
co-factor CtBP with these viral oncoproteins will be discussed later. 
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The nature of the proliferative arrest and the reversible phenotype 
It is generally unknown whether B cells ‘senesce’ similar to fibroblasts and other cell types 
and whether following EBNA3C inactivation, some LCL could undergo senescence per se, 
a durable block of cell proliferation that becomes independent of p16INK4A expression or Rb 
hypophosphorylation (Dai and Enders, 2000).  Although following EBNA3C inactivation, 
LCL upregulate p16INK4A and accumulate in G1 phase of the cell cycle, there are no 
apparent changes in the cell morphology and beta-galactosidase accumulation is not 
detectable (data not shown). It has not been tested whether the proliferative arrest is 
accompanied with expression of known components of senescence-associated secretory 
phenotype. 
 
The p16INK4A-Rb pathway in LCL, although under suppression, remains intact and can be 
activated if EBNA3C function is withdrawn (Fig. 3.1.6 and Fig.3.1.7). I have shown that 
both the de-repression of the p16INK4A locus and the proliferative arrest following EBNA3C 
withdrawal in LCL 3CHT system are reversible at the level of total cell population after 
EBNA3C is reactivated by re-adding HT (Fig. 3.1.4B and C and Fig. 3.1.6 and Fig. 3.1.9). It 
is possible that either the elevated p16INK4A levels are re-repressed in the majority of cells 
following EBNA3C reactivation allowing the entry into the cell cycle (i.e. a genuine reversal 
of proliferative arrest) or a small non-arrested subpopulation of cells (i.e. the portion of cell 
which retained p16INK4A repression and kept proliferating) comes to dominate the culture 
following EBNA3C reactivation.   
 
Further evidence acquired using a system of continuously proliferating LCL 3CHT where 
the selection based on proliferative advantage has been removed (described in detail in 
Chapter 3.2.1) indicated that, although both of the above scenarios remain possible, the 
gradual p16INK4A repression and the reversal of the proliferative arrest following EBNA3C 
reactivation are unlikely to be driven by the pro-proliferative selection pressures in cell 
culture, since even when EBNA3C is reactivated in continuously proliferating LCL that have 
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not been arrested, EBNA3C reactivation still leads to gradual epigenetic repression of 
p16INK4A (described in detail in Chapter 3.2.1). 
 
Bivalent domain and stability of H3K27me3 
A narrow well-defined peak of H3K4me3 is present at the p16INK4A exon 1 even when LCL 
are cultured with HT, EBNA3C is active and p16INK4A expression is repressed (Fig. 3.1.9B). 
The co-existence of H3K4me3 and H3K27me3 peaks on the p16INK4A exon1 represents 
a bivalent domain and enables the expression flexibility of this locus. In the event of 
abberant pro-proliferative signal or anti-proliferative signals (such as oncogenic stress, 
oxidative stress or DNA damage), the p16INK4A locus is prepared for efficient rapid 
activation. 
 
H3K27me3 is known to cause local formation of heterochromatin which is labile or readily 
reversible; however, this type of histone methylation can facilitate methylation of DNA of 
the same region, particularly in the development of cancer (Baylin, 2005). DNA methylation 
represents a more stable modification and can ‘fix’ the repression of the locus. It has been 
shown that PcG interact with DNMT and recruit them to chromatin. The sites of PcG 
binding which are largely unmethylated in normal tissues serve during tumorigenesis as a 
map to direct methylation. CpG islands de novo methylated in cancer have often been 
previously marked by the presence of PcG proteins and H3K27me3 (Cedar and Bergman, 
2009). CpG methylation of the p16INK4A promoter frequently occurs in high-grade non-
Hodgkin lymphoma, mucosa-associated lymphoid tissue lymphoma and most BL (Klangby, 
et al., 1998; Platt, Carbone and Mittnacht, 2002). Oncoviruses frequently cause the same 
modifications or mutations as seen in sporadic cancers of non-viral aetiology, only with 
much greater efficiency. DNA methylation of the p16INK4A promoter could represent a ‘hit 
and run’ mechanism of permanent oncogenic alteration established by the transient activity 
of the EBNA3C and EBNA3A viral oncoproteins.  The stable, initiation factor- independent 
repression of p16INK4A by promoter DNA methylation could contribute to the 
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lymphomagenesis even in EBV-associated tumours that no longer express the latency III 
programme that includes EBNA3C and EBNA3A.  
 
Rb independence 
An LCL 3CHT cell line in which Rb protein is undetectable, regardless of the presence of 
functional EBNA3C, was produced. In this operationally Rb-negative cell line, p16INK4A was 
epigenetically repressed in the presence of functional EBNA3C and de-repressed after 
EBNA3C inactivation (Fig. 3.1.11). Therefore, p16INK4A regulation by EBNA3C in LCL 3CHT 
appears to be Rb-independent. The repression of p16INK4A in Rb-negative LCL 3CHT-E is 
functionally irrelevant. The observation that EBNA3C epigenetically repressed p16INK4A 
expression even when no additional proliferation advantage could be gained implies that 
repression of p16INK4A by EBNA3C is specific, although not necessarily direct. 
 
EBNA3C and EBNA3A co-operation with CtBP supports tumorigenesis 
CtBP was discovered by virtue of its binding to adenoviral oncoprotein E1A. Binding of E1A 
to CtBP antagonizes the function of CtBP; E1A mutants unable to bind CtBP show 
enhanced transformation efficiency (Schaeper et al., 1995). In contrast, EBNA3C and 
EBNA3A mutants unable to bind CtBP have been less effective in immortalizing and 
transforming primary rat embryo fibroblasts in cooperation with oncogenic Ras (Touitou et 
al., 2001; Hickabottom et al., 2002). In addition, LCL produced by transformation with 
CtBP-binding mutant viruses grow out much slower than WT LCL and fail to repress 
p16INK4A. Taken together, binding of EBNA3C and EBNA3A to CtBP seems to augment the 
transformation efficiency and LCL outgrowth. Similarly, Marek’s disease virus, a 
herpesvirus which induces T cell lymphoma in chickens, requires its nuclear oncoprotein 
Meq to interact with CtBP for tumorigenesis (Brown et al., 2006).  
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Although the outgrowth of CtBP-binding mutant LCL was delayed and the established 
mutants still exhibited a partial growth defect in comparison to revertant or WT LCL, they 
were still capable of proliferation despite the elevated p16INK4A levels. It is therefore not 
surprising that CtBP-binding mutant LCL generally contained reduced overall Rb protein 
levels (Fig. 3.1.14). In addition, decreased Rb mRNA has been reported by others in 
EBNA3A KO LCL (Hertle et al., 2009). Since Rb loss confers a common proliferative 
advantage, it is probable that elevated p16INK4A in CtBP-binding mutant LCL as well as in 
EBNA3A KO LCL creates a selection pressure during transformation and outgrowth leading 
to the loss or decreased expression of Rb. 
 
Contribution of CtBP in EBNA3C and EBNA3A-mediated epigenetic repression of 
cellular genes 
Throughout the duration of this project, others have reported that EBNA3C and EBNA3A 
seem to modulate their target genes mainly through H3K27me3 (White et al., 2010; 
Paschos et al., under revision; Ian Groves, personal communication). I have shown in this 
study, that co-operation of EBNA3C and EBNA3A with CtBP is required for repression of 
p16INK4A via H3K27me3 and perhaps its interplay with H3K4me3 (Fig. 3.1.15). In addition, in 
BL31 infected with EBV-BACs carrying CtBP-binding mutants of EBNA3C and EBNA3A, 
the repression of another EBNA3C and EBNA3A-target gene BIM by H3K27me3 is 
modestly but significantly reduced (Kostas Paschos, personal communication). 
Furthermore, in an microarray analysis comparing the gene sets regulated by EBNA3C 
and/or EBNA3A in B-cell derived lines with the cellular genes regulated in the cell lines 
carrying the CtBP-binding mutants of EBNA3C and/or EBNA3A, CtBP was shown to be 
important for the regulation of a subset of cellular targets of EBNA3C and/or EBNA3A (Rob 
White, personal communication). 
 
However, the same microarray analysis also clearly identified a large group of EBNA3C 
and/or EBNA3A-regulated genes, expression of which was not influenced by the ability of 
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EBNA3C and/or EBNA3A to bind CtBP (Rob White, personal communication). Although 
CtBP is known to have a role in PcG-mediated repression (Atchison et al., 2003; Basu and 
Atchison, 2010), I propose a model in which EBNA3C and EBNA3A possess a CtBP-
independent ‘core’ ability to recruit PcG, through as yet uncharacterized domain(s) outside 
of the CtBP-binding site, which is important for the regulation of majority of EBNA3C and 
EBNA3A target genes (Fig. 3.1.31).  
 
In addition, EBNA3C and EBNA3A can associate with CtBP which might augment the 
repression of a distinct subset of cellular genes.  Interaction of CtBP with EBNA3C and 
EBNA3A might mediate association with targeting sequence-specific elements (TF or non-
coding RNA), stabilize assembly of PRC complexes at the EBNA3C and/or EBNA3A-target 
loci, recruit chromatin remodelling enzymes other than PcG that enforce the repression 
(such as HDACs or G9a) and recruit LSD1 which can act in H3K4 demethylation and in the 
maintenance of bivalency.  
 
EBNA3C and/or EBNA3A might interact with several other cellular co-factors or TFs such 
as RBPJk/CBF1 to regulate distinct gene sets or allow for different context-dependent 
transcriptional outcome. Interaction of EBNA3C and EBNA3A with RBPJk/CBF1 was 
shown to be essential for the maintenance of LCL proliferation (Maruo et al., 2005 and 
2009). The role of RBPJk/CBF1 in the EBNA3C and/or EBNA3A-mediated epigenetic 
regulation of cellular genes (e.g. in the recruitment of PRC2 complex to the promoters of 
EBNA3C and/or EBNA3A-regulated target genes) remains to be investigated.  
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Fig. 3.1.31.  Scheme of the possible CtBP contribution in the epigenetic regulation of cellular 
genes by EBNA3C and/or EBNA3A.  Putative mechanisms of epigenetic repression of cellular 
genes by EBNA3C and EBNA3A – either dependent or independent of CtBP (explanation in text).  
 
 
 
EBNA3C, EBNA3A, CtBP and macromolecular complexes 
In eukaryotic cells, multidimensional protein networks consisting of numerous 
macromolecular protein assemblies carry out most cellular processes (Gavin et al., 2002). 
The varying modes of co-operation and communication of the protein subunits in 
macromolecular assemblies enable complex fine-tuned cellular processes but are very 
challenging to dissect.   
 
CtBP is known to have the potential to recruit multiple different chromatin remodelers 
depending on the cellular context. Incorporation of EBNA3C and EBNA3A in CtBP co-
repressor supercomplexes might alter either stability or composition of these assemblies at 
EBNA3C and/or EBNA3A-regulated loci. EBNA3C and EBNA3A might bridge the 
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chromatin remodelling enzymes and other constituents within the CtBP supercomplex or 
with other cofactors and enzymes. More than 30 different transcription factors and DNA-
binding factors have been reported to recruit CtBP to mediate the transcriptional repression 
of various target genes, mostly through the PLDLS binding motifs (Kuppuswamy et 
al.,2008). Although neither EBNA3C nor EBNA3A appear to have a direct DNA-binding 
activity, this does not exclude the possibility that they have an active role in gene targeting. 
It has been shown that non-DNA-binding factors can enhance DNA-binding specificity of 
transcriptional regulatory complexes or even generate a novel specificity (Siggers et al., 
2011). 
 
LSD1, Co-REST and HDAC1 were found to co-immunoprecipitate with EBNA3C and with 
EBNA3A, which indicates they might be a part of the same complex within a cell (Fig. 
3.1.18, Fig. 3.1.19 and Fig. 3.1.20). LSD1, a part of a new class of histone demethylating 
enzymes, removes the activating H3K4 mono- and dimethylation mark but can also remove 
the repressive H3K9 dimethylation (H3K9me2) mark when complexed with the androgen 
receptor. In addition, LSD1 is essential for the maintenance of global DNA methylation 
through demethylation of a non-histone substrate, DNMT1 (Nicholson and Chen, 2009).  
Co-immunoprecipitation of EBNA3C and also EBNA3A with LSD1 (even if mediated via 
CtBP, Fig. 3.1.21) is of particular interest since LSD1 functions in the maintenance of 
bivalent promoters. In human embryonic stem cells, LSD1 acts in the silencing of several 
developmental genes by regulating the balance of H3K4 and H3K27 methylation at their 
promoters (Adamo et al., 2011). In a similar manner, LSD1 can promote tumour 
development by maintaining the undifferentiated phenotype in cancer through aberrant 
silencing of a subset of tumour suppressor genes (Schulte et al., 2009). 
Furthermore, LSD1/Co-REST was shown to be co-recruited to DNA with members of PRC2 
complex by long intergenic non-coding (linc) RNA HOTAIR (Tsai et al., 2010). HOTAIR 
physically bridges LSD1 and PRC2 complexes and this mechanism was proposed to 
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couple histone H3K27 trimethylation and H3K4 demethylation and act in the maintenance 
of bivalent domains at the promoters. LincRNAs may provide a widespread mechanism for 
coordinating the activity of several histone-modifying enzymes. EBNA3C and EBNA3A 
could (via an interaction with LSD1/Co-REST) partake in the assembly of such complex 
structures of chromatin modifiers on the promoters of their target genes (Fig. 3.1.32). 
 
Fig. 3.1.32. Synchronized recruitment of PRC2 and LSD1/Co-REST to cellular gene promoters 
by linc RNAs (modified from Kaikkonen, Lam and Glass, 2011).  EBNA3C and EBNA3A through 
associating with LSD1/Co-REST could partake in the assembly of such complexes at the promoters 
of their target genes. 
 
ANRIL 
ANRIL was found to be expressed at a relatively low level in WT LCL (data not shown). 
However, the majority of ncRNAs (with some notable exceptions) are low-abundance 
transcripts when compared to messenger RNAs and many are only present in certain cell 
types, developmental stages, or growth conditions. Even very low abundance transcripts 
might be functionally important. For example, any mechanism involving a high-affinity 
interaction of RNA with DNA sites might proceed with only a few transcripts per cell (Pontig 
and Belgard, 2010). In theory, no more than two copies of ANRIL transcripts per cell would 
be necessary to mediate epigenetic repression in cis at a single gene locus. Recently, two 
such models of ANRIL-mediated epigenetic repression were described, ANRIL’s function 
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being the recruitment of polycomb complexes to the promoters of neighbouring genes. In 
diploid fibroblasts, ANRIL was bound to PRC2-component SUZ12 and was required for the 
repression of the p15INK4B locus. In prostate cancer cell lines and tissues, ANRIL bound 
CBX7, one of five mammalian orthologues of Drosophila Polycomb, within the PRC1 and 
was associated with the recruitment of the polycomb proteins to the p16INK4A locus.  In 
addition, both CBX7 and ANRIL were found at elevated levels in prostate cancer tissues 
(Kotake et al., 2010; Yap et al., 2010).  
 
In contrast to the prostate cancer model, a positive correlation between ANRIL and 
CDKN2A expression was found in LCL (Fig. 3.1.24 and Fig. 3.1.25). Such co-regulated 
expression of CDKN2A and ANRIL has been previously described in several genome-wide 
association studies (Cunnington et al., 2010; Pasmant et al., 2010). CDKN2A and 
antisense-localized ANRIL genes are transcribed divergently from transcription start sites 
that are in close proximity. Transcription of DNA across or in the surrounding area of the 
CDKN2A promoters can influence CDKN2A expression in several ways. Although the 
ANRIL promoter is currently not characterised, it may share promoter elements with 
CDKN2A that allow for co-regulation (Cunnington et al., 2010). Alternatively, antisense 
transcription might facilitate removal of nucleosomes and allow easier access of 
transcription factors to the surrounding DNA elements. Furthermore, epigenetic changes 
are not always confined into discrete loci, but frequently span large regions encompassing 
both coding and non-coding sequences, e.g. large organized chromatin K9 modifications 
(LOCKs) span up to several megabases (Wen et al., 2009). Genes co-localized in the 
same part of the chromosome might be co-regulated by the expanding chromatin 
modifications and contribute to the phenotype. I can therefore also hypothesise that 
CDKN2A is the critical locus specifically regulated by EBNA3C and EBNA3A, while ANRIL 
is a bystander gene co-regulated due to its localization.  
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p14ARF regulation by EBNA3C 
The participation of p14ARF in the phenotype that results from EBNA3C inactivation has 
been a matter of controversy.  In functional studies performed by Maruo et al. (2011) using 
shRNAs against either p16INK4A or p14ARF or both, silencing of p16INK4A alone only partially 
rescued the growth of LCL 3CHT in the absence of HT. Preventing the expression of both 
proteins arising from CDKN2A locus was necessary to fully restore the growth rate. My 
data show that even in the instances of p14ARF transcriptional upregulation after EBNA3C 
inactivation, p14ARF protein expression is very low, p53 stability is not increased and p21CIP1 
is not transcriptionally upregulated (Fig. 3.1.28). A similar situation occurs in CtBP-binding 
mutant LCL; p14ARF seems to be somewhat upregulated at the level of transcription in the 
CtBP-binding mutant LCL in comparison to the revertants; however, this still translates to 
only barely detectable protein in the cell (Fig. 3.1.29 and data not shown). 
 
It is not entirely understood whether (and how) the p14ARF promoter in human pre-
senescent and tumour cells is repressed by polycomb and H3K27me3. At the p14ARF 
promoter region in human cells, primary and tumour cells alike, PcG and H3K27me3 can 
be detected, but these are present only in low quantities even when p14ARF transcription is 
repressed and do not form a distinct ‘peak’ (Bracken et al., 2007; Kia et al., 2008 and 
Barradas et al., 2009). The same appears to be true in LCL regardless of the EBNA3C 
activity or the ability of EBNA3C and EBNA3A to bind CtBP. Strikingly, there is a peak of 
H3K4me3 present at the p14ARF promoter during its repressed state (Fig. 3.1.30). So 
currently, it is not clear which mechanisms or chromatin modifications are repressing 
p14ARF promoter in the WT LCL or the functional significance of its regulation. 
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Limitations of the study 
 
Although, there is no doubt that LCL 3CHT have already greatly enhanced our knowledge 
of EBNA3C functions, there are two main limitations of LCL 3CHT system. Firstly, even in 
the presence of HT, the repression of p16INK4A is not complete. The levels of p16INK4A are 
higher than in WT LCL, almost equivalent to the accumulation seen in EBNA3A KO LCL 
and CtBP-binding mutant LCL. The presence of elevated p16INK4A levels (relative to those 
in WT LCL) and of p130 in LCL 3CHT in the presence of HT might indicate that EBNA3C 
activation is not sufficient in a subpopulation of cells and these exit from the cell cycle. 
Alternatively, fusion of EBNA3C with the rather large HT domain might slightly compromise 
some EBNA3C functionality in all the cells in the population.  
 
The protein-based regulation of HT-fusion proteins should allow for more immediate control 
than systems based on transcriptional induction. However, EBNA3C disappears from 
whole cell lysates following HT withdrawal and is most likely targeted for proteasomal 
degradation. Therefore, following HT re-addition, in addition to activation of the remaining 
available EBNA3C protein, which should be immediate, the bulk of the protein needs to be 
re-synthesized, folded and post-translationally modified. Therefore the functional ‘switch’ is 
not as rapid as initially expected and there might be delays especially in instances when 
the intracellular concentration of EBNA3C is important.  
 
I have attempted to investigate the composition of EBNA3C and/or EBNA3A and CtBP-
containing complexes in B-cell derived lines. However, co-immunoprecipitation 
experiments indicate only the potential of various proteins to bind and interact physically 
within the protein extract. Successful co-immunoprecipitation represents a biochemical but 
not necessarily functional link between the proteins.  Such protein binding may not occur in 
vivo and even if the co-immunoprecipitated proteins are indeed constituents of one 
complex in vivo, the precise localization and actual function of the complex is not being 
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assessed.  The function should therefore be further verified by ChIP experiments, showing 
association of the members of the CtBP co-repressor complex with the promoters of 
EBNA3C and EBNA3A-regulated genes. Another elegant alternative to gain insight into the 
EBNA3C- and EBNA3A-associated macromolecular assemblies is the tandem affinity 
purification (TAP) technology combined with mass spectrometry. Strep-FLAG (TAP) tag 
fused with either EBNA3C or EBNA3A would allow for purification of EBNA3C or EBNA3A-
associated proteins and their identification by mass spectrometry analysis.  This technique 
would provide a ‘bigger picture’, simultaneously examining multiple elements of EBNA3C 
and/or EBNA3A-containing complexes rather than binary interactions. 
 
EBNA3C, EBNA3A and CtBP co-repressor complex (CtBP, LSD1, HDAC1) ChIPs at 
p16INK4A locus were unsuccessful, most likely due to issues related to antibody quality.  
Although ChIP is a powerful tool to detect direct association of proteins with chromatin, 
ChIP captures just a snapshot of a dynamic process, while the co-repressors, chromatin 
remodelers, EBNA3C and EBNA3A might associate with chromatin transiently. Large 
multiprotein complexes might assemble on chromatin and the proteins that associate with 
chromatin through intermediates would be more difficult to detect by ChIP. Lastly, although 
the p16INK4A locus and promoter region is well characterized, EBNA3C, EBNA3A, CtBP and 
the chromatin remodelers may bind only to a very discrete and relatively small region within 
the locus.   
Lastly, in this study I have shown a positive correlation between the expression of CDKN2A 
and ANRIL transcripts in LCL.  However, at least 8 ANRIL splice variants have been 
indentified to date and it is possible that various splice variants have different tissue 
distributions and functions. The qPCR assays used in this study are not comprehensive 
and could not distinguish between these multiple splice variants. 
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Future work 
. 
 EBNA3C and EBNA3A ChIP at p16INK4A locus using LCL carrying EBNA3C or 
EBNA3A strep-FLAG (TAP)-tagged recombinant viruses which have been produced 
by Gill Parker (personal communication). The feasibility of EBNA3C and EBNA3A 
ChIP would greatly enhance the study of EBNA3C and EBNA3A function not only in 
p16INK4A repression but more generally in other aspects of EBV-associated 
lymphomagenesis. 
 Co-immunoprecipitation to test LSD1 association with EBNA3A in CtBP-binding 
mutant LCL. LSD1-GST pull-downs to probe the direct interaction of LSD1 with 
EBNA3C, EBNA3A and their deletion mutants (which have been constructed by Gill 
Parker, personal communication). Simultaneously, probe the function of LSD1 in 
EBNA3C and EBNA3A–mediated gene repression using either an LSD1 inhibitor 
such as trans-2-phenylcyclopropylamine derivatives  (Mimasu, et al., 2010) or virally 
transduced LSD1 shRNA.   
 RNA immunoprecipitations (RIP) in LCL using antibodies against strep-FLAG 
(TAP)-tagged EBNA3C and EBNA3A followed by qPCR or profiling of all pulled 
RNAs using deep-sequencing technologies (RNA-seq analysis) to investigate 
whether ncRNA (including ANRIL), which may serve as scaffold for chromatin 
remodelling enzymes or target the epigenetic machinery to the DNA, physically 
associate with EBNA3C and/or EBNA3A. 
 
142 | P a g e  
 
3.2 The functional significance of p16INK4A 
repression by EBNA3C 
3.2.1 p16INK4A  functionally null LCL 3CHT system 
 
Objectives 
 
In the course of this study, several reports were published by others using a similar system, 
in which conditional EBNA3C was expressed in LCL. These describe the contribution of 
various EBNA3C-mediated alterations of cellular gene expression to the LCL transformed 
phenotype.  Zhao et al. (2011a) reported that 550 genes are regulated by EBNA3C in LCL 
and Maruo et al. (2011) found that EBNA3C and EBNA3A maintain LCL growth by 
repressing p14ARF expression in addition to p16INK4A. 
Therefore I decided to re-address the functional importance of p16INK4A repression by 
EBNA3C (and EBNA3A) in LCL proliferation and B cell transformation and immortalization 
by using an elegant system in which p16INK4A function is entirely abrogated. 
 
Results 
 
Production of p16INK4A functionally null (p16-null) LCL 3CHT 
We received PBL from an individual homozygous for a 19bp germline deletion in the 
second exon of CDKN2A as a kind gift from Gordon Peters (London Research Institute) 
and Alison Sinclair (University of Surrey). LCL produced by immortalizing these cells with 
WT EBV were characterized previously (Hayes et al., 2004). Since exon 2 is shared by 
both p16INK4A and p14ARF, neither of the two WT proteins is produced.  Instead, two 
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chimerical proteins originate from the locus: p16/X, comprising the first 74 residues of 
p16INK4A followed by 64 amino acids specified by the +1 reading frame and p14/p16, in 
which the amino-terminal 88 residues of p14ARF are fused to the last 76 residues of p16INK4A 
(Fig. 3.2.1).  The p14/p16 chimera retains all the known functions of p14ARF; however 
neither protein exhibits any of the known functions of p16INK4A (Brookes et al., 2002; Hayes 
et al., 2004). 
 
 
Fig. 3.2.1. CDNK2A transcripts in normal cells and in individual with a 19bp deletion in the 
gene (reproduced from Hayes et al., 2004). The coding sequence of p16
INK4A
 is shown in stipples 
boxes, p14
ARF
 coding sequence in grey boxes, the deletion is shown as a black box highlighted by 
an arrow. Normal p16
INK4A
 and p14
ARF
 transcripts are depicted above the two chimerical transcripts 
p16/X and p14/p16. 
 
Here, PBL containing the above described deletion were infected with recombinant BAC-
based EBV viruses expressing the EBNA3C-HT fusion in the presence of the activating 
ligand HT (see Material and Methods,pp. 64-65 and p.67). After the outgrowth of p16-
functionally null LCL 3CHT, cultures were divided in half and cultured in parallel either with 
or without HT in all subsequent experiments. Similar to p16-competent LCL 3CHT lines, in 
four p16-null LCL 3CHT lines (A1, A2, C1, C2) cultured without HT, EBNA3C expression 
declined with time, probably due to proteasomal degradation in the cytoplasm (Fig. 3.2.2 
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and Fig. 3.2.3B and C). The expression of other EBV latent proteins in p16-null lines was 
similar as in p16-competent lines and was not consistently impacted by EBNA3C 
inactivation, with the exception of EBNA2 and LMP1 which seemed to be modestly 
increased in several LCL 3CHT cultured over prolonged time without HT (Fig. 3.2.2). A 
modest increase in EBNA2 and LMP1 was already observed previously during validation of 
p16-competent LCL 3CHT (Fig. 3.1.2) in some but not all cases.  
 
 
Fig. 3.2.2.  Expression of EBV latent proteins in p16-null and p16-competent LCL 3CHT with 
or without HT. p16-competent lines LCL 3CHT-A and LCL 3CHT-C were previously used in 
Chapter 3.1. p16-null LCL 3CHT-A corresponds to clone A2, and p16-null LCL 3CHT-C to the clone 
C2.  In LCL cultured 30 days without HT, EBNA3C is degraded. The expression of other EBV latent 
proteins does not consistently change, apart from modest EBNA2 and LMP1 increase. p16-
competent LCL 3CHT in this blot appear to express little EBNA-LP; however, EBNA-LP expression 
in LCL is generally highly variable and EBNA-LP did not appear to be consistently reduced in p16-
competent LCL 3CHT (Fig. 3.1.2). γ-tubulin  (γ-tub) was used as a loading control. 
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Next, two monoclonal antibodies were used to visualize the proteins that arise from 
CDKN2A locus in p16-null and p16-competent LCL cultured 21 days with or without HT. 
The mAb JC8 detects an epitope at the N-terminus of WT p16INK4A, while DCS50 mAb was 
raised against an epitope at C-terminus of WT p16INK4A (Fig. 3.2.3A). The mAb JC8 was 
used to detect p16/X fusion protein which appeared as a double band, with the upper part 
of similar size or modestly smaller as the WT p16INK4A. and the bottom part distinctly 
smaller. As observed previously (Hayes et al., 2004) the p16/X product was consistently 
more difficult to detect than WT p16INK4A, suggesting that it may be less stable. The 
p14/p16 product, recognized by the DCS50 mAb, was larger than WT p16INK4A (Fig. 
3.2.3C).  
As expected, in p16-competent cells, robust p16INK4A de-repression was detected by both 
JC8 and DCS50 mAb following EBNA3C inactivation. In p16-null LCL 3CHT, no WT 
p16INK4A protein was expressed regardless of EBNA3C activity. The p14ARF function-
carrying p14/p16 chimera was consistently marginally upregulated following EBNA3C 
inactivation (Fig. 3.2.3C), while the non-functional p16/X was upregulated only in some 
cases (Fig. 3.2.3B and C). 
Since the deletion is localized in the second exon of the CDKN2A locus, a qPCR assay 
detecting an amplicon in p16INK4A exon 1 could be used to assess the quantity of exon 1-
comprising transcripts (see Fig. 3.1.5 for the localization of the assay). In p16-competent 
LCL 3CHT, the amount of functional p16INK4A transcripts was tightly controlled - very low in 
the cells cultured with HT and upregulated around 7-fold in the same lines cultured 21 days 
without HT. In the p16-null LCL 3CHT, exon 1-containing transcripts accumulated up to 30-
fold above the levels found in p16-competent cells. Modest increase after EBNA3C 
inactivation was visible; however, most likely due to the accumulation of these non-
functional transcripts, the difference in their abundance in p16-null LCL 3CHT cultured with 
or without HT was not as obvious as in the p16-competent lines (Fig. 3.2.4). 
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Fig. 3.2.3.  Characterization of the p16-null LCL 3CHT. (A) Schematic representation of the WT 
p16
INK4A
 protein produced in p16-competent LCL and the two chimerical proteins produced in p16-
null LCL 3CHT lines. The epitopes detected by both JC8 and DCS50 anti-p16
INK4A
 antibodies are 
depicted. (B) Western blot illustrating expression of EBNA3C-HT and the non-functional p16/X 
chimera in four p16-null LCL 3CHT (A1, A2, C1, C2) cultured 21 days with (+) or without (-) HT. After 
21 days without HT, EBNA3C is degraded while p16/X is either unchanged or increased. (C) 
Western blot comparing expression of EBNA3C and proteins arising from CDKN2A locus in two p16-
null LCL 3CHT (corresponding to A2 and C2 in Fig. 3.2.3B) and two p16-competent LCL 3CHT (-A 
and -C) cultured 21 days with (+) or without (-) HT. Data are representative of two independent 
experiments including four p16-null and two p16-competent LCL 3CHT lines. 
 
 
A 
 
C 
 
B 
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Fig. 3.2.4. Quantification of p16
INK4A
 exon1-comprising transcripts in p16-null and competent 
LCL 3CHT with or without HT. (A) Uncalibrated relative quantities of the amplicon located in the 
p16
INK4A
 exon1 in four p16-null LCL 3CHT (A1, A2, C1 and C2) and two p16-competent LCL 3CHT-A 
and -C (ctrl A and ctrl C) cultured for 21 days with or without HT. p16-null lines contain markedly 
increased quantities of p16
INK4A
 exon1-comprising transcripts in comparison to their p16-competent 
counterparts. (B) Values for each cell line are calibrated to the samples cultured with HT.  The 
p16
INK4A
 transcripts are upregulated about 7-fold in p16-competent LCL 3CHT cultured for 21 days 
without HT, while the exon1 amplicon is increased only about 2-fold in majority of p16-null lines. 
 
EBNA3C inactivation in p16INK4A functionally null LCL does not impair cell cycle 
progression  
It was immediately apparent that the proliferation of p16-null LCL 3CHT cultured without HT 
was not inhibited in comparison to the same lines cultured with HT (i.e. the p16-null LCL 
3CHT cultured without HT reached similar cell densities and were split with the same 
frequency as the p16-null LCL 3CHT controls grown with HT). To precisely quantify the 
proliferation rate, the p16-null and -competent LCL 3CHT cultured for up to 30 days with or 
without HT were incubated at day 14, 21, 27 and 30 for 1 hour in the medium containing 
BrdU, fixed, stained with anti-BrdU-FITC and PI and analyzed with flow cytometry. The 
p16-null LCL 3CHT cultured with HT proliferated about 20% more rapidly than the p16-
A 
 
B 
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competent lines.  As expected, the proliferation rate of p16-competent lines progressively 
declined following EBNA3C inactivation. In stark contrast, proliferation rate of all four p16-
null LCL 3CHT remained unchanged for up to 30 days after EBNA3C inactivation (Fig.3.2.5 
and Fig. 3.2.6). 
 
 
S-phase (R3) 
22 days with HT 22 days without HT 
 Mean (%) SD Mean (%) SD 
p16-competent 30.85 2.61 11.6 0.56 
p-16-null 38 4.24 41.5 2.12 
 
 
A 
 
B 
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Fig. 3.2.5. Proliferation rate of p16-null and -competent LCL 3CHT lines following EBNA3C 
inactivation. (A) Representative FACS analysis of cells cultured for 22 days with or without HT, 
then incubated for 1 hour with BrdU and stained with anti-BrdU-FITC/PI. The gated population 
comprises the cells that have undergone DNA replication while incubated with BrdU (cells that have 
DNA content between 2N and 4N and highly incorporate BrdU). (B)  The percentage of gated cells 
for each line and condition  in (A). The mean and SD of two biological replicates are shown. While 
the cell population in S phase decreases by about two thirds in p16-competent LCL 3CHT-A cultured 
for 22 days without HT, in 16-null LCL 3CHT (A2) the degree of proliferation remains unaltered. (C) 
Comparison of the proliferation of four p16-null LCL 3CHT (C1, C2, A1, A2) and two p16-competent 
LCL 3CHT (-C and -A, line A in replicate experiment), quantified by BrdU incorporation, in the time-
course of up to 30 days following removal of HT. The BrdU incorporation in every cell line cultured 
without HT was normalized in each time-point by the values measured in respective cell line cultured 
with HT. The proliferation rate of the p16-competent LCL 3CHT cultured without HT progressively 
declines with time, while the proliferation of the p16-null LCL 3CHT without HT remains unaltered. 
 
 
 
 
C 
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Fig. 3.2.6. Alternative representation of the data summarized in Fig. 3.2.5C.  Proliferation rate 
of multiple p16-null LCL 3CHT cultured with or without HT and in various time-points 
following EBNA3C inactivation. (A) Proliferation of three p16-null LCL 3CHT lines (A1, A2 and C2) 
cultured for 27 days with or without HT that were incubated with BrdU, stained and analyzed as 
described previously. (B) Proliferation of p16-null LCL 3CHT line (C1) cultured for 21, 27 and 30 
days with or without HT. The proliferation is not impacted by EBNA3C inactivation in neither of the 
p16-null LCL 3CHT. No difference is detectable between the proliferation of p16-null LCL 3CHT 
cultured with or without HT for up to 30 days. Error bars represent the standard deviation from the 
mean of two technical replicates. 
 
EBNA3C inactivation does not lead to activation of the p16INK4A-Rb-E2F1 axis and 
provides a system to study EBNA3C-regulated genes in a cell cycle-independent 
manner  
In p16-competent LCL 3CHT following EBNA3C inactivation, Rb was hypophosphorylated 
and the overall levels of Rb were decreased. Consistent with proliferative arrest, p130 was 
upregulated and p107 downregulated (Fig. 3.2.7 and Fig. 3.1.7). In contrast, no changes in 
the quantity or phosphorylation of the pocket proteins were detected following EBNA3C 
inactivation in p16-null LCL 3CHT, confirming that p16INK4A-Rb-E2F1 axis was not activated 
(Fig.3.2.7).  
A 
 
B 
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Fig. 3.2.7.  Quantity and phosphorylation of the pocket proteins in p16-null and competent 
LCL 3CHT lines with or without HT. Anti-pan-Rb antibody (pan-Rb) used in this WB detects all 
forms of Rb from hypophosphorylated (lower bands annotated pRb) to hyperphosphorylated (upper 
bands annotated ppRb). Anti-phospho-Rb antibody (Rb-PO4) detects only the hyperphosphorylated 
forms. γ-tubulin (γ-tub) was used as a loading control.  In p16-competent LCL 3CHT cultured for 21 
days without HT, Rb is downregulated and hypophosphorylated; p130 upregulated and p107 
downregulated. In p16-null LCL 3CHT (corresponding to A2 and C2 in Fig. 3.2.3B), no difference in 
the quantity of Rb, p130 and p107 nor Rb phosphorylation is detectable regardless of EBNA3C 
activity. Data are representative of two independent experiments each including at least two p16-null 
LCL 3CHT lines.  
 
Since the E2F1-mediated transcription was not blocked in p16-null LCL 3CHT after 
EBNA3C inactivation and the proliferation rate was not influenced, I was able to test the 
regulation of cellular genes by EBNA3C independently of proliferation and E2F1-mediated 
transcription, helping clarify the cause-effect relationship between the gene regulation and 
the change of LCL phenotype in response to EBNA3C. For example, the SET 
methyltrasferase EZH2, a known direct E2F1 target, was downregulated in p16-competent 
LCL 3CHT cultured without HT, while there was no regulation in the p16-null counterparts 
(Fig. 3.2.8). This is consistent with my previous findings (Fig. 3.1.16) and indicates that the 
regulation of EZH2 expression does not causally contribute to the p16INK4A upregulation and 
cell cycle inhibition following EBNA3C inactivation in LCL but is on the contrary associated 
with reduced proliferation of LCL. 
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Similarly, the increase in phosphorylation of H2AX observed after EBNA3C inactivation in 
p16-competent lines was not detected in the p16-null proliferating LCL 3CHT (Fig. 3.2.8). In 
a recent study, it was shown that EBNA3C suppresses DDR pathway mediated by 
ATM/CHK2 in the initial phases of primary B cell transformation by EBV (Nikitin et al., 
2010). I also found that in the p16-competent LCL 3CHT, a modest increase in H2AX 
phosphorylation is detectable following EBNA3C inactivation. A similar modest increase 
was found in all CtBP-binding mutant LCL in comparison to revertant or WT LCL (Fig. 
3.1.22). However, since no change in H2AX phosphorylation could be detected in the 
proliferating p16-null lines following EBNA3C inactivation, I conclude that EBNA3C does 
not directly block H2AX phosphorylation (or the upstream events leading to H2AX 
phosphorylation) in the established proliferating LCL and that it is rather the proliferative 
arrest in p16-competent LCL 3CHT cultured without HT or in the CtBP-binding mutant LCL 
that is associated with increased H2AX phosphorylation. Nevertheless, it is possible that 
EBNA3C might be important for suppression of DDR or prevention of DNA damage during 
the initial phases of primary B cell transformation by EBV or when the established LCL are 
challenged by DNA-damage causing agents. 
 
 
 
 
 
Fig. 3.2.8. Proliferation- and E2F1-dependent modulation of genes in p16-competent LCL 
3CHT. Western blot of EZH2 and γ-H2AX in two p16-null LCL 3CHT (corresponding to A2 and C2 in 
Fig. 3.2.3B) and two competent LCL 3CHT (-A and -C) cultured for 21 days with (+) or without (-) 
HT. γ-tubulin (γ-tub) was used as a loading control. Downregulation of EZH2 and phosphorylation of 
H2AX (γ-H2AX) are detected only in p16-competent lines cultured without HT. Data are 
representative of two independent experiments each including at least two p16-null LCL 3CHT lines. 
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p14ARF-p53-p21CIP1 pathway is not activated following EBNA3C inactivation in p16-
null LCL 3CHT 
The p14/p16 chimerical protein that exhibits all the known functions of p14ARF was 
marginally but consistently upregulated in p16-null LCL 3CHT after EBNA3C inactivation 
(Fig. 3.2.3C). I tested whether the p14ARF-p53-p21CIP1 pathway was activated (perhaps in a 
compensatory manner after the abrogation of p16INK4A-Rb-E2F1 axis) in p16-null LCL 3CHT 
cultured without HT. However, p53 protein was not consistently stabilized after EBNA3C 
inactivation, and neither p21CIP1 transcripts nor protein were upregulated (Fig. 3.2.9).  
 
 
 
 
 
 
 
 
Fig. 3.2.9.  p14
ARF
-p53-p21
CIP1
 pathway is not activated in p16-null LCL 3CHT following 
EBNA3C inactivation.  (A) Western blot of p53 and p21
CIP1
 in four p16-null LCL 3CHT cultured for 
21 days with (+) or without (-) HT. No consistent changes in expression of p53 or p21
CIP1
 are 
observed. (B) qPCR of p21
CIP1
 transcripts in four p16-null LCL 3CHT (A1, A2, C1, C2) and two p16-
competent LCL-3CHT-A and -C (ctrl A and ctrl C) cultured for 20 days with or without HT.  
 
The p16INK4A locus is epigenetically regulated by EBNA3C even in the absence of 
p16INK4A function 
The system with non-functional p16INK4A provided a unique opportunity to test whether the 
regulation of p16INK4A locus by EBNA3C can be separated from the production of the 
B 
 
A 
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functional p16INK4A protein.  The composition of chromatin at the p16INK4A   locus could be 
assessed in the cells with active or inactive EBNA3C, proliferating at the exactly same rate. 
The polycomb-imposed repressive H3K27me3 was convincingly diminished at the p16INK4A 
locus following EBNA3C inactivation in all p16-null LCL 3CHT tested (Fig. 3.2.10B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2.10.   Epigenetic regulation of p16
INK4A
 locus by EBNA3C in p16-null LCL 3CHT. (A) A 
scheme of the CDKN2A locus depicting the location of the assays used in ChIP-qPCR. Assays C is 
located in p16
INK4A   
exon 1 and the histone modifications in this region have the major impact on 
p16
INK4A 
transcription. The details of the primer position and sequence are listed in Table 2.7 and 
Table 2.8. (B) ChIP-qPCR analysis quantifying the H3K27me3 across CDKN2A locus in two p16-null 
LCL 3CHT (corresponding to C1 and C2 in Fig. 3.2.3B) cultured 27 days with or without HT. The 
peak of H3K27me3, centred at 
  
p16
INK4A   
exon 1, is detected in p16-null LCL 3CHT cultured with HT 
and is diminished in the lines cultured without HT. 
  
H3K27me3 mark at the control γ-globin promoter 
remains stable regardless of EBNA3C activity.
                                   
B 
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The levels of H3K27me3 were stable at the control γ-globin locus regardless of EBNA3C 
activity demonstrating that H3K27me3 was not diminished genome-wide after EBNA3C 
inactivation but was specifically erased at the p16INK4A locus (Fig. 3.2.10). H3K27me3 is 
catalyzed by SET domain of EZH2. Although EZH2, as a direct E2F1 target (Bracken et al., 
2003), decreased considerably in p16-competent LCL 3CHT during the proliferative arrest 
following EBNA3C inactivation, it remained constant in p16-null LCL 3CHT lines (Fig. 
3.1.16 and Fig. 3.2.8). Since the p16INK4A locus was differentially regulated by EBNA3C in 
p16-null lines despite the stable expression of EZH2, I can confirm the findings obtained 
previously from Rb-reduced LCL 3CHT-E (Fig. 3.1.11 and Fig. 3.1.16) and convincingly 
show that the regulation of H3K27me3 mark at the p16INK4A locus by EBNA3C is 
independent of the overall EZH2 expression.  
A peak of activation-related H3K4me3 is co-localized with the repressive H3K27me3 at 
p16INK4A exon 1, forming a bivalent domain. I showed previously that H3K4me3 was 
modestly increased after EBNA3C inactivation in p16-competent LCL 3CHT (Fig.3.1.9B).  
In p16-null LCL 3CHT, the levels of H3K4me3 did not substantially change after EBNA3C 
inactivation (Fig. 3.2.11).  
 
 
 
 
 
 
Fig. 3.2.11.  ChIP-qPCR analysis quantifying the H3K4me3 across CDKN2A locus in p16-null 
LCL 3CHT.  The peaks of H3K4me3 centred at 
  
p16
INK4A   
exon 1 detected in two p16-null LCL 3CHT 
(C1 and C2) cultured for 27 days with or without HT do not considerably differ. Analyzing the 
GAPDH promoter serves as a positive control.
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The kinetics of epigenetic regulation of p16INK4A locus by EBNA3C are similar in p16-
null and p16-competent LCL 3CHT 
After 30 days of culture without HT, HT was re-added to the p16-null LCL 3CHT and the 
kinetics of p16INK4A repression were monitored. Three days after re-adding HT, a subtle but 
significant H3K27me3 increase could be detected at p16INK4A exon 1 in the total cell 
population. By day 14 after re-adding HT, a H3K27me3 peak at p16INK4A  exon1 could be 
detected, although perhaps not yet fully developed (i.e. there seemed to be an increased 
H3K27me3 deposition in the control upstream region A and the difference between the 
upstream region -A- and p16INK4A exon1 -C - had reached only 2-fold) (Fig. 3.2.12A). The 
H3K4me3 mark was not significantly regulated after re-adding HT (Fig. 3.2.12B). 
As reported previously, in p16-competent LCL 3CHT, the peak of H3K27me3 at the 
p16INK4A locus was fully restored 20 days after re-adding HT (Fig. 3.1.9). Surprisingly, the 
repressive mark at p16INK4A in p16-null lines was reconstituted in a similar time-scale, 
requiring weeks rather than days. This strongly implies, that the elapsed time and/or the 
high number of cell divisions required for p16INK4A repression by EBNA3C are related 
directly to the mechanism of repression and not to the outgrowth of selected populations. 
Since the p14/p16 protein was consistently modestly upregulated in the p16-null LCL 3CHT 
following EBNA3C inactivation (Fig. 3.2.3C), the chromatin status at the p14ARF promoter 
was also assessed. Consistent with the findings in p16-competent LCL 3CHT (Fig. 3.1.30), 
in p16-null LCL 3CHT, only low quantities of H3K27me3 mark were detectable at p14ARF 
promoter in cells cultured with HT, when EBNA3C was active and p14ARF locus repressed; 
the mark perhaps further slightly decreased after 30 days following EBNA3C inactivation 
(Fig. 3.2.13A). However, 21 days following EBNA3C reactivation in two p16-null LCL 
3CHT, the H3K27me3 mark at p14ARF promoter, in contrast to p16INK4A exon1, did not 
increase (Fig. 3.2.13B). H3K4me3 formed a peak at p14ARF promoter, quantitatively 
comparable to that present at p16INK4A exon1 (assay C), irrespectively of EBNA3C activity 
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(3.2.13A). I conclude that similar to p16-competent LCL 3CHT, in p16-null LCL 3CHT 
p14ARF did not seem to be regulated by H3K27me3 or H3K4me3 in response to EBNA3C 
activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2.12.  The kinetics of epigenetic modulation of 
 
p16
INK4A 
locus
  
by EBNA3C. (A) ChIP-
qPCR analysis quantifying the H3K27me3 mark across the CDKN2A locus in p16-null LCL 3CHT 
(A2) cultured with HT, 30 days without HT or 72h or 14 days after HT was re-added. The peak of 
H3K27me3 centred at p16
INK4A 
exon 1 detected in p16-null LCL 3CHT cultured with HT is diminished 
in lines cultured without HT and subsequently gradually restored following the readdition of HT.
 
(B) 
Similar analysis quantifying H3K4me3. H3K4me3 does not change significantly across the CDKN2A 
locus in p16-null LCL 3CHT in response to EBNA3C activity.
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Fig. 3.2.13.  Histone modifications at CDKN2A locus including p14
ARF
 promoter in p16-null 
LCL 3CHT. (A) H3K27me3 and H3K4me3 quantified by ChIP-qPCR at CDKN2A locus including 
p14
ARF
 promoter (p14) in p16-null LCL 3CHT (A2) cultured for  30 days with or without HT. (B) 
H3K27me3 quantified by ChIP-qPCR at CDKN2A locus including p14
ARF
 promoter (p14) in two p16-
null LCL 3CHT (A2 and C2) cultured for 30 days without HT or 21 days after HT was re-added. 
Neither of the modifications at p14
ARF  
 promoter appears regulated by EBNA3C. 
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The cumulative nature of H3K27me3 restoration at p16INK4A exon 1 following EBNA3C 
reactivation 
Since the epigenetic repression of p16INK4A by EBNA3C requires a surprising length of time, 
the kinetics were studied and modelled in detail. Firstly, time-course ChIP experiments 
performed on p16-null and -competent LCL 3CHT  following HT removal or readding were 
compared. The time required for the loss and restoration of the H3K27me3 mark in 
response to changes in EBNA3C activity was similar in multiple lines  (Fig. 3.2.14A, Fig. 
3.1.8B and C and data not shown). Approximately 14 days were required for a convincing 
decrease or increase in H3K27me3, while by 21 days there was a pronounced loss of 
H3K27me3 at p16INK4A exon 1 if EBNA3C was inactivated or a well-defined H3K27me3 
peak at p16INK4A exon 1 if EBNA3C was re-activated. It is possible that in p16-null lines, the 
H3K27me3 mark was fully restored in a slightly shorter period of time (i.e. 14 days)  
following EBNA3C reactivation than in p16-competent lines (Fig. 3.2.12A and 3.2.14A). In 
addition, since H3K27me3 was progressively erased at p16INK4A exon 1 with increasing time 
of culture without functional EBNA3C, the time required for restoration of H3K27me3 at 
p16INK4A exon 1 after EBNA3C reactivation seemed partially dependent on the time the line 
was cultured without functional EBNA3C; the longer time EBNA3C was inactivated, the 
longer (in days) it would take to restore H3K27me3 at p16INK4A exon1. This is in agreement 
with the previous data showing that the period needed for the full repression of p16INK4A and 
restoration of proliferation after reactivation of EBNA3C in p16-competent LCL 3CHT was 
dependent on the time the cells were previously cultured without functional EBNA3C (Fig. 
3.1.4 and Fig. 3.1.6). 
Strikingly, the proccess of H3K27me3 deposition at the p16INK4A  locus was cumulative and 
very gradual. As an example, following prolonged EBNA3C inactivation (35 days) in p16-
null LCL 3CHT, the repressive H3K27me3 was erased from exon 1 of p16INK4A even to 
levels below the surrounding upstream and downstream regions. Early after re-adding HT 
(3 days), the first signs of H3K27me3 restoration at the p16INK4A exon1 could be observed 
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(Fig. 3.2.14B), and the accumulation of H3K27me3 continued over weeks to form a mature 
peak (Fig. 3.2.14C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2.14. Cumulative nature of H3K27me3 restoration at p16
INK4A
 locus following EBNA3C 
reactivation in p16-null LCL 3CHT. (A) The illustration of the configuration of H3K27me3 mark at 
p16
INK4A
 locus in p16-null lines cultured for various times with or without HT. p16-competent lines 
with or without active/WT EBNA3C are added for comparison. Although the results of several 
independent ChIP experiments were combined in this figure, the distribution of H3K27me3 across 
p16
INK4A
 locus (i.e. the shape of the peaks) is directly comparable. (B) ChIP-qPCR mapping 
H3K27me3 at the p16
INK4A
 locus in p16-null LCL 3CHT (A2) cultured for 35 days without HT and  for 
3 days after HT was re-added. (C) Similar ChIP-qPCR analysis depicting the well-defined 
H3K27me3 peak at p16
INK4A
 locus in two p16-null LCL 3CHT (A2 and C2)  21 days after re-adding 
HT.  
A 
 
B 
 
C 
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EBNA3A is required for additional functions in the maintenance of LCL proliferation 
apart from p16INK4A repression 
 
Functionally p16-null EBNA3A KO and revertant LCL were produced by infecting the p16-
deleted PBL with respective recombinant EBV-BAC viruses. However, due to the limited 
number of these rare PBL, only one pair of EBNA3A KO and revertant LCL was 
established and the results presented below were acquired using this single pair. 
As in p16-null LCL 3CHT, there was no WT p16INK4A produced in p16-null EBNA3A KO or 
revertant LCL; however, the non-functional p16/X and the p14ARF function-carrying p14/p16 
chimerical proteins were expressed. Both chimeras were marginally upregulated in p16-null 
EBNA3A KO LCL in comparison to the revertant (Fig 3.2.15). 
 
 
 
 
 
 
Fig. 3.2.15. Characterization of the p16-null EBNA3A KO and revertant LCL. Western blot 
illustrating the expression of EBNA3A and proteins arising from the CDKN2A locus in p16-null and –
competent  EBNA3A KO and revertant LCL. p16
INK4A
, detected by both N-terminal and C-terminal 
mAb, is upregulated in p16-competent EBNA3A KO line in comparison to the revertant. In p16-null 
lines, no WT p16
INK4A
 is detectable. The p16/X chimerical protein detected by N-terminal mAb and 
p14/p16 chimera detected by C-terminal mAb both appear modestly upregulated in EBNA3A KO line 
in comparison to the revertant. WB shown is representative of two experiments performed using the 
only available p16-null EBNA3A KO line.  
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The proliferation of the newly established p16-null EBNA3A KO and revertant LCL, i.e. 
three months after infection, was assessed by BrdU incorporation and compared with their 
p16-competent counterparts which spent approximately equal time in culture following 
infection with EBV. I have reported previously that p16-competent EBNA3A KO LCL  
(similarly to CtBP-binding mutant LCL) seem to undergo a selection in culture for the loss 
of Rb expression and might recover the proliferation rate similar to the respective 
revertants. Here, I show p16-competent EBNA3A KO LCL early after outgrowth (three 
months after infection). The proliferation rate, assessed by BrdU incorporation, in LCL 
lacking EBNA3A was decreased by two thirds in comparison to the respective revertant.  In 
contrast to the unaltered proliferation of the p16-null LCL 3CHT cultured without HT, the 
proliferation of p16-null EBNA3A KO LCL was also reduced, suggesting that additional 
functions of EBNA3A other than p16INK4A repression were required for maintenance of LCL 
proliferation (Fig. 3.2.16). Although only one pair of p16-null EBNA3A KO and revertant 
LCL was available, the reduction of proliferation in EBNA3A KO was reliably reproduced in 
several independent measurements.  
Similar to p16-null LCL 3CHT, the p16INK4A locus was epigenetically regulated by EBNA3A 
even in the absence of p16INK4A function. H3K27me3 was decreased at the p16INK4A locus in 
a p16-null EBNA3A KO LCL in comparison to the revertant, although to a lesser extent 
than in the case of EBNA3C inactivation (Fig. 3.2.17). It is nevertheless clear that EBNA3A 
contributes to the epigenetic regulation of p16INK4A locus in LCL. 
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S-phase (R3) EBNA3A  revertant EBNA3AKO 
 Mean (%) SD Mean (%) SD 
p16-competent 34 
 
 
2.82 12.3 
 
 
1.83 
p-16-null 38.45 
 
 
4.87 21.56 
 
 
2.20 
 
Fig. 3.2.16.  Proliferation rate of p16-null and -competent EBNA3A KO and revertant LCL. (A) 
One representative FACS analysis (of three similar measurements) of cells incubated for 1hour with 
BrdU and stained with anti-BrdU-FITC/PI. The gated population (R3) comprises the cells that have 
undergone DNA replication while incubated with BrdU (the cells which have DNA content between 
2N and 4N and highly incorporate BrdU). (B) The mean and SD of percentage of cells in the S 
phase for the same lines in three separate measurements. The population in S phase decreases by 
almost two thirds in p16-competent EBNA3A KO LCL and by almost half in p16-null EBNA3A KO 
LCL in comparison to the respective revertants.  
 
A 
 
A 
 
B 
 
A 
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Fig. 3.2.17. Epigenetic regulation of p16
INK4A
 locus by EBNA3A in p16-null LCL. ChIP-qPCR 
analysis quantifying the H3K27me3 mark across CDKN2A locus in EBNA3A KO and revertant p16-
null LCL. The peak of H3K27me3 centred at 
  
p16
INK4A   
exon 1 in the revertant is visibly diminished in 
EBNA3A KO. 
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3.2.2 Expression of p16INK4A during the transformation of primary B 
cells by EBV 
 
Objectives  
 
The induction of p16INK4A was shown to robustly repress LCL proliferation and there is no 
doubt that a strong requirement for very tight control of p16INK4A  exists in established LCL. 
EBV seems to have evolved several proteins dedicated to p16INK4A repression (i.e. 
EBNA3C, EBNA3A, LMP1). This led me to hypothesize that p16INK4A induction might 
present a barrier not only in maintenance of LCL growth but also during the transformation 
of B cells by EBV.  In order to test this, the expression of p16INK4A in the early stages of B 
cell transformation was assessed.  
The results presented in this section should be considered only preliminary, since the 
experiments did not contain all necessarry controls (see discussion) that would allow 
definitive conclusions to be drawn. 
 
Results 
 
CDKN2A/p16INK4A expression is not maintained at the basal levels found in primary B 
cells, but is increased after EBV infection 
CDKN2A mRNA, quantified by an assay targeting the exon 2/3 boundary shared by 
p16INK4A and p14ARF, was expressed at basal, barely detectable levels in primary B cells 
purified by anti-CD19 coated MACS micro-beads. Surprisingly, after EBV infection, 
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CDKN2A transcripts were not maintained in this highly repressed state and increased with 
time reaching up to 6-fold by 14 days post-infection. (Fig. 3.2.18). 
  
 
Fig. 3.2.18. CDKN2A transcripts after EBV 
infection of purified primary B cells.  CDKN2A 
transcripts quantified by qPCR at day 0 (two separate 
samples) 2, 4, 7 and 14 following EBV infection of 
primary B cells. CDKN2A transcripts increase up to 6-
fold following EBV-infection of primary B cells. 
 
 
Transcripts of other EBNA3C or EBNA3C and EBNA3A-regulated genes (BIM EL, TGFβR2 
and NOTCH2) and a non-regulated gene (RPLP0 and possibly Rb) on the level of 
transcription were assessed in the same samples as CDKN2A transcripts. BIM EL, 
TGFβR2 and NOTCH2 play essential roles in the B lymphocyte function and are modulated 
in B cell-derived malignancies. BH3-only protein BIM, a member of the Bcl-2 family, 
regulates B lymphocyte apoptosis (Clybouw et al., 2005; Biswas et al., 2007). NOTCH2 is 
preferentially expressed in mature B cells; conditionally targeted deletion of NOTCH2 
results in the defect of marginal zone B cells and their precursors (Witt et al, 2003; Saito et 
al., 2003). Depending on cancer-type, NOTCH2 can serve as both oncogene and tumour 
suppressor (O’Neill et al., 2007; Chu et al., 2009). TGFβ induces apoptosis in BL cell lines 
and in primary human B lymphocytes (Spender and Inman, 2009). TGFβR2 mediates the 
tumour suppressor activity of the TGFβ signalling pathway and is inactivated in several 
cancers (Kaklamani and Pasche, 2004). BIM EL and TGFβR2 are expressed at very low 
levels in established LCL lines, while NOTCH2 is well expressed; however, in established 
LCL all three are repressed by EBV at the level of transcription, specifically by either 
EBNA3C or by co-operation of EBNA3C and EBNA3A (White et al., 2010 and unpublished 
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data). RPLP0 encodes a ribosomal protein that is a component of the 60S subunit; RPLP0 
transcription is not regulated by EBNA3C or EBNA3A (data not shown) and was used 
throughout this entire study to normalize gene expression. The transcriptional regulation of 
Rb by EBNA3C, EBNA3A or EBV has not been previously excluded; the Rb transcription 
was estimated following infection of primary B cells with EBV due to the possible interplay 
of Rb and p16INK4A  expression (Rb-p16INK4A feedback loop) (see Introduction, p.31).  
Bim EL, NOTCH2 and TGFβR2 were found robustly down-regulated in the early stages of 
B cell transformation while RPLP0 and Rb transcripts were not markedly altered (Fig. 
3.2.19). 
   
              
Fig. 3.2.19. Control transcripts repressed or unaltered after EBV infection of purified primary 
B cells.  BIM EL, NOTCH2, TGFβR2, RPLP0 and Rb transcripts quantified by qPCR at day 0 (two 
separate samples) 2, 4, 7 and 14 following EBV infection of purified primary B cells. BIM EL, 
NOTCH2 and TGFβR2 transcripts are soon repressed, while RPLP0 and Rb transcripts remain 
mostly unaltered in the early stages of B cell transformation. 
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In a further experiment, PBL were used instead of purified B cells.  A small number of B 
cells was purified from PBL by anti-CD19 coated MACS micro-beads at the start of the 
experiment to serve as a day 0 control. The first harvesting point was set only at day 7 
post-infection when the majority of PBL other than B cells should be eliminated from the 
culture (i.e. T cells and NK cells will be eliminated, while macrophages/monocytes will still 
be present). PBL infected with EBV were separated at day 7, 14 and 25 using Ficoll-Paque 
gradient (see Materials and Methods Fig. 2.2) and the transcripts were quantified in RNA 
isolated from both normal- and high-density fractions. Normal-density fraction consists of 
the subpopulation of the normal, live cells while the high-density fraction comprises cells 
that are most likely apoptotic (Czene et al., 2002; Belloni et al., 2008). p16INK4A mRNA 
expression was assessed in the normal-density fraction of  EBV-infected PBL. Consistent 
with the previous experiment (Fig. 3.2.18), p16INK4A mRNA increased following EBV 
infection (Fig. 3.2.20). 
 
 
Fig. 3.2.20.  p16
INK4A
 transcripts in the normal-density cell population after EBV infection of 
PBL.  The p16
INK4A
 transcripts quantified by qPCR at day 0, 7, 14 and 25 were upregulated following 
EBV infection of PBL. 
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The accumulation of growth-inhibitory CDKN2A/p16INK4A transcripts seems to be 
more pronounced in the high-density fraction 
 
Analysis of the realtive quantities of CDKN2A, p16INK4A and Rb transcripts in the normal 
and high-density fraction of  EBV-infected PBL  was perfromed on the group of about 20 
samples harvested at various time-points (between day 7 and day 25) following EBV 
infection of PBL in two independent experiments. Interestingly, higher amounts of CDKN2A 
and p16INK4A transcripts seemed to be found in high-density population (Fig.3.2.21). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2.21. Accumulation of p16
INK4A
 and CDKN2A transcripts in the high-density fraction of 
EBV-infected PBL. The histogram shows relative quantities of p16
INK4A
, CDKN2A and control Rb 
transcripts in the high and normal-density fractions of PBL infected with EBV in 20 samples from two 
independent experiments. The table shows the increase in expression in high-density fractions as a 
fold difference relative to the respective normal-density fractions.  
Separation 
p16
INK4A
 
mRNA 
CDKN2A 
mRNA 
Rb 
mRNA 
EBV infected high density 14.13 4.04 1.25 
EBV infected normal density 1 1 1 
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Summary key points 
 
 Repression of p16INK4A  transcripts is the major function of EBNA3C in EBV-driven 
LCL  proliferation 
 The  p16INK4A  locus is specifically targeted and repressed by EBNA3C even in the 
absence of functional p16INK4A protein  
 The p16-null LCL 3CHT system allows the study of EBNA3C-regulated genes in a 
proliferation–independent manner  
 p16INK4A is induced as naive B cells are activated to proliferate by EBV 
 
Discussion  
 
EBNA3C is a multifunctional protein and regulates an entire subset of cellular genes at the 
level of transcription (White et al., 2010; Zhao et al., 2011a).  Functional analysis performed 
previously by Maruo et al. (2011), using RNA interference to decrease the expression of 
p16INK4A and p14ARF separately and in combination indicated that p14ARF contributes to the 
cell cycle arrest following EBNA3C inactivation. Others have also reported several 
EBNA3C-mediated alterations in expression of genes such as TCL1 expected to contribute 
to the EBNA3C-dependent maintenance of LCL proliferation (Lee et al., 2009; Zhao, et al., 
2011a). Surprisingly, I obtained unambiguous data proving that the absence of p16INK4A 
abrogates the need for EBNA3C activity in the maintenance of proliferation in established 
LCL (Fig. 3.2.5 and Fig.3.2.6). I show that p16INK4A repression is the main and the only 
necessary function of EBNA3C in EBV-driven LCL proliferation. 
In addition, EBNA3C can cause epigenetic modification of p16INK4A even in a system where 
the regulation is separated from the functional outcome and the selection based on the 
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proliferative advantage does not play any role (Fig. 3.2.10 and Fig. 3.2.12). This finding 
puts forward convincing evidence that EBNA3C can directly or indirectly modify histones at 
the specific cellular locus and alter the cellular identity towards a malignant phenotype. 
 
Kinetics of p16INK4A regulation by EBNA3C 
At the level of cell population – when a total population of p16-null LCL 3CHT is analyzed 
at various time-points with or without HT rather than a single cell - the kinetics of p16INK4A 
regulation is relatively slow (Fig. 3.2.12A and Fig. 3.2.14). The H3K27me3 peak on p16INK4A 
is fully reconstituted only after a period of at least 14 days following EBNA3C reactivation. 
Before the establishment of p16-null LCL, it could have been argued that the epigenetic 
modifications of p16INK4A occur as a few stochastic events followed by the selection after 
EBNA3C reactivation. However, the modification of p16INK4A regardless of its function 
implies that this locus is specifically targeted for repression by EBNA3C and precludes the 
acquisition of the p16INK4A repression in the cell population as a consequence of selection. 
Therefore the relatively slow kinetics of p16INK4A modulation by EBNA3C seem to be 
genuinely related to the mechanism of its regulation. 
 
I and others (Maruo et al., 2006 and Zhao et al., 2011a) failed to identify any phenotypic 
changes early in the hours or first days after EBNA3C reactivation in p16-competent LCL 
3CHT. The first detectable (subtle) increase in proliferation -at the level of the whole cell 
population- correlated with a decrease in p16INK4A expression and occured only 4-6 days 
after EBNA3C reactivation (Fig. 3.1.4). The loss and re-establishment of H3K27me3 at 
p16INK4A locus in p16-competent and -null LCL 3CHT is gradual and appears almost 
passive (Fig.3.1.8B and C, Fig. 3.2.12A and Fig. 3.2.14). Furthermore, another well-defined 
EBNA3C and EBNA3A-regulated promoter – BIM, has been shown to be de-repressed in 
BL31 3CHT following EBNA3C inactivation with similar kinetics as seen for p16INK4A 
(Paschos et al., under revision). At the level of the cell population, the complete loss or re-
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appearance of the H3K27me3 mark in response to EBNA3C reproducibly occurs only after 
a rather high number of cell divisions (estimated to be about 15-20). 
A possible explanation for the delayed H3K27me3 regulation is the combination of the slow 
EBNA3C inactivation or reactivation and stability of H3K27me3 mark. The EBNA3C fusion 
protein is degraded following its inactivation and time is required for the newly synthesised 
protein to form and fold after re-adding HT. H3K27me3 arises from monomethylation of 
H3K27me2 and is thought to be one of the most stable post-translational histone 
modifications. The average half-maximal time of fully labelled H3K27me3 histones in 
proliferating HeLa cells, measured by combining stable isotope labeling of amino acids in 
cell culture (SILAC) pulse with quantitative mass spectrometry-based proteomics, is 
estimated to be as long as 3.1 days (Zee et al., 2010).  
In such a scenario, when re-adding HT to the population of p16-null LCL 3CHT, which have 
been previously cultured without HT for 21-30 days and have lost the H3K27me3 peak at 
p16INK4A exon 1, an initial latency of about 24-72h following readdition of HT would be 
expected while EBNA3C-HT protein is synthesised and the levels usually found in cells 
cultured with HT are reached. However, the remaining non-degraded EBNA3C-HT 
molecules should be reactivated shortly after readdition of HT, so some EBNA3C activity 
should be present immediately after HT is re-added. According to current data on 
H3K27me3 turnover (Zee et al., 2010) and the timing of the regulation of the p16INK4A locus 
by H3K27me3 in human fibroblasts (Barradas et al., 2009) at the level of cell population, 
the peak of H3K27me3 equivalent to that found in LCL 3CHT cultured with HT would be 
expected to form in maximum 6-7 days after EBNA3C reactivation, if the H3K27me3-
establishing complexes (i.e. PRC2) were available and active at p16INK4A locus in all cells 
simultaneously. Taken together, if the p16INK4A locus in all cells in the population was 
actively modified by PRC2 following readdition of HT, a more rapid restoration of the 
H3K27me3 peak at p16INK4A locus would be expected over the time period of 6 to 9 days 
(Fig. 3.2.22).  My current data do not fit this model, since surprisingly, even in the cycling 
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and exponentially dividing population of p16-null LCL 3CHT, a longer period of about 14 to 
21 days following readdition of HT is needed- at the level of cell population- for the 
reconstitution of H3K27me3 at p16INK4A exon 1 to the quantities observed in controls 
cultured with HT. 
 
 
 
 
 
 
 
 
Fig. 3.2.22.  The model of the expected timing of H3K27me3 restoration at p16
INK4A 
exon 1 
following readdition of HT on p16-null LCL 3CHT cultured previously without HT. After the 
initial latency of about 3 days, which allows for synthesis and posttranslational modification of the 
EBNA3C-HT protein (depleted in the absence of HT), the peak of H3K27me3 would be expected to 
fully form in about 6-7 days. However, this model is not consistent with my current data, which show 
that the H3K27me3 at p16
INK4A
 locus is, at the level of cell population, deposited in a gradual manner 
following readdition of HT. The full peak of H3K27me3 at p16
INK4A
 locus is restored slower than 
expected, after about 20 cell divisions. 
 
The de-repression of both p16INK4A and BIM after EBNA3C inactivation implies that the 
initiating factor needs to persist in LCL and BL31, in the absence of DNA methylation, in 
order to maintain the epigenetic repression. Modelling of the epigenetic repression at 
p16INK4A locus by EBNA3C illustrates the gradual cumulative nature of the process at the 
level of cell population (Fig. 3.2.14), which can be interpreted as increasing number of cells 
acquiring repressive H3K27me3 mark at p16INK4A locus with each cell division. These 
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findings imply that the process is mitosis-dependent (i.e.dependent on the number of 
mitotic divisions) even when the potential selection pressure in culture has been eliminated. 
It is therefore possible that EBNA3C (perhaps in co-operation with EBNA3A) plays a role in 
the transmission of H3K27me3 at the target loci throughout the cell division. 
Several models of H3K27me3 transmission - the maintenance of the H3K27me3 mark in 
proliferating cells - have been proposed so far, but the mechanism of propagation of this 
and other histone modifications is largely unknown (Bonasio, Tu and Reinberg, 2010; Zhu 
and Reinberg, 2011). During cell division, chromatin undergoes transient genome-wide 
disruption followed by restoration on the DNA of the daughter cells. Histone modifications 
could be either copied according to a parental template or re-established in a DNA 
replication-coupled process (Jasencakova and Groth, 2010; Zhu and Reinberg, 2011).  
Combination of the crystal structure of the methyllysine histone-binding  WD40 domain 
from the EED subunit  in complex with H3K27me3 peptides and in vitro  histone 
methylation assays has demonstrated that the binding of H3K27me3 to EED allosterically 
stimulates PRC2 and promotes formation of new H3K27me3 marks (Margueron et al., 
2009). Similar to DNA methylation maintenance, the reading of existing H3K27me3 marks 
by EED is thought to lead to the PRC2-mediated writing of the new ones (Margueron et al., 
2009; Xu et al., 2010a).  EBNA3C could assist in directing such templated copy event by 
acting like a locus-specific methylation reader and it would therefore be of interest to 
assess the quantitative binding of H3K27me3 peptides to EBNA3C. Such a mechanism of 
H3K27me3 transmission by templated copying is feasible, provided the histones are 
divided in a semi-conservative manner, when H3-H4 tetramer split into two copies with 
each daughter cell containing one of the original H3-H4 dimers and one newly deposited.  
This has not been convincingly proven; on the contrary the recent findings argue that the 
H3-H4 tetramer splitting is generally infrequent and the majority of H3-H4 tetramers 
segregate in a conservative manner, resulting in nucleosomes bearing exclusively old or 
new H3–H4 tetramers. This would exclude histone modifications transmission based on 
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copying preexisting modifications within the same nucleosome (Xu and Zhu, 2010; Katan-
Khaykovich Y, Struhl, 2011; Zhu and Reinberg, 2011). 
 
Another potential mechanism of epigenetic inheritance of histone modifications is 
replication-dependent re-establishment of histone modifcations at the nascent chromatin. It 
was suggested that either transcription factors or transactivators are retained at the locus 
on mitotic chromosomes and tag the locus for subsequent fast activation or repression 
(Zaidi et al., 2010 and 2011; Zhao et al., 2011b). The information about the functional state 
of the gene is so conveyed to the daughter cells and can be readily reproduced post-
mitotically in both daughter cells. This concept was termed gene bookmarking and is 
currently being explored using in vivo real-time imaging systems at high temporal resolution 
(Zaidi et al., 2010; Zhao et al., 2011b).  Once the EBNA3C ChIP assay has been 
established using the strep-FLAG (TAP) tagged EBNA3C proteins, it would be of great 
interest to see, not only whether EBNA3C can be detected at the p16INK4A locus, but also 
whether it remains associated with the locus during cell division or more generally whether 
EBNA3C is retained on mitotic chromosomes. 
 
In addition, the requirement for a rather high number of cell divisions in the epigenetic 
regulation of p16INK4A might also stem from different availability or activity of EBNA3C 
throughout the cell cycle. EBNA3C might be posttranslationally modified or the complexes 
containing EBNA3C might be disrupted or assembled in association with cell division.  
 
Lastly, I still have not excluded the possibility that EBNA3C regulates p16INK4A indirectly and 
there could be a number of molecular events intercalated between EBNA3C inactivation or 
reactivation and the transcriptional modulation of p16INK4A.  
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p16INK4A as a driver locus 
Cancers are thought to arise as a result of an accumulation of genetic and epigenetic 
abnormalities within a cell (Hanahan and Weinberg, 2000; Billaud and Santoro, 2011). 
Although numerous genetic anomalies and extensive epigenetic reprogramming have been 
identified in cancerous cells, there seems to be a hierarchy in such alterations in regards to 
their contribution to the transformed phenotype. Certain mutations and epimutations appear 
to be crucial drivers of transformation while others are more auxiliary. It has been shown 
that a modulation of a few ‘driver’ loci or in an extreme case a single locus could induce or 
reverse a very profound malignant phenotype challenging the paradigm of multi-step 
tumorigenesis (Jain et al., 2002; Felsher, 2004; Jonkers and Berns, 2004; Shachaf and 
Felsher, 2005; Geyer, 2010). For example, c-myc, once its proapoptotic functions had been 
abrogated, could alone induce carcinogenesis in β-islets of pancreas (Greenwood, 2002, 
Pelengaris, Khan and Evan, 2002). Strikingly, this process could be reversed even at the 
stage of extensive angiogenic tumours invading local blood vessels and draining lymph 
nodes, solely by inactivating c-myc (Greenwood, 2002, Pelengaris, Khan and Evan, 2002).  
 
In LCL 3CHT, 550 genes were found to be differentially regulated 7 days after EBNA3C 
inactivation, before the p16INK4A-Rb axis was engaged. Furthermore, p14ARF in addition to 
p16INK4A is thought to contribute to the proliferative arrest following EBNA3C inactivation 
(Maruo et al., 2011; Zhao et al., 2011a). However, in p16-null lines, the proliferation rate in 
the absence of this single gene remained constant following EBNA3C inactivation despite 
the regulation of approximately 200 cellular genes (microarray by Rob White, personal 
communication). The repression of p16INK4A by EBNA3C thus seems to be an overriding 
regulatory event in LCL. In addition, it is known that cell cycle checkpoint defects tend to 
make cells more reliant on the remaining intact pathways and checkpoints (Dixon and 
Norbury, 2002; Reinhardt et al., 2007). Therefore it would be reasonable to expect that the 
p14ARF pathway or other proliferation-controling genes/pathways regulated by EBNA3C 
might take over p16INK4A function and inhibit the proliferation in p16-null LCL 3CHT 
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following EBNA3C inactivation. However, this is clearly not the case, since none of the 
EBNA3C-regulated genes in LCL could compensate for or, at least partially, substitute for 
the p16INK4A function (Fig. 3.2.5, Fig. 3.2.6 and Fig.3.2.9). This is yet another demonstration 
of the notion that not all gene modifications are equally functionally significant and that 
regulation of certain driver loci is highly important in particular contexts. 
 
p16INK4A is specifically important for B cell resistance to transformation 
Increases in p16INK4A and p14ARF in lymphoid progenitors were found to be causally 
associated with age-related decreases in B lymphopoiesis and increased resistance to 
transformation (Signer et al., 2008). A B lineage-specific ablation of p16INK4A in mice was 
associated with an increased incidence of systemic, high-grade B cell neoplasms (Liu et 
al., 2011). This is in contrast to other tissues; e.g. T-lineage specific deletion of p16INK4A 
was not associated with increased tumour formation (Liu et al., 2011). Although these 
studies were performed on B cell progenitors as opposed to differentiated B lymphocytes, 
they further reinforce the view that p16INK4A tumour suppressor mechanism might be 
particularly important for the B cell lineage. 
 
p16INK4A as a barrier to B cell transformation and  immortalization by EBV 
In the experiments presented in this study, PBL or purified primary B cells were infected 
with EBV and the transcripts of CDKN2A/p16INK4A and several control genes were 
quantified for up to 25 days. The timescale of 25 days was chosen to assess the dynamic 
changes rather than a snapshot of cellular transcription. By the final time-point (25th day), 
EBV-infected cell cultures could be considered as emerging transformed LCL; they were 
actively proliferating and comprising cell clumps.  
 
CDKN2A/p16INK4A transcription was not maintained at its original very low level after EBV 
infection of primary B cells or PBL, but increased several fold (Fig. 3.2.18 and Fig. 3.2.20). 
Nikitin et al. (2010) showed in a similar experiment that EBV infection of primary B cells 
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leads to hyperproliferation and replication stress, resulting in DNA double-strand breaks 
that induce the DDR. After EBV infection, the host cell activates protective ATM/CHK2 
mediated DDR signalling pathways to suppress B cell transformation. However, EBNA3C 
appears to disable ATM/CHK2-mediated host defence and permits B cell proliferation 
(Nikitin et al., 2010). If my data regarding an increase in CDKN2A/p16INK4A transcripts 
following EBV infection of primary B cells prove to be reproducible, they would suggest that 
CDKN2A/p16INK4A could act, in an analogous manner to ATM/CHK2 pathway, as a barrier 
to transformation. Although CDKN2A/p16INK4A transcripts increased in the normal-density 
subpopulation, considerably higher levels were found in the high-density fraction (Fig. 
3.2.21). Even if CDKN2A/p16INK4A transcription was not silenced in the live transformed 
cells, we may hypothesize that it was retained below a critical threshold that permits 
proliferation. EBNA3C (and EBNA3A) might be important, in addition to blocking the host 
cell DDR, to control the induction of p16INK4A during primary B cell transformation by EBV. 
 
It has been reported previously (Maruo et al., 2011) that the p16INK4A locus in LCL contains 
lower levels of H3K27me3, relative to resting B cells, and these are further reduced 
following EBNA3C inactivation. This supports the notion that p16INK4A expression increases 
during transformation of B cells, and in the newly formed LCL, a new equilibrium in 
p16INK4A-Rb pathway is established, with steady-state p16INK4A expression higher than in 
resting B cells but tightly controlled by EBNA3C and EBNA3A. Once the equilibrium in 
p16INK4A-Rb pathway in LCL is set, even relatively small increase in p16INK4A expression 
(e.g. 2 or 3-fold) following EBNA3C inactivation already inhibits LCL proliferation (Fig. 3.1.4 
and Fig.3.1.6 – the measurement of LCL 3CHT proliferation and p16INK4A transcript levels in 
the same samples). 
 
Previously, transformation/immortalization experiments were performed by comparing the 
outgrowth of p16-competent and p16-functionally null B cells infected with the WT B95-8 
strain of EBV (Hayes et al., 2004). Outgrowth occurred simultaneously for both sets of cells 
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by 14-days post-infection. The authors concluded that p16INK4A status does not have a 
major impact on the rate of outgrowth of early established LCL, although subtle changes in 
the outgrowth in the initial stages of transformation could not be excluded. I would offer an 
alternative interpretation of the outcomes of Hayes et al. (2004) study, specifically the facts 
that the p16-competent cells could be transformed similarly to p16-null B cells, and that the 
proliferation of established LCL in normal conditions, were unaffected by the p16INK4A 
status.  I suggest that rather then p16INK4A lacking its crucial tumour suppressive functions 
in B cells, EBV has evolved sufficient mechanism to overcome the barrier to transformation 
posed by activation of the p16INK4A-Rb pathway, by keeping CDKN2A/p16INK4A expression 
within the range that allows transformation, most likely with a combination of several very 
efficient mechanisms (EBNA3C, EBNA3A, possibly LMP1). 
 
The benefit of p16INK4A repression for EBV 
The control of an inappropriate induction of p16INK4A is advantageous for EBV in the initial 
stages of EBV infection when it is crucial for the virus to force a subset of resting naive B 
cells into the cell cycle. It is probable that p16INK4A repression has a ‘physiological‘ function 
also later in a latently infected cell useful to the persistence of the virus. I hypothesise that it 
is cell rejuvenation. EBV, similarly to other herpesviridea, requires very close contact 
between its human hosts for transmission. If a pathogen depends on the host for mobility, if 
it needs to be spread by host to another host, the mild pathogens are favoured by natural 
selection (Ewald, 2004). In the evolution towards lower pathogenicity, EBV was likely to 
develop mechanisms to ensure the survival and longevity of the target cells for persistence 
in its host. In their seminal work, Thorley-Lawson and his team described how EBV 
achieves persistence by gaining entrance into the long-lived compartment of memory B 
cells (Thorley-Lawson and Gross, 2004). However, it is possible that EBV might contribute 
to the extended life-span of the cells it resides in. EBV latent infection might modify the 
pathways involved in cell longevity and impose modifications that extend cellular lifespan 
(i.e. H3K27me3 at p16INK4A locus preventing significant p16INK4A increase). The repression 
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of p16INK4A in infected B cells could be maintained by latent EBV to ensure these cells stay 
‘biologically younger’. It is generally accepted that EBV transiently drives proliferation of the 
naive B cells and after their maturation takes advantage of the intrinsic long-lived properties 
of the memory B cell. However, EBV latency genes may also act directly to promote more 
long-lived B cells through modulations of genes having anti-senescence and antiapoptotic 
functions. The repression of p16INK4A would be advantageous for EBV in both of the 
scenarios. 
 
In summary, although EBNA3C seems to directly or indirectly govern a reprogramming of 
the entire subset of cellular genes, in this work I have identified the repression of p16INK4A 
by EBNA3C in LCL as the major phenotype-determining event, the switch between the 
benign or senescent phenotype and the malignant proliferative phenotype. The absence of 
this ‘driver’ locus in LCL overrides the phenotypic change otherwise observed after 
EBNA3C inactivation and renders EBNA3C dispensable for proliferation of established 
LCL. 
In addition, the p16-null LCL 3CHT system enables the study of cellular genes regulated by 
EBNA3C without the interference of E2F1- or otherwise cell cycle -mediated transcription 
(Fig. 3.2.5 and Fig.3.2.7). Since the LCL proliferation remains unchanged regardless of 
EBNA3C activity, the selection pressure based on faster outgrowth of advantageously 
modified subset of cells is removed. This system therefore bypasses several problems 
associated with the study of EBNA3C and should allow new insights into EBNA3C function. 
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Limitations of the study 
 
The 19bp germline deletion in CDKN2A was identified in Leiden University Medical Centre 
within the families with hereditary occurrence of melanoma of the skin and other cancers, 
e.g. pancreatic cancer (de Vos tot Nederveen Cappel, 2003; de Snoo, 2008). The vast 
majority of the carriers contain a heterozygous germline deletion in the locus; however, at 
least two patients with homozygous germline deletion have been identified so far (Gruis et 
al., 1995; Brookes, 2002), including the patient that supplied the blood used in this study 
(Gordon Peters and Alison Sinclair, personal communication). The patient included in this 
study was a male in his 20s with the clinical history of multiple atypical naevi and several 
superficially spreading malignant melanomas (Gordon Peters and Alison Sinclair, personal 
communication). It cannot be excluded that the patient carrying the homozygous germline 
defect in CDKN2A does not carry additional mutations in genes regulating cell proliferation. 
However, Brookes et al. (2002) investigated the karyotype and the functionality of the p53 
pathway in p16-null fibroblasts of the same individual, and excluded any gross genetic 
instability, pre-existing cytogenetic abberations or defects in p53 function. Furthermore, I 
have observed 50% reduction in proliferation of p16-null EBNA3A KO LCL in comparison to 
the respective p16-null EBNA3A revertant LCL (Fig.3.2.16), which implies that p16-null LCL 
are not generally resistant to the inhibition of proliferation. 
Findings from studies using in vitro LCL systems should only be carefully extrapolated into 
in vivo situations. The EBV transformation efficiency in vitro is much greater than the ability 
of EBV to cause tumours in vivo. About 95% of the world adult population has been 
infected with EBV and, following primary infection, remains lifelong carriers of the virus. In 
some cases, tumours characterized by the presence of multiple extrachromosomal copies 
of the viral genome in tumour cells and the expression of part of the EBV genome arise in 
carriers. However, the development of the EBV-related tumour is a relatively rare event. 
Latent EBV infection creates an environment permissible for transforming events, but 
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usually further aberrant pro-proliferative or anti-differentiation lesions are necessary for 
lymphomagenesis. The loss of p16INK4A function due to repressive modifications mediated 
by EBV is likely to facilitate survival of EBV-infected cells following other EBV-related and 
random EBV-unrelated oncogenic events. The H3K27me3 mark might direct DNA 
methylation of the p16INK4A locus which would further stabilize the repression. Such 
heritable modifications could occur in other loci as well, e.g. of proapoptotic genes such as 
BIM. These non-neoplastic but epigenetically disrupted persisting precursor cells could 
create a reservoir with an epigenetic environment favouring neoplastic transformation.   
While studying the primary B cell transformation and immortalization by EBV, in order to 
make meaningful conclusions, the phenotype of  EBV-infected  B-cells needs to be 
accurately assessed – in regards to the rate of apoptosis (by eg. annexin V with 7-AAD 
flow cytometry), activation (eg. anti-CD23 flow cytometry) and proliferation (using BrdU 
incorporation or CFSE proliferation-tracking dye). In addition, the more precise isolation of 
cells into the pure subpopulations than by Ficoll-Paque gradient could be achieved by flow 
cytometry assessing EBNA2 or CD23 expression (sorting for EBV-infected 
subpopulation),or using proliferation-tracking dye CFSE (sorting for proliferating cells). 
Furthermore, in order to distinguish the changes in the gene expression related either to 
activation of resting B cells into B blasts or specifically to EBV, EBV-infected cells can be 
compared to cells activated by soluble CD40L in the presence of interleukin-4. This 
combination of signals mimics B cell activation by CD4+ T cells and efficiently induces B 
cell proliferation for up to ten weeks in vitro (O’Nions and Allday, 2004). 
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Future work 
 
 Re-introduce p16INK4A into p16-null LCL 3CHT by p16INK4A-expressing lentivirus. 
Inhibition of proliferation of p16-null LCL 3CHT following enforced p16INK4A 
expression would demonstrate that p16-null LCL 3CHT are responsive to WT 
p16INK4A and do not contain defects down-stream of p16INK4A. 
 Microarray of cellular transcripts of p16-null LCL 3CHT cultured 30 days with and 
without HT, and cultured 30 days without HT and after HT was re-added for 30 
days, have already been performed (Rob White, personal communication). The 
data will be compared with the previously reported sets of genes regulated by 
EBNA3C in p16-competent LCL 3CHT (Zhao et al., 2011a) and in BL31 infected 
with WT and EBNA3C KO recombinant EBV-BAC (White et al., 2010). In addition, 
to determine the role of EBNA3C-CtBP co-operation in regulation of cellular genes 
other than p16INK4A, the gene set regulated by EBNA3C in p16-null LCL 3CHT will 
be compared with the cellular genes regulated in LCL carrying the CtBP-binding 
mutant of EBNA3C (3CCtBP LCL) (Rob White, personal communication). 
 Attempt to immortalize p16-null B lymphocytes with EBNA3C KO virus (assess 
whether the control of p16INK4A expression is the single reason why EBNA3C is 
essential for transformation). 
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3.3 EBNA3C and/or EBNA3A-regulated 
cellular microRNAs 
 
Objectives 
 
Recent genome-wide analyses have shown that virtually all DNA nucleotides of the human 
genome are, to some degree, transcribed into RNA. Only 2% of the mammalian genome 
encodes mRNAs that are translated into proteins, while the vast majority is transcribed into 
regulatory non-protein-coding RNAs, including miRs, small interfering RNAs, PIWI-
interacting RNAs and various classes of long ncRNAs (Taft et al., 2010). Thousands of 
ncRNAs are regulated in response to acute virus infection (Peng et al., 2010) and during 
cancer development (Braconi et al., 2011a and 2011b).  Since tools for robust functional 
analysis of ncRNA are only just becoming available (e.g. siRNA libraries), functions of the 
majority of ncRNA are currently uncharacterized. 
In the past, identification of the cellular targets of viral oncoproteins led to the discovery of 
several important growth and cell cycle regulators (Ferrari, Berk and Kurdistani, 2009). In 
this study, I investigated whether EBNA3C and EBNA3A in addition to their well-known role 
in regulating cellular protein-coding transcripts (White et al., 2010) also modify the 
expression of ncRNAs, in particular miRs. 
All of the results listed below were acquired using the p16-competent LCL expressing the 
WT p16INK4A, unless otherwise indicated. 
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Results 
 
EBNA3C and EBNA3A regulate expression of several cellular miRs in LCL 
In order to determine whether EBNA3C and EBNA3A can trigger changes in cellular miR 
expression, the expression of 377 human biologically active mature miRs was examined 
using Taqman real-time qPCR low density arrays (TLDA) to analyse two LCL 3CHT lines 
cultured for 28 days with or without HT and two EBNA3A KO LCL and their respective 
revertants. The TaqMan® Array Human MicroRNA A Card v 2.0 contained a selection of 
cellular miRs that are functionally defined, broadly expressed and/or highly expressed. 
Three ncRNA endogenous controls were available on the card to aid in data normalization, 
including U6snRNA assay which was repeated four times on each card. The RNA 
preparations used in the screen were enriched for miRs and small RNAs up to 200bp and 
analyzed directly by TLDA without pre-amplification (see Materials and Methods, pp.75-76).  
Several cellular miRs were found to be regulated by either EBNA3A or EBNA3C or both 
(data not shown). The data acquired were screened for positive leads to be followed-up by 
further qPCR measurements and was not statistically analyzed for several reasons. As the 
result of the high complexity of the miR pool, it was reported that fold change 
measurements of some assays within the card may be less than the true value. 
Furthermore, the expression of many cellular miRs is strictly context and tissue-specific, 
and a large proportion of miRs in LCL are intrinsically expressed at low levels. Due to 
simultaneous high background from a subset of assays within the card, it was difficult to set 
meaningful cut-off values. In addition, since the effectiveness of miRs largely depends on 
the quantity of their regulated cellular mRNA targets, it would be problematic to set a 
uniform level of miR differential expression that could be biologically significant. 
The positive leads from the screen were followed-up using the single Taqman microRNA 
expression assays. The oncogenic growth-promoting miR-221 was found to be regulated 
by both EBNA3C and EBNA3A. MiR-221 was induced approximately 2-3 fold by EBNA3C 
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and 6-20 fold by EBNA3A (Fig. 3.3.1A). MiR-221 was relatively well expressed in LCL and 
even the 2.5-fold increase therefore translates to a considerable change in the miR-221 
copy number in a cell (Fig. 3.3.1B). 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.1. Regulation of miR-221 by EBNA3C and EBNA3A in LCL. (A) qPCR of miR-221 in two 
LCL 3CHT (-A and -C) cultured for 28 days with (+HT) or without HT (-HT) and in EBNA3A KO 
(3AKO) and revertant (rev) LCL. MiR-221 is induced about 2-3 fold in LCL 3CHT cultured with HT 
and 6-20 fold in EBNA3A revertant LCL. (B) Comparison of the absolute amounts of miR-221 and 
U6snRNA quantified by qPCR in miR-enriched RNA preparation from LCL 3CHT-A and -C cultured 
for 28 days with or without HT. MiR-221 belongs to miRs with medium abundance in LCL. 
 
B 
 
A 
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MiR-138, a tumour suppressor miR, was found robustly repressed by EBNA3A alone. 
EBNA3A KO LCL expressed 12-24 fold more miR-138 than the respective revertants (Fig. 
3.3.2A). Similar to miR-221, miR-138 was well expressed in LCL in comparison to 
U6snRNA and other miRs (Fig. 3.3.2B and data not shown).  Mir-138 expression was 
found unchanged in LCL 3CHT cultured for 28 days with or without HT (Fig. 3.3.2A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.2. Regulation of miR-138 by EBNA3A in LCL. (A) qPCR of miR-138 in two EBNA3A KO 
(3AKO) and revertant (rev) LCL and two LCL 3CHT (-A and -C) cultured for 28 days with or without 
HT (+HT or -HT). miR-138 is upregulated about 12-24 fold in EBNA3A KO LCL. (B) Comparison of 
the absolute amounts of miR-138 and U6snRNA quantified by qPCR in miR-enriched RNA 
preparation from EBNA3A KO and revertant LCL. MiR-138 belongs to miRs with medium abundance 
in LCL. 
B 
 
A 
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EBNA3C and EBNA3A repress the anti-proliferative miR cluster mir-143/145 
MiR cluster 143/145 has emerged in recent years as a major universal tumour suppressor 
across a variety of tissues. MiR-143/145 are down-regulated in a wide range of cancers, 
including B cell malignancies. They co-operatively promote differentiation and repress 
proliferation in several cancer and primary cell lines and are both up-regulated during 
senescence in human fibroblasts (Elia et al., 2009; Kent et al., 2010; Bonifacio and Jarstfer, 
2010). 
MiR143/145 were found almost undetectable in the LCL containing WT and active 
EBNA3C and EBNA3A, but their expression was released once either EBNA3C or 
EBNA3A activity was withdrawn (Fig. 3.3.3A). Mature miR-143 and miR-145 were 
upregulated about 8-12 fold  28 days following EBNA3C inactivation in LCL 3CHT and 
about 20-50 fold in EBNA3A KO LCL in comparison to the respective revertants (Fig. 
3.3.3B).  
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Fig. 3.3.3. Regulation of mature miR-143 and miR-145 by EBNA3C and EBNA3A. (A) Absolute 
amounts of miR-143 and miR-145 quantified by qPCR in miR-enriched RNA preparations from two 
EBNA3A KO (3AKO) and revertant (rev) LCL and two LCL 3CHT (-A and -C) cultured for 28 days 
with or without HT (+HT or -HT). MiR-143/145 are barely detectable in the presence of active 
EBNA3C and EBNA3A and even after their repression is released by EBNA3C inactivation or in the 
absence of EBNA3A, they still belong to low-expressed group of miRs in LCL. (B) qPCR -
representative of three independent experiments- of miR-143 and miR-145 in two LCL 3CHT (-A and 
-C) cultured for 28 days with or without HT and in two EBNA3A KO and revertant LCL. MicroRNA 
143/145 cluster is upregulated in LCL after EBNA3C inactivation or in the absence of EBNA3A. 
B 
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The expression of the miR*-143/145 carrier strand is consistent with miR-143/145  
guide strand  
The functional significance of the carrier strand of the miR duplex, i.e. the strand that is not 
incorporated into RNA-induced silencing complex (RISC), is currently the topic of ongoing 
investigations (Guo and Lu, 2010). It has been proposed that the carrier strands are not 
merely a vehicle for the active guide strand of the miR duplex but that at least in some 
cases possess their own regulatory functions (Okamura et al., 2008; Guo and Lu, 2010). 
MiR* carrier strands frequently mimic the expression of the guide strand. The regulation of 
the carrier strands is typically less pronounced since they tend to be degraded faster. 
The quantities of the carrier strands complementary to miR-143/145 were assessed in LCL 
3CHT cultured for 28 days with or without HT and in EBNA3A KO and revertant LCL. The 
expression of the carrier miR*-143/145  was similar to the expression of the guide strand, 
although perhaps in some cases, such as miR*-145 in EBNA3A KO LCL, the de-repression  
was less pronounced (Fig. 3.3.4). 
    
 
Fig. 3.3.4. Regulation of the carrier miR*-143 and miR*-145 by EBNA3C and EBNA3A. qPCR of 
miR*-143/145 in two LCL 3CHT (-A and -C) cultured for 28 days with or without HT (+HT or -HT) and 
in EBNA3A KO (3AKO) and revertant (rev) LCL. The expression of the mircroRNA* 143/145 is 
analogous to the expression of the respective guide strands.  
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EBNA3C and EBNA3A repress the long non-coding RNA precursors of miR 143/145 
cluster 
According to Iio et al. (2010), repression of miR-143/145 in human cancer cell lines and in 
cancer tissues is caused by the down-regulation of host gene expression, specifically the 
11, 7.5, and 5.5 kb long transcripts that are the precursors of miR-143/145 (NCR-143/145, 
see Introduction, pp.47-48). It was therefore tested whether EBNA3C and/or EBNA3A 
repress miR-143/145 in LCL via downregulation of NCR-143/145. 
NCR 143/145 were quantified in LCL 3CHT cultured with or without HT using qPCR assays 
developed by Iio et al. (2010) and annotated as loc 10 and loc 3. Localization of the assays 
is depicted in Fig. 3.3.5A.  In LCL 3CHT cultured with HT, NCR 143/154 were barely 
detectable; however, their expression increased progressively with time of culture without 
HT. By day 31 without HT, both amplicons were upregulated about 20 to 30-fold in 
comparison to the controls cultured with HT. When HT was re-added, the accumulation of 
NCR 143/145 was reversed (Fig. 3.3.5B). 
Next, I assessed whether the expression of the mature miRs and their precursors 
correlated in the same samples. The expression was very well matched in both LCL 3CHT 
cultured for 28 days with or without HT (Fig. 3.3.6A) and in EBNA3A KO and revertant LCL 
(Fig. 3.3.6B).  
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Fig. 3.3.5.  NCR-143/145 expression in LCL 3CHT cultured with or without HT. (A) Scheme of 
the chromosomal region 5q33 encoding the long non-coding precursosr of miR-143/145. Position of 
loc3 and loc10 amplicons within the long precursors of miR-143/145 is depicted (adapted  from  Iio 
et al., 2010). (B) qPCR of loc3 and loc10 amplicons in two LCL 3CHT lines cultured with or without 
HT. LCL 3CHT-A was cultured with HT (A +HT), 14 and 31 days without HT (A -14 and A -31) and 
12 days after HT was readded (A re-add HT). Similarly, LCL 3CHT-C was cultured with HT (C +HT) 
and 21 days without HT (C -21). NCR 143/145 are progressively de-repressed with time following 
EBNA3C inactivation; however, the process is reversed after EBNA3C  reactivation. 
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Fig. 3.3.6. The correlation of mature miR-143/145 and their long non-coding precursors in the 
same LCL samples. (A) miR-143/145 and NCR143/145 were assessed by qPCR in two LCL 3CHT 
(-A and -C) cultured for 28 days with or without HT (+HT or -HT). The de-repression of NCR 143/145 
correlated well with that of the mature miRs in LCL following EBNA3C inactivation. (B) Similar 
analysis in EBNA3A KO (3AKO) and revertant (rev) LCL. 
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The regulation of the NCR 143/145 by EBNA3C and EBNA3A is less pronounced in 
p16-null LCL 
Since the expected function of miR-143/145 in LCL is inhibition of proliferation, the 
regulation of both mature miRs and their precursors by EBNA3C was assessed in the 
proliferation-independent p16-null LCL 3CHT system. EBNA3A KO and revertant p16-null 
lines were included for completeness. 
NCR 143/145 were quantified simultaneously in p16-null and p16-competent LCL 3CHT 
cultured for 21 days with or without HT and in EBNA3A KO and revertant LCL.  As 
expected, in the p16-competent lines lacking EBNA3C or EBNA3A function, the NCR-
143/145 were de-repressed. The de-repression of the NCR 143/145 transcripts in the p16-
competent lines seemed about 2 to 2.5-fold greater than reported previously (Fig. 3.3.5B 
and 3.3.6), this was probably due to the use of a different set of housekeeping genes in the 
normalization procedure. 
In the p16-null lines, the NCR-143/145 transcripts were also found to be upregulated 
following EBNA3C inactivation and in EBNA3A KO cells; however, the de-repression 
seemed to be less pronounced than in the p16-competent cell lines (Fig. 3.3.7). 
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Fig. 3.3.7.  Regulation of NCR 143/145 by EBNA3C and EBNA3A in p16-null LCL. (A) qPCR of 
NCR 143/145 in p16-competent (ctrl A and ctrl C) and p16-null (A1, A2, C1, C2) LCL 3CHT cultured 
for 21 days with or without HT. NCR143/145 are de-repressed in p16-null lines following EBNA3C 
inactivation; however, to a lesser degree than in p16-competent lines. (B) Similar qPCR analysis 
performed using p16-competent EBNA3A KO (ctrl 3AKO), revertant (ctrl rev) and their p16-null 
counterparts. 
 
At the moment, insufficient data is available to make similar meaningful comparisons 
between p16-null and -competent cell lines at the level of mature miR-143/145. The miRs 
were quantified in both p16-competent and p16-null LCL; however not alongside each 
other in a single measurement (using the same RNA isolation protocol and the same 
endogenous controls).  In p16-null lines, miR 143 was de-repressed to a lesser degree 
than observed in p16-competent LCL after EBNA3C inactivation or in the absence of 
EBNA3A (Fig. 3.3.8 and Fig. 3.3.3B or Fig. 3.3.6). However, miR-145 seemed to be 
similarly regulated by both EBNA3C and EBNA3A in p16-null lines as in their p16-
competent counterparts (Fig. 3.3.8 and Fig. 3.3.3B or Fig. 3.3.6). 
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Fig. 3.3.8.  Regulation of the mature miR-143/145 by EBNA3C and EBNA3A in p16-null LCL. 
qPCR of mature miR-143/145 in three p16-null LCL 3CHT (A2, C1 and C2) cultured for 27 days with 
or without HT and in p16-null EBNA3A KO (3AKO) and respective revertant (rev) LCL.  The p16-
competent lines were not available for direct comparison. MiR-143 might be regulated to a lesser 
degree by EBNA3C and EBNA3A in p16-null LCL. 
 
Several miR-143/145 putative targets are regulated in LCL in response to EBNA3C 
and EBNA3A 
In the preparation for functional studies, I assembled a set of putative miR-143/145 target 
genes in B cell-derived lines using miR target prediction software (miRDB) and including 
miR-143/145 target genes validated by others in a variety of cancer models. EBV 
microarray data (www.ebv.org.uk) containing expression profiles of WT BL31 and BL31 
infected with various EBNA3 mutants (White et al., 2010) as well as WT LCL and EBNA3A 
KO LCL (Hertle et al., 2009) were then searched for the putative miR-143/145 target genes 
regulated by EBNA3C and/or EBNA3A. In the next step, qPCR and WB analysis of the 
selected putative miR-143/145 targets was performed in LCL 3CHT cultured with or without 
HT and in EBNA3A KO and revertant LCL. The preliminary data showed that several miR-
143/145 target genes were regulated at the transcript and protein level by EBNA3C and/or 
EBNA3A in LCL, specifically the signalling molecule RTKN and epigenetic regulator 
DNMT3A.  
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RTKN (rhotekin) is a scaffold protein that interacts with GTP-bound Rho proteins; binding 
of this protein inhibits the GTPase activity of Rho proteins (Ito et al., 2005). DNMT3A is a 
DNA methyltransferase that functions in de novo methylation (Gao et al., 2011). In an EBV 
microarray database, RTKN transcripts were found modestly decreased in EBNA3C KO 
BL31 lines in comparison to the WT BL31 (Fig. 3.3.9A). DNMT3A transcripts were found to 
be modestly downregulated in EBNA3A KO LCL in comparison to the respective revertant; 
however, they were stable in LCL 3CHT cultured with and without HT (Fig. 3.3.9B). 
 
             
 
 
 
 
 
 
 
Fig. 3.3.9.  Regulation of RTKN and DNMT3A transcripts by EBNA3C and/or EBNA3A in B 
cell-derived lines. (A) Microarray dot plot illustrating the quantity of RTKN mRNA in BL31 infected 
with WT, EBNA3C KO and EBNA3A KO recombinant EBV viruses. RTKN transcripts are modestly 
downregulated in EBNA3C KO BL31 (White et al., 2010). (B) qPCR of DNMT3A transcripts in two 
LCL 3CHT (-A and -C) cultured for 28 days with or without HT (+HT and -HT) and in EBNA3A KO 
(3AKO) and revertant (rev) LCL. DNMT3A transcripts seem to be stable following EBNA3C 
inactivation and modestly downregulated in EBNA3A KO LCL. 
 
At the level of protein, both RTKN and DNMT3A were regulated by EBNA3C and EBNA3A 
in multiple LCL; the decrease in these proteins was modest following EBNA3C inactivation 
in LCL 3CHT (Fig. 3.3.10A) but pronounced in LCL lacking EBNA3A (Fig. 3.3.10B). The 
expression of several other predicted targets of miR-143 and/or miR-145, i.e. ERK5, fascin 
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and K-Ras was not changed in LCL following EBNA3C inactivation or in the absence of 
EBNA3A (Fig. 3.3.10A and data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.10. Regulation of RTKN and DNMT3A protein by EBNA3C and EBNA3A in LCL. (A) 
Western blot depicting the quantities of RTKN, DNMT3A and two other putative miR-143/145 targets 
(ERK and fascin) in four LCL 3CHT (-B, -C, -D, -A) cultured for 31 days with or without HT. The 
quantities of RTKN and DNMT3A protein modestly decrease in all lines following EBNA3C 
inactivation, as opposed to ERK and fascin which expression remains unaltered. (B) Similar analysis 
in  two EBNA3A KO (3AKO) and revertant (rev) LCL. RTKN and DNMT3A are robustly decreased in 
EBNA3A KO lines while the control γ-tubulin (γ-tub) expression remains stable. WBs shown are 
representative of two similar experiments. 
 
 
 
 
 
A 
 
B 
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Summary key points 
 
 Several cellular miRs are regulated by either one or both EBNA3C and EBNA3A in 
LCL 
 The anti-proliferative miR 143/145 cluster is robustly repressed by both EBNA3C 
and EBNA3A in LCL 
 EBNA3C and EBNA3A repress the mature miR-143/145 by down-regulating their 
long non-coding precursors NCR 143/145 
 MiR-143/145 targets in LCL might include DNTM3A and RTKN 
 
Discussion 
 
Regulation of transcription and posttransctiptional gene silencing represent two major 
pathways determining gene expression. Posttranscriptional silencing is transient and 
depends on the continued presence of the miR effector molecules, whereas transcriptional 
gene regulation occurs at the level of DNA via chromatin changes at the gene 
promoters/regulatory regions and can lead to long-term change in gene expression (Turner 
and Morris, 2010). I have shown that in addition to epigenetically regulating production of 
the protein-coding transcripts (e.g. p16INK4A), EBNA3C and EBNA3A also regulate the 
expression of several miRs and in extension participate in posttranscriptional regulation of 
cellular genes. 
As shown recently in a study that combined microarrays and shotgun proteomics to 
quantify absolute mRNA and protein levels for over 1000 genes in a tumour cell line, 
transcriptional regulation accounts for only about half of protein abundance. The remaining 
regulation is posttranscriptional, including miRs (Vogel et al., 2010). MiRs negatively 
regulate the stability and translation of target messenger RNAs and offer a flexible mode of 
200 | P a g e  
 
regulation by circumventing the need for translation. EBV itself encodes at least 40 miRs 
that are expressed in latently infected cells (Amoroso et al., 2011; Barth, Meister and 
Grasser, 2011). In addition, EBV might modulate processing of viral and cellular miRs via 
its own miR BART6 that inhibits production of endoribonuclease DICER, an enzyme 
necessary to cleave dsRNA and pre-miR into 20-25nt long fragments (Iizasa et al., 2010). 
EBV has been shown previously to induce changes in the transcription of cellular miRs in 
infected cells (Imig et al., 2010; Linnstaedt et al., 2010); however, the regulation of cellular 
miRs by EBNA3C and/or EBNA3A has not yet been explored. I screened the response of 
377 cellular miRs to the withdrawal of EBNA3C or EBNA3A function by real-time qPCR 
low-density miR array. Several cellular miRs were found to be regulated by either one or 
both EBNA3C and EBNA3A and the miR 143/145 cluster was selected for further study. 
 
 
MiR-143/145 abundance in LCL 
MiR-221 and miR-138 were well expressed in LCL and therefore even a small fold 
difference in expression would translate into a considerable change in the miR copy 
number in the cell (Fig. 3.3.1B and Fig. 3.3.2B). However, miR-143/145 and their 
precursors were barely detectable in WT LCL and expressed moderately in LCL lacking 
functional EBNA3C or EBNA3A - in the range of ten(s) of copies per cell (Fig. 3.3.3A and 
data not shown). Although the cellular concentration of miR is critical to their function, the 
downregulation of the target mRNA by miR is also the function of the target’s abundance 
(Arvey et al., 2010). Low abundance miRs are effective in regulating low-abundance 
transcripts and about 11 thousand different messages in the cell are expressed in the 5-15 
copies per cell range. 
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Regulation of miR-143/145 locus  
I found that both EBNA3C and EBNA3A contribute to the repression of mature miR-
143/145 and their precursor NCR-143/145 in LCL. The mechanisms of miR processing are 
accountable in large part for the final miR abundance; however, a primary level of control of 
miR expression is thought to be transcriptional (Cullen, 2004). According to the study by 
Iio, et al. (2010), expression of miR-143/145 in normal and cancer tissues accurately 
correlates with the expression of their precursor long ncRNAs. This holds true also in LCL 
with or without active EBNA3C or EBNA3A (Fig. 3.3.6). 
 
The mechanism of miR-143/145 promoter regulation by the two viral proteins in LCL is yet 
to be investigated. Several intriguing modes of regulation have been proposed in other 
cancer models. The miR-143/145 promoter was shown to be induced by Notch signalling 
activity in vascular smooth muscle cells, and a RBPJk/CBF1 site was necessary for this 
induction (Boucher et al., 2011). Oncogenic Ras repressed the miR-143/145 promoter in 
both human and murine cells through the Ras-responsive element-binding protein (RREB1) 
(Kent et al., 2010). Furthermore, different epigenetic marks were found at the miR-143/145 
promoter in various contexts. In human colon cancer cell lines, treatment with DNMT or 
HDAC inhibitors did not upregulate miR-143/145 expression (Akao et al., 2007). However, 
miR-145 was silenced through DNA hypermethylation in laser capture microdissected 
prostate tissues (Suh et al., 2011) and miR-143 was epigenetically repressed by promoter 
hypermethylation in MLL–AF4 positive B-cell ALL, but not in normal bone marrow cells or  
MLL–AF4-negative primary blasts (Dou et al., 2011). Since the precise localization of the 
regulatory regions of miR-143/145 promoter has now been well defined by others, it should 
facilitate our own studies of miR-143/145 regulation by EBNA3C and EBNA3A in LCL. 
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Functional significance of miR-143/145 regulation by EBNA3C and EBNA3A in LCL 
Since the functional outcome might depend not only on the degree of miR-143/145 
upregulation in the absence of EBNA3C or EBNBA3A function but also on other factors 
including miR-143/145 final quantity within a cell, it will be crucial to establish whether 
upregulation of miR-143/145 causally contributes to the growth inhibition in LCL. During 
senescence of human fibroblasts, miR-143/145 were upregulated and transfecting a 
synthetic mimic of miR-143 was able to inhibit the proliferation of fibroblasts in a dose-
dependent manner (Bonifacio and Jarstfer, 2010). Gain-of-function and loss-of-function 
studies in other tumour cell lines also implicated miR-143/145 in direct proliferation 
inhibition (Chen et al. 2010b; Kent et al., 2010; Zhang et al., 2010; Peng et al., 2011).  
 
In this study, miR-143/145 and their precursor NCR 143/145 were upregulated also in p16-
null LCL 3CHT where EBNA3C inactivation does not lead to any detectable change in LCL 
proliferation. However, the regulation of the NCR-143/145 seemed to be less pronounced 
in p16-null lines than in their p16-competent counterparts (Fig. 3.3.7). The mature miRs in 
p16-null and -competent lines have not yet been directly compared.   
 
The pattern of expression of miR-143/145 and their precursors in LCL is similar to p16INK4A 
mRNA. They are repressed in WT LCL, upregulated in EBNA3A KO LCL and in LCL3CHT 
without HT but with considerable delay, and again repressed with similar delay following 
HT re-adding (Fig. 3.3.3B and Fig. 3.3.5B). Furthermore, miR-143/145 are both up-
regulated during senescence in primary human fibroblasts (Bonifacio and Jarstfer, 2010).  
It is possible that there might be a cross-talk between the miR-143/145 pathway and 
functional p16INK4A-Rb pathway. Therefore the de-repression of miR-143/145 in the 
proliferating p16-null LCL in the absence of EBNA3C or EBNA3A activity, whether or not 
less pronounced than in the p16-competent lines, should not discourage the notion that 
these miRs can indeed directly inhibit LCL proliferation.  
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Limitations of the study and future work 
 
 
According to the Comparative Genomic Hybridization database, the mir-143/145 (5q33) 
locus is frequently involved in chromosome copy number loss in various types of cancers 
including non-small cell lung cancer and gastric cancer (Iio et al., 2010).  Although the 
integrity of this genomic locus in B cell derived lines used in this study was not investigated, 
the LCL 3CHT conditional system by-passes this concern and allows for convincing 
reversible de-repression of the host gene and its residing miRs. 
 
The data presented in this chapter represent a preliminary finding of miR regulation by 
EBNA3C and/or EBNA3A in LCL, but are limited to correlations rather than direct functional 
studies. More work will be needed to assess the role of miR143/145 in LCL proliferation 
and to validate the selected protein targets by direct gain-of-function and loss-of-function 
studies. Re-expression of miR143/145 in WT LCL or their inhibition in LCL after EBNA3C 
inactivation or in LCL lacking EBNA3A could also dissect the possible cross-talk between 
the miR-143/145 miR pathway and p16INK4A-Rb pathway. Furthermore, it will be of great 
interest to investigate the chromatin status at the miR-143/145 locus in WT LCL and in LCL 
without EBNA3C or EBNA3A function and determine whether the regulation of the miR-
143/145 locus by these proteins is similar to the epigenetic regulation of the previously 
studied p16INK4A  and BIM loci. 
. 
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Chapter 4 
 Thoughts and Final Conclusions 
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The functional significance of EBNA3C and EBNA3A in LCL proliferation and B cell 
transformation and immortalization by EBV 
 
Around 20% of cancers world-wide are of infectious aetiology, with leading agents being 
viruses of hepatitis B and C, herpesviruses EBV, KSHV and the retrovirus HTLV-1 (Parkin, 
2006; Wang et al., 2007b). EBV latently persists in more than 90% of world population and 
is associated with approximately 1% of tumours worldwide (Delecluse et al., 2007). A 
complex interaction between virally encoded proteins and B cell-specific cellular factors 
contributes to lymphomagenesis.  
In the in vitro model of EBV-mediated lymphomagenesis, intact EBNA3C is essential for 
transformation of primary B cells into LCL and EBNA3A greatly enhances the efficiency of 
B cell transformation. EBNA3C and EBNA3A are both required for the maintenance of LCL 
proliferation (Maruo et al., 2003 and 2006). Integration of cellular transcript microarray and 
ChIP analysis of histone modifications at cellular promoters in B cell-derived lines has 
shown that EBNA3C and EBNA3A co-operate in the epigenetic regulation of a subset of 
cellular genes, most notably the negative inhibitor of the cell cycle progression p16INK4A and 
the pro-apoptotic protein BIM. 
In this work, I have found that the main and perhaps only necessary role of EBNA3C in 
EBV-driven LCL proliferation lies in the repression of p16INK4A. This finding reinforces the 
view that EBNA3C and EBNA3A are required in LCL proliferation and most likely also B 
cell transformation to repress cellular tumour suppressor defences. EBNA3C and EBNA3A 
thus complement the action of EBNA2 which acts as an activated oncogene, driving the B 
cell activation and hyperproliferation. Replication stress is sensed by cellular surveillance 
systems and activates protective pathways to suppress uncontrolled proliferation. These 
consist of mediators of apoptosis and oncogene-induced senescence or growth arrest. 
However, EBNA3C and EBNA3A via suppression of BIM (Anderton et al., 2007; Paschos 
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et al., 2009), p16INK4A (Skalska et al., 2010 and this study) microRNA 143/145 (this study) 
and the ATM/CHK2 DDR  (Nikitin et al., 2010) disable cellular defences and permit further 
cell survival and proliferation (Fig. 4.1). 
 
 
 
 
 
 
 
 
 
Fig. 4.1. Scheme of the roles of EBNA3C and EBNA3A in the maintenance of LCL proliferation 
and in B cell immortalization. EBNA3C and EBNA3A suppress the host cell defences (OIS, DDR 
and apoptosis) and allow the survival and proliferation of EBV-infected B cells. The major function of 
EBNA3C in maintenance of LCL proliferation and likely also in B cell immortalization is repression of 
p16
INK4A
. 
 
In vivo, the transforming potential of EBV is much lower than in vitro and EBV acts as a co-
factor alongside other transformation events such as chromosomal translocations. 
Extrapolating from in vitro findings, EBNA3C- and EBNA3A-primed inactivation of p16INK4A, 
BIM and microRNAs with tumour suppressor functions in vivo is likely to substantially 
decrease the threshold for the number of subsequent mutagens and/or inappropriate 
growth stimuli required to promote oncogenesis. 
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Mechanism of epigenetic modification of cellular genes by EBNA3C and EBNA3A 
Previous work in our lab has established that EBNA3C and EBNA3A-mediated  changes in 
the expression of cellular genes are accompanied by simultaneous changes in  the 
chromatin structure (and sometimes DNA methylation) at the cellular promoters in B cell-
derived cell lines (Paschos et al., 2009;  White et al., 2010). Using p16-null LCL 3CHT, 
I have shown that epigenetic regulation of p16INK4A locus by EBNA3C is truly specific and 
independent of the functional outcome.  
Although there is accumulating evidence showing that EBNA3C, probably in co-operation 
with EBNA3A, can directly or indirectly modify histones at the regulatory regions of cellular 
genes and direct its activities specifically to certain crucial cellular loci, several key 
questions regarding this mechanism remain unanswered and need further investigation. 
 
Do EBNA3C and EBNA3A trigger a cascade of transcription-regulating events or do they 
directly regulate multiple (hundreds of) cellular promoter regions for the benefit of the virus? 
A small number of well-defined factors are sufficient to reprogram a differentiated cell into 
induced pluripotent stem cell (Takahashi and Yamanaka, 2006) and the unscheduled 
expression of a single transcription factor can cause the transdifferentiation of a mature 
differentiated cell into another cell type, e.g. forced expression of C/EBPa leads to 
conversion of B lymphocytes into macrophages (Masip et al., 2010). Similarly, EBNA3C 
and EBNA3A could achieve the change of cellular expression profile by modifying the 
expression of a single or a few cellular master regulators. 
Zhao et al. (2011a) performed a network-centred analysis of EBNA3C-regulated genes in 
LCL 3CHT lines cultured with HT, without HT and without HT but complemented with WT 
EBNA3C. They have identified 550 genes that were at least 1.5-fold up- or down-regulated 
with false discovery rates < 0.01. In a Bayesian network analysis RAC1, LYN and TNF 
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were found regulated upstream of other EBNA3C-regulated genes. RAC1 is a GTPase 
which belongs to the Ras superfamily of small GTP-binding proteins and regulates multiple 
cellular events, including cell growth, cytoskeletal reorganization, and the activation of 
protein kinases (Rathinam, Berrier and Alahari; 2011). LYN, a member of the Src family of 
protein tyrosine kinases, regulates cell activation through signalling cascades in B 
lymphocytes and myeloid cells (Scapini et al., 2009). TNF consists of a group of cytokines 
that have a key role in the regulation of apoptosis and inflammation, as well as proliferation, 
invasion and angiogenesis (Mathew et al., 2009). EBNA3C was suggested to modulate 
RAC1 signalling, down-regulate LYN and up-regulate TNF. This genome-wide analysis 
provided bioinformatic correlations but lacked direct functional experimentation. 
Nevertheless, the implication of these findings is that by direct regulation of only several 
loci, EBNA3C could indirectly control multiple diverse cellular processes. 
 
Alternatively, EBNA3C and/or EBNA3A could directly regulate large sets of cellular 
promoters, similarly to adenoviral small E1A or the latency-associated nuclear antigen 
LANA of KSHV. Although small E1A does not bind directly to DNA, during E1A-mediated 
cellular transformation, E1A associates with different subsets of cellular promoters in 
defined temporal order causing either transcriptional activation or repression (Ferrari et al., 
2008). Similarly, LANA was shown to associate directly with several cellular promoters 
(Shamay et al., 2006; Su et al., 2011). In both cases, the viral oncoprotein recruits and 
targets a component of the epigenetic machinery to the occupied cellular promoters.  
In our lab, the question which cellular promoters are regulated directly by EBNA3C and/or 
EBNA3A will be addressed by ChIP-seq using BL and LCL carrying strep-FLAG (TAP)-
tagged EBNA3C and EBNA3A-containing recombinant EBV-BACs. 
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In what way is the epigenome of BL and LCL with WT active EBNA3C and/or EBNA3A 
different from the epigenome of the same lines after EBNA3s have been inactivated or 
mutated? 
It remains to be confirmed whether EBNA3C and/or EBNA3A regulate cellular gene 
expression predominantly via H3K27me3 or whether modifications of different type and 
position are altered on histones as a result of EBNA3C and/or EBNA3A activity. Integration 
of mRNA microarray data and ChIP-chip or ChIP-seq data mapping the histone 
modification in the same cell lines containing WT or inactivated EBNA3C or EBNA3A 
should show whether the transcriptional profile following EBNA3 inactivation overlaps that 
of differentially H3K27me3-regulated promoters. Since both EBNA3C and EBNA3A can 
bind CtBP and thus potentially associate with a number of chromatin remodelers, it is 
possible that EBNA3C and/or EBNA3A activity will be associated not just with H3K27me3 
regulation but rather a more complex combinatorial chromatin signature or a variety of 
epigenetic states dictated by the context of EBNA3C and/or EBNA3A binding. 
 
What roles do EBNA3C and/or EBNA3A have in modulating the cellular epigenome? 
The establishment and maintenance of epigenetic information requires several linked 
processes: the targeting of the modification to the specific promoters or regulatory regions, 
the actual establishment of the mark by the chromatin remodelling enzymes, the 
transmission of the mark to the daughter cells in the next cell division and finally the 
signalling that connects the establishment of the epigenetic marks with the environmental 
cues. EBNA3C and/or EBNA3A could be modulating the cellular epigenome in several 
ways: 
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A) By physically participating in chromatin remodelling complexes 
EBNA3C and EBNA3A do not bind DNA directly (Young et al., 2008; Saha et al., 2011) and 
do not possess any obvious intrinsic enzymatic activity (Jiang, Cho and Wang, 2000; West, 
2006). Although the attempts to localize EBNA3C and EBNA3A at the promoters of their 
target genes BIM and p16INK4A failed using the antibodies against the WT endogenous 
EBNA3s, the direct binding of EBNA3C and/or EBNA3A at these loci will now be re-
addressed in the cell lines carrying the strep-FLAG (TAP)-tagged EBNA3C or EBNA3A 
recombinant EBV-BACs. EBNA3C and EBNA3A are required for establishment and 
maintenance of H3K27me3 at p16INK4A and BIM locus. In addition, both viral proteins are 
required for PRC2 recruitment and block phosphorylation of Pol II on ser 5 at the BIM 
promoter (Paschos et al., 2009; Skalska et al., 2010; Paschos et al., under revision). It is 
possible that EBNA3C and EBNA3A physically associate with their target loci through a 
DNA-binding intermediate to carry out the above functions. EBNA3C and/or EBNA3A could 
facilitate PcG-mediated gene repression by influencing the stoichiometry or stabilizing the 
repressive complexes at EBNA3C and/or EBNA3A-regulated loci. In addition, both viral 
proteins associate with the cellular co-repressor of transcription CtBP and, via CtBP, could 
recruit a number of chromatin remodelers in addition to PcG (such as LSD1, HDACs and 
G9a) (Fig.4.2). 
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3C/3ACtBP
PcG 
(H3K27me3)
 
 
Fig.  4.2. Direct association of EBNA3C and/or EBNA3A with the chromatin remodelling 
complex at the target cellular promoter. (A) Legend annotating the symbols used in subsequent 
figures. (B) Physical participation of EBNA3C and/or EBNA3A at the target locus. EBNA3C and/or 
EBNA3A could, through an intermediate DNA-binding element, associate with the promoter of the 
target gene and either recruit, in a CtBP-dependent or –independent manner, the chromatin 
remodelers or impact on the stability or stoichiometry of the repressive complexes at the locus.  
 
 
B 
 
A 
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B) In the targeting of chromatin remodelling complexes (enzymes) to specific loci 
EBNA3C and/or EBNA3A could target the chromatin remodelers to the cellular promoters 
directly through association with DNA-binding elements such as ncRNA or sequence-
specific TF (Fig. 4.3A). For example, EBNA3C and EBNA3A both bind the sequence-
specific TF RBPJk/CBF1. In ChIP experiments performed in BL31 infected with 
recombinant EBV-BAC carrying WT EBNA3C and EBNA3A, RBPJk seems to be present at 
the BIM promoter close to the transcription start site when BIM is repressed (Kostas 
Paschos, personal communication).  
EBNA3C and/or EBNA3A molecules could undergo different posttranslational modifications 
in diverse cellular contexts which might give them the ability to bind various TFs, co-factors 
or ncRNAs and modulate distinct subsets of cellular genes in a context-specific manner. 
Alternatively, EBNA3C and/or EBNA3A could up- or down-regulate the expression of 
sequence-specific TFs or ncRNAs (Fig. 4.3B). 
 
C) By ‘bookmarking’ the target genes 
Since 16-null LCL 3CHT in culture proliferate at the same rate regardless of EBNA3C 
activity, most or all of the selection pressures based on proliferative advantage following 
EBNA3C reactivation have been removed. However, the removal or acquisition of 
H3K27me3 peak at the p16INK4 exon1 at the level of cell population following EBNA3C 
switch is gradual and requires approximately 20 cell divisions. Similar kinetics of 
H3K27me3 removal has been observed for another PcG- and H3K27me3-regulated 
EBNA3C- and EBNA3A-target gene BIM (Paschos et al., under revision). It is possible, that 
EBNA3C and EBNA3A act in the transmission of the existing repressive marks at the target 
loci in the proliferating cell population. EBNA3C and EBNA3A could maintain the 
association with target loci during the cell division and ensure the restitution of the 
epigenetic mark in the daughter cells at the exact same location (Fig. 4.4). The population 
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of cells containing the target gene in the repressed state would be maintained in the 
proliferating LCL or BL containing WT active EBNA3C and/or EBNA3A, or would be 
gradually lost following the inactivation of EBNA3C and/or EBNA3A.  
 
 
OFF
target  promoter
TF
OFF
target  promoter
3C/3A
PcG 
(H3K27me3)
3C/3A
PcG 
(H3K27me3)
 
 
 
 
 
 
 
 
Fig. 4.3.  Direct and indirect targeting of chromatin remodelling complexes to the cellular 
promoters by EBNA3C and/or EBNA3A. (A) EBNA3C and/or EBNA3A could directly associate 
with sequence-specific TFs or ncRNA and simultaneously (in CtBP-dependent or –independent 
manner) with chromatin remodelers and thus facilitate targeting of the chromatin remodelers to the 
promoters of EBNA3C and/or EBNA3A-regulated genes. (B) EBNA3C and/or EBNA3A could 
regulate the expression of sequence-specific TFs and/or ncRNA and indirectly modulate the 
targeting of the chromatin remodelers to other EBNA3C and/or EBNA3A-regulated promoters.  
 
B 
 
A 
 
B 
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Fig. 4.4. Gene bookmarking by EBNA3C and EBNA3A. EBNA3C and EBNA3A are 
represented as dark dots that maintain their association with the promoters of their target genes 
during mitosis and serve as a docking station for the chromatin remodelling enzymes re-
establishing the mark in the daughter cells. 
 
 
D)  By regulating expression of the components of the epigenetic machinery (e.g. 
chromatin remodelling enzymes or microRNAs) 
In cancer, components of epigenetic machinery such as chromatin remodelling enzymes 
are frequently deregulated skewing the expression of multiple genes. In this study I 
excluded the regulation of expression of EZH2 and H3K27 demethylases (JMJD3/KDM6B 
and UTX/KDM6A) by EBNA3C in LCL (Fig.3.1.16 and data not shown). Furthermore, the 
steady-state levels of EZH2, SUZ12, EED, RbAp48 and JMJD3 were assessed by western 
blotting protein extracts from an uninfected BL31 and BL31 infected with WT EBV-BAC or 
recombinant EBV-BAC viruses lacking EBNA3C and/or EBNA3A. None of the chromatin 
remodelers mentioned above was found to be consistently regulated in correlation with the 
EBV or EBNA3 status of the cells (Paschos et al., under revision). However, it is possible 
that EBNA3C and/or EBNA3A regulate the expression of some other component of 
epigenetic machinery (Fig. 4.5). In addition, EBNA3C and/or EBNA3A were shown to 
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transcriptionally regulate a subset of cellular microRNAs, which are as well considered one 
of the means of epigenetic regulation. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5. Transcriptional regulation of the essential component(s) of epigenetic machinery by 
EBNA3C and/or EBNA3A. EBNA3C and/or EBNA3A could regulate the expression of a chromatin 
remodelling enzyme or some other component of the epigenetic machinery and thus impact on the 
regulation of multiple cellular genes. 
 
 
E) By regulating signal transduction cascades that result in alterations of chromatin 
structure (e.g. TGFβ  or/and Notch2 pathways)  
 
Although the cellular epigenomes are able to respond dynamically to the outside stimuli, 
the mechanism by which target genes are regulated by environmental cues and signalling 
pathways is not yet well defined (Gehani et al., 2010). EBNA3C and EBNA3A are known to 
interfere with major cellular signalling pathways including the TGFβ pathway (Lydia 
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Eccersley, personal communication) and could mediate the communication of 
environmental signals towards the cellular epigenome. 
 
In order to further address the mechanism of the role of EBNA3C and EBNA3A in 
chromatin remodelling in LCL, it would be informative to integrate genome-wide data 
including epigenetic marks, nucleosome turnover, promoter DNA methylation status and 
non-coding RNA expression with the gene expression and phenotype in the WT LCL and 
after the inactivation or mutation of EBNA3C and/or EBNA3A. With advancing 
developments of genome-wide technologies (e.g. ChIP-seq), it is now possible to adopt a 
dynamic approach, i.e. analyze data from several time-points as well as a single snapshot. 
 
EBNA3C and EBNA3A expression and their relevance during the initiation and 
progression of malignancy in vivo 
Due to the technical difficulties with detection of EBNA3C and EBNA3A in vivo, their 
expression has not been explored in a variety of tumours. In addition, the expression of 
EBNA3C and EBNA3A was assumed to be constantly associated with the expression of 
EBNA2, consistent with the latency III expression programme. However, it appears that in 
tumours in vivo, a more varied expression patterns of EBV latent proteins are present than 
the ‘classic’ latency expression programmes and the assumption of EBNA3C and EBNA3A 
co-expression with EBNA2 might not hold true. 
EBNA3A expression has been detected in the majority of  EBV-positive diffuse large B cell 
lymphomas (Nguyen-Van et al., 2011) and expression of EBNA3s was found to be retained 
in small but significant subset (about 10%) of BL (Kelly et al., 2006). Nevertheless to date, 
EBNA3C and EBNA3A have not been reported to be expressed in majority of EBV-
associated lymphomas (Tsang and Munz, 2011).  However, they have probably been 
expressed transiently in majority of the B cells containing EBV episome. It is possible that 
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transient expression of EBNA3C and EBNA3A is sufficient to prime the cell for long-term 
repression of p16INK4, BIM and/or tumour-suppressor microRNAs. The priming might mark 
the genes for subsequent modifications such as DNA methylation that would serve to 
preserve the EBNA3C and/or EBNA3A-mediated repression of their target genes in at least 
a subset of EBV-infected cells even after the expression of EBNA3C and EBNA3A is shut-
off.   
In the EBV-positive tumours associated with immunosuppression, EBNA3C and EBNA3A 
are frequently detectable in EBV-carrying cells (Heslop et al., 2005; Heslop et al., 2010) 
and might contribute to rapid cell cycle deregulation in a number of B cells in parallel. 
 
Therapeutic implications in cancer 
p16INK4A as a therapeutic target 
At the level of the organism, p16INK4A regulation requires a fragile equilibrium, weighing the 
costs and benefits between the risk of cancer and accelerated aging.  p16INK4A is not merely 
a biomarker of aging but causally contributes to the tissue loss in aging organisms by 
reduced self-renewal  and senescence of  tissue stem cells with age  (Molofsky et al., 
2006). Recently, it has been shown using a transgenic strategy for initiating selective 
apoptosis of senescent cells, that the removal of p16INK4A-positive senescent cells in mice 
can prevent or delay age-associated diseases such as wrinkles, muscle wasting and 
cataracts (Baker et al., 2011).  In general, it seems that therapeutically silencing p16INK4A 
would constitute a trade-off between increased cancer and reduced aging. However, it is 
not clear whether p16INK4A plays this dual role in all tissues or only some. It has been 
suggested that in some cellular compartments, such as melanocytes, p16INK4A exhibits a 
strong tumour suppressor effect but has very little impact on aging (Liu et al., 2011). 
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At this moment, the findings regarding p16INK4A relevance in aging and tumour-suppression 
in B lymphoid progenitors and B cell lineage are conflicting. The study by Liu et al. (2011) 
supports a view that p16INK4A has major tumour-suppressive effects and lesser role in aging 
in murine B cell progenitors. On the contrary, Signer et al. (2008) reported that p16INK4A and 
p14ARF accumulation in aged murine B lymphoid progenitors leads not only to an increase 
in their resistance to transformation but also to their reduced growth and survival. The 
authors believe that the age-related p16INK4A and p14ARF accumulation is actually the major 
underlying cause of severe growth defects in B lymphoid progenitors during aging not only 
in mice but in humans.  These intriguing initial findings were obtained mainly in mice 
models and on the population of early B cell progenitors and so further research will be 
necessary to assess whether p16INK4A reactivation in lymphomas in humans would be an 
effective treatment. 
 
Virally targeted restoration of WT p16INK4A expression into p16-deleted glioma cells inhibited 
angiogenesis induced by tumour cells in vivo (Harada et al., 1999). In hepatocellular 
carcinoma, virally targeted p16INK4A restoration in cancer cells lead to their growth arrest 
and apoptosis (Hu et al., 2011). It therefore seems feasible to specifically restore p16INK4A 
expression only in the tumour tissue and thus avoid the potential negative effects of 
increased p16INK4A expression in the remaining tissues of the individual.  Taken together, 
despite the dual role of p16INK4A in both promoting aging and suppressing tumorigenesis, 
p16INK4A should still be considered a potential therapeutic target in lymphoproliferations. 
 
Epigenetic therapy 
DNA methyltransferase inhibitors and histone deacetylase inhibitors are currently approved 
for treatment of myelodysplastic syndrome and other haematological malignancies by the 
US Food and Drug Administration and have been in clinical use for several years (Kelly, de 
Carvalho and Jones, 2010).  Current drugs are pan-inhibitors that block the entire family of 
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DNMTs and HDACs rather than a specific enzyme. The challenge of current epigenetic 
drug development is to produce specific epigenetic therapies.  This includes the 
development of specific enzyme inhibitors such as PcG-specific inhibitors and therapies 
targeted to specific loci as opposed to genome-wide (Tuma, 2010; Crea et al., 2011). 
 
In summary 
EBV induces and maintains transformation of normal B cells in vitro through expression of 
only few viral genes. In this work I have studied the effects of inactivation of two EBV 
nuclear antigens - EBNA3C and EBNA3A -on regulation of the cell cycle in LCL, with the 
remainder of the EBV latent programme intact. The rationale behind the project was that 
both EBV cellular targets and the mechanisms the virus employs in their modulation can 
inform on the general mechanisms of B cell lymphomagenesis. 
Several novel microRNA target genes are identified in this report, notably tumour 
suppressor cluster miR-143/145.  Furthermore, I describe the mechanism by which 
EBNA3C and EBNA3A, in co-operation with a cellular co-repressor of transcription CtBP, 
specifically target and epigenetically re-programme the p16INK4A locus, preventing exit from 
the cell cycle and/or differentiation. The absence of p16INK4A abolishes the need for 
EBNA3C in the proliferation of established LCL, raising the questions regarding the relative 
functional relevance of the other EBNA3C-regulated proliferation-related genes in LCL and 
simultaneously offering a proliferation-independent system to explore EBNA3C function. 
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